

23-11-2018

10:00 - 11:30 **Type: Opening session** **Hall 406**
Title: Opening & Keynote
 Chair: Josep Tabernero, ES

10:00 - 10:10 **Opening**

10:10 - 10:15 **Welcome address by the ESMO President**
J. Tabernero, ES

10:15 - 10:25 **Welcome address by the Senior Minister of State in the Ministry of Health and the Ministry of Transport**
L.P. Min, SG

10:25 - 10:30 **Welcome address by the President of the Singapore Society of Oncology**
S.P. Choo, SG

10:30 - 10:50 **Presentation of Token of Appreciation to the Endorsing National Oncology Societies**
J. Tabernero, ES

10:50 - 11:00 **Scientific address**
T.S.K. Mok¹, S. Banerjee²; ¹HK, ²GB

11:00 - 11:30 **ESMO Presidential Address**
J. Tabernero, ES

11:45 - 12:30 **Type: Challenge Your Expert session** **Hall 405**
Title: Treatment of node positive bladder
 Chair: Ji Youl Lee, KR; Ben Tran, AU

11:45 - 12:05 **Treatment of node positive bladder**
J.Y. Lee¹, B. Tran²; ¹KR, ²AU

12:05 - 12:30 **Discussion led by**
J.Y. Lee¹, B. Tran²; ¹KR, ²AU

11:45 - 12:30	Type: Challenge Your Expert session Title: Treatment for stage IIB cervical cancer: Surgery or chemoradiation? Chair: Andres Maria Poveda Velasco, ES	Hall 404
11:45 - 12:00	Treatment for stage IIB cervical cancer: Surgery or chemoradiation? <u>J.-W. Kim</u> , KR	
12:00 - 12:30	Discussion led by <u>A.M. Poveda Velasco</u> , ES	
11:45 - 12:30	Type: Challenge Your Expert session Title: Management of early breast cancer in young women Chair: Binghe Xu, CN	Hall 407
11:45 - 12:00	Management of early breast cancer in young women <u>L. Del Mastro</u> , IT	
12:00 - 12:30	Discussion led by <u>B. Xu</u> , CN	
11:45 - 12:30	Type: Challenge Your Expert session Title: Skull base tumours Chair: Lisa Licitra, IT	Room 324
11:45 - 12:00	Skull base tumours <u>P. Pai</u> , IN	
12:00 - 12:30	Discussion led by <u>L. Licitra</u> , IT	
11:45 - 12:30	Type: Challenge Your Expert session Title: What is the optimal first-line chemotherapy for advanced soft-tissue sarcoma? Chair: Herbert Loong, HK	Room 311
11:45 - 12:00	What is the optimal first-line chemotherapy for advanced soft-tissue sarcoma? <u>A. Le Cesne</u> , CEDEX/FR	
12:00 - 12:30	Discussion led by <u>H. Loong</u> , HK	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 405

12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 404
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 407
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Room 324
12:45 - 14:15	Type: ESMO Colloquium Title: ESMO COLLOQUIUM - Immunotherapy of lung cancer: Alone or in combination?	Room 311

- 12:45 - 12:50 **Introduction**
T. Mitsudomi, JP
- 12:50 - 13:10 **1st line immunotherapy options for patients without an oncogene driver**
R. Soo, SG
- 13:10 - 13:30 **What is the biological rationale for combining chemotherapy with immune checkpoints inhibitors?**
M. Garassino, IT
- 13:30 - 13:50 **Are ICPs better as single agent, doublet ICPs or combined with Chemo +/- anti-angiogenics?**
S. Peters, CH
- 13:50 - 14:10 **What's new in the guidelines for immune therapy of metastatic NSCLC?**
D. Planchard, FR
- 14:10 - 14:15 **Conclusions**
T. Mitsudomi, JP

14:30 - 16:00 **Type: Educational session** **Hall 405**
Title: Controversies in lung cancer immuno-oncology
 Chair: Raffaele Califano, GB; Ross Soo, SG

14:30 - 14:55 **Immuno checkpoint blockade for advanced NSCLC: What is the role in the elderly and patients with PS2?**
R. Califano, GB

14:55 - 15:20 **Immuno checkpoint blockade for oncogene-addicted NSCLC**
R. Soo, SG

15:20 - 15:45 **Immuno checkpoint blockade in patients with brain metastases**
S. Ekman, SE

15:45 - 16:00 **Discussion**

14:30 - 16:00 **Type: Educational session** **Hall 404**
Title: Immunotherapy in GI cancers: Current status & future perspectives
 Chair: Claus-Henning Koehne, DE; Yung-Jue Bang, KR

14:30 - 14:45 **Biomarkers for immunotherapy**
B. Ma, HK

14:45 - 15:05 **Immunotherapy in gastric cancer**
Y.-J. Bang, KR

15:05 - 15:25 **Immunotherapy in hepatocellular carcinoma (HCC)**
T. Okusaka, JP

15:25 - 15:45 **Immunotherapy in other GI cancers**
C.-H. Koehne, DE

15:45 - 16:00 **Discussion**

14:30 - 16:00 Type: Proffered Paper session Hall 407
Title: Proffered Paper session 1

- 14:30 - 14:42 **390 - Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized Phase III MONALEESA-7 study**
S.-A. Im¹, J. Sohn¹, D. Tripathy², L. Chow³, K.S. Lee¹, K.H. Jung¹, G. Babu⁴, Y.-H. Im¹, N. El Saghir⁵, M.-C. Liu⁶, I. Diaz-Padilla⁷, J. Alam⁸, O. Kong⁸, M. Miller⁸, Y.-S. Lu⁶; ¹KR, ²TX/US, ³HK, ⁴IN, ⁵LB, ⁶TW, ⁷CH, ⁸NJ/US
- 14:42 - 14:52 **Invited discussant**
M. Toi, JP
- 14:52 - 15:04 **690 - Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach**
D.S.W. Tan¹, U. Lassen², C. Albert³, S. Kummar⁴, C. van Tilburg⁵, S. Dubois⁶, B. Georger⁷, L. Mascarenhas⁸, N. Federman⁸, A. Basu-Mallick⁹, F. Doz⁷, J. Berlin¹⁰, D.-Y. Oh¹¹, S. Bielack⁵, R. McDermott¹², S. Cruickshank⁸, N. Ku⁸, M. Cox⁸, A. Drilon¹³, D. Hong¹⁴; ¹SG, ²DK, ³WA/US, ⁴US, ⁵DE, ⁶MA/US, ⁷FR, ⁸CA/US, ⁹PA/US, ¹⁰TN/US, ¹¹KR, ¹²Belgard Square North/IE, ¹³NY/US, ¹⁴TX/US
- 15:04 - 15:16 **LBA4 - Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001**
G.D. Demetri¹, L. Paz-Ares², A. Farago³, S.V. Liu³, S. Chawla⁴, D. Tosi³, E. Kim⁵, C. Blakely⁴, J. Krauss⁶, D. Sigal⁴, L. Bazhenova⁴, T. John⁷, B. Besse⁸, J. Wolf⁹, T. Seto¹⁰, E. Chow-Maneval⁴, P. Multani⁴, A. Johnson⁴, B. Simmons³, R. Doebele¹¹; ¹GB, ²ES, ³US, ⁴CA/US, ⁵NC/US, ⁶MI/US, ⁷AU, ⁸CEDEX/FR, ⁹DE, ¹⁰Fukuoka/JP, ¹¹CO/US
- 15:16 - 15:31 **Invited discussant**
T. Yap, Surrey/US
- 15:31 - 15:43 **2520 - MMR deficiency(d) in an unselected cohort of endometrial cancer (EC) patients, the Royal Marsden experience**
C. Orbegoso Aguilar, K. Vroobel, A. Attygalle, S. Lalondrelle, A. Taylor, M. Nobbenhuis, S. Banerjee, A. George; GB
- 15:43 - 15:53 **Invited discussant**
C. Scott, AU

14:30 - 16:00 **Type: Special Session** **Room 324**
Title: Skin toxicity
Chair: Carsten Bokemeyer, DE

- 14:30 - 14:35 **Introduction**
C. Bokemeyer, DE
- 14:35 - 14:55 **Hair loss and management**
F. Boyle, AU
- 14:55 - 15:15 **EGFR associated skin toxicities**
C. Bokemeyer, DE
- 15:15 - 15:35 **Immuno-related skin reactions**
- 15:35 - 15:55 **Hand-foot syndrome**
Y.S. Yap, SG
- 15:55 - 16:00 **Conclusion**

14:30 - 16:00 **Type: Special Session** **Room 311**
Title: Controversial cases of melanomas and sarcomas
Chair: Axel Le Cesne, FR; Akira Kawai, JP; Richard Quek, SG

- 14:30 - 14:35 **Presentation of case/condition**
A. Le Cesne, CEDEX/FR
- 14:35 - 14:55 **A 32-year old woman presenting with a large right thigh mass (high risk synovial sarcoma)**
A. Kawai, JP
- 14:55 - 15:15 **A 32-year old man presenting with gastrointestinal bleeding (intra-abdominal clear cell sarcoma)**
A. Le Cesne, CEDEX/FR
- 15:15 - 15:35 **A 32-years old man with an acral lentiginous melanoma of the big toe with popliteal lymph node involvement**
R. Quek, SG
- 15:35 - 16:00 **General discussion**

14:30 - 16:00 **Type: Educational session** **Room 310**
Title: The challenges of cancer care in low and middle-income countries
 Chair: Soe Aung, MM

14:30 - 14:55 **Education and training in low and middle-income countries: How can ESMO foster regional collaboration among Asian regional institutions?**
K. Sharma, IN

14:55 - 15:20 **How to build capacity to perform clinical trials and cancer research in LMICs**
B. Gyawali, Aichi/US

15:20 - 15:45 **Strategies for managing cancer treatment and palliative care with limited resources**
G.S. Bhattacharyya, West Bengal/IN

15:45 - 16:00 **General discussion**

16:00 - 16:30 **Type: Young Oncologist session** **Exhibition area**
Title: Meet your mentor

16:30 - 18:00 **Type: Multidisciplinary tumour board** **Hall 405**
Title: Recurrent cervical cancer
 Chair: Keiichi Fujiwara, JP; Jae-Weon Kim, KR

16:30 - 16:40 **Presentation of case of recurrent cervical cancer**
J.-W. Kim, KR

16:40 - 17:00 **Prognostic and predictive factors including human papillomavirus (HPV)**
H.Y.-S. Ngan, HK

17:00 - 17:20 **Surgical considerations**
M.-C. Lim, KR

17:20 - 17:40 **Advances in systemic therapy**
A. Oaknin, ES

17:40 - 18:00 **General discussion and conclusions**
K. Fujiwara, JP

16:30 - 18:00 **Type: ESMO Colloquium** **Hall 404**
Title: ESMO COLLOQUIUM - Oncology biosimilars in Asia

- 16:30 - 16:35 **Introduction**
J. Taberbero, ES
- 16:35 - 16:45 **Existing challenges for uptake of oncology biosimilars in Asia**
J. Taberbero, ES
- 16:45 - 17:00 **ESMO survey on biosimilars in oncology - results**
M. Vyas, BE
- 17:00 - 17:15 **India: Tackling the rising demand for medicines with locally developed biosimilars**
G.S. Bhattacharyya, West Bengal/IN
- 17:15 - 17:30 **One year on - state of play in the APAC region on oncology biosimilars**
S. Magaz, SG
- 17:30 - 17:50 **Panel Discussion with industry representatives**
- 17:50 - 17:55 **Conclusions**
J. Taberbero, ES

16:30 - 18:00 **Type: Proffered Paper session** **Hall 407**
Title: Proffered Paper session 2

- 16:30 - 16:45 **LBA7 - Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)**
M. Hochmair¹, A. Morabito², D. Hao³, C.-T. Yang⁴, R. Soo⁵, J. Yang⁴, R. Gucalp⁶, B. Halmos⁶, L. Wang⁴, A. Golembesky⁷, A. Märten⁷, T. Cufer⁸; ¹AT, ²IT, ³AB/CA, ⁴TW, ⁵SG, ⁶AL/US, ⁷DE, ⁸SI
- 16:45 - 17:00 **LBA8 - Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study**
B.C. Cho¹, Y. Cheng², C. Zhou³, Y. Ohe⁴, F. Imamura⁴, M.-C. Lin⁵, M. Majem⁶, R. Shah⁷, Y. Rukazenkov⁸, A. Todd⁸, A. Markovets⁹, C. Barrett⁹, J. Chmielecki⁹, J. Gray¹⁰, S. Ramalingam¹¹; ¹KR, ²Jilin/CN, ³CN, ⁴JP, ⁵TW, ⁶ES, ⁷Kent/GB, ⁸GB, ⁹ME/US, ¹⁰FL/US, ¹¹US
- 17:00 - 17:15 **Invited discussant**
S. Ekman, SE
- 17:15 - 17:30 **LBA9 - IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations**
T.S.K. Mok¹, M. Socinski², M. Reck³, R. Jotte², D. Lim⁴, F. Cappuzzo⁵, F.J. Orlandi⁶, D. Stroyakovskiy⁷, N. Nogami⁸, D. Rodríguez-Abreu⁹, D. Moro-Siblot¹⁰, C. Thomas¹¹, F. Barlesi¹², G. Finley¹³, A. Lee¹⁴, G. Shankar², W. Yu², M. Kowanetz², W. Lin², M. Nishio⁸; ¹HK, ²US, ³DE, ⁴SG, ⁵IT, ⁶CL, ⁷Krasnogorski District/RU, ⁸JP, ⁹ES, ¹⁰FR, ¹¹ME/US, ¹²CEDEX 20/FR, ¹³PA/US, ¹⁴CA/US
- 17:30 - 17:40 **Invited discussant**
S. Lu, CN
- 17:40 - 17:55 **5470 - Stereotactic Ablative Radiotherapy for oligometastatic cancers: Efficacy and Toxicity Results from the randomized SABR-COMET Trial**
S. Senan¹, R. Olson², S. Harrow³, S. Gaede⁴, A. Louie⁴, C. Haasbeek¹, L. Mulroy⁵, M. Lock⁴, G. Rodrigues⁴, B. Yaremko⁴, D. Schellenberg⁵, B. Ahmad⁴, G. Griffioen¹, S. Senthil⁶, M. Liu⁷, K. Moore³, S. Currie³, G. Bauman⁴, A. Warner⁴, D. Palma⁴; ¹NL, ²BC/CA, ³GB, ⁴ON/CA, ⁵AB/CA, ⁶ACT/AU, ⁷CA
- 17:55 - 18:05 **Invited discussant**
M.L.K. Chua, SG

16:30 - 18:00 **Type: Educational session** **Room 324**
Title: Rational development of immuno-oncology combinations
 Chair: Daniel Shao Weng Tan, SG

16:30 - 16:55 **Non-clinical models (including immunoavatars) for development of immuno-oncology combinations**

R. Stripecke, DE

16:55 - 17:20 **Lessons learned from immuno-oncology combinations in the clinic**

T. Yap, Surrey/US

17:20 - 17:45 **Clinical trial designs, biomarkers and endpoints for immuno-oncology combinations**

S.-B. Kim, KR

17:45 - 18:00 **Cancer evolution and immuno escape**

N. McGranahan, GB

16:30 - 18:00 **Type: Multidisciplinary tumour board** **Room 311**
Title: Oligometastatic prostate cancer
 Chair: Ravindran Kanesvaran, SG; Shigeo Horie, JP; Ji Youl Lee, KR; Yuji Miura, JP

16:30 - 16:35 **Presentation of case/condition**

S. Horie, JP

16:35 - 16:55 **Cutting edge science of oligometastatic**

R. Kanesvaran, SG

16:55 - 17:15 **Role of surgery in oligometastatic prostate cancer**

J.Y. Lee, KR

17:15 - 17:35 **ADT and chemotherapy in oligometastatic prostate cancer**

Y. Miura, JP

17:35 - 18:00 **Discussion**

16:30 - 17:30	Type: Special Session Title: Caring for AYA with cancer in Europe and Asia: Different challenges, same Goals Chair: Jean-Yves Douillard, CH; Chi-kong Li, CN	Room 310
16:30 - 16:35	Introduction <u>J.-Y. Douillard</u> , CH	
16:35 - 16:50	The current situation in Europe: Challenges and opportunities <u>G. Mountzios</u> , GR	
16:50 - 17:05	The current situation in Asia: Challenges and opportunities <u>C.-K. Li</u> , CN	
17:05 - 17:25	Results of the Joint ESMO/SIOPE/SIOP Asia survey on AYA with cancer <u>R. Dalvi</u> , IN	
17:25 - 17:30	Conclusions <u>C.-K. Li</u> , CN	

24-11-2018

09:00 - 10:30 **Type: Educational session** **Hall 405**
Title: Impact of germline genetics on current care of breast cancer
 Chair: Suzette Delaloge, FR; Giuseppe Curigliano, IT

09:00 - 09:25 **Landscape of somatic and germline mutation in patients with breast cancer in Asia**
P. Yuan, CN

09:25 - 09:50 **Management of patients with BRCA1 and BRCA2 mutated early breast cancer**
S. Delaloge, FR

09:50 - 10:15 **Targeting BRCA mutations and BRCAness in patients with metastatic breast cancer: Evidences from clinical trials**
Y.-H. Im, KR

10:15 - 10:30 **Discussion**

09:00 - 10:30 **Type: ESMO Clinical Practice Guidelines session** **Hall 406**
Title: ESMO Clinical Practice Guidelines
 Chair: George Pentheroudakis, GR; Andrés Cervantes, ES

09:00 - 09:05 **Introduction**
G. Pentheroudakis, GR

09:05 - 09:25 **Hepatoma Case Presentation**
C.-H. Koehne, DE

09:25 - 09:45 **Hepatoma Case Discussion**
S.P. Choo, SG

09:45 - 10:05 **BRCA-related cancer syndromes: prevention, follow up, counselling Case Presentation**
A. Trainer, AU

10:05 - 10:25 **BRCA-related cancer syndromes: prevention, follow up, counselling Case Discussion**
S.Y. Yoon, MY

10:25 - 10:30 **Conclusions**
A. Cervantes, ES

09:00 - 10:30 **Type: Multidisciplinary tumour board** **Hall 407**
Title: Challenges in the management of ALK positive stage III NSCLC
Chair: Benjamin Solomon, AU; Suresh Senan, NL; Masahiro Tsuboi, JP

- 09:00 - 09:05 **Presentation of case/condition**
B. Solomon, VIC/AU
- 09:05 - 09:25 **Medical oncologist's perspective**
B. Solomon, VIC/AU
- 09:25 - 09:45 **Radiation oncologist's perspective**
S. Senan, NL
- 09:45 - 10:05 **Thoracic surgeon's perspective**
M. Tsuboi, Chiba/JP
- 10:05 - 10:30 **Discussion**

09:00 - 10:30 **Type: Young Oncologist session** **Room 324**
Title: Unusual challenges in clinical oncology: case discussions
Chair: Susana Banerjee, GB; Guillem Argilés Martinez, ES

09:00 - 09:05 **Introduction**

09:05 - 09:10 **YO1 - Pulmonary Metastases From Anaplastic Meningioma Presenting with Non-Islet-Cell Tumour Hypoglycemia (NICTH) : A Case Report**

N. Salimin¹, G.F. Ho²; ¹MY, ²Wilayah Persukutuan/MY

09:10 - 09:20 **Q&A**

09:20 - 09:25 **YO2 - Response to panitumumb monotherapy in patient with metastatic colorectal cancer harbouring novel KRAS p.A59T and NRAS p.A59T missense substitutions**

R. Tan, S.J. Ong, M.H. Tan, M. Ng; SG

09:25 - 09:35 **Q&A**

09:35 - 09:40 **YO3 - Hyperprogression after Immunotherapy in Non-clear cell RCC patient**

T. Ruchakorn, TH

09:40 - 09:50 **Q&A**

09:50 - 09:55 **Summary**

09:00 - 09:45	Type: Mini Oral session Title: Mini Oral - Supportive and palliative care	Room 311
	Chair: Kirsty Lee, HK; Carsten Bokemeyer, DE	
09:00 - 09:05	3580 - Evaluation Of Functional Decline In Elderly Breast Cancer Patients Receiving First Line Chemotherapy <u>Y. Khamis</u> , A. Darwish, N. Lotfy, S. Abou-Raya, S.-E. Abdelmoneim; EG	
09:05 - 09:10	4200 - The rate of Hepatitis B virus screening before systemic anticancer therapy among patients in Japan <u>S. Yazaki</u> , T. Yamauchi, T. Higashi; JP	
09:10 - 09:15	4210 - Assessment and comparison of CISNE model versus MASCC model in clinically stable febrile neutropenia patients <u>D. Koppaka</u> ¹ , L.C. Kuntegowdanahalli ² , D. Lokanath ¹ , K. Govind Babu ¹ , L. Jacob ¹ , M. Suresh Babu ¹ , K.N. Lokesh ² , A. Rudresha ² , L. Rajeev ¹ , S. Smitha ¹ , A. Anand ¹ , V. Asati ¹ , R. Chethan ¹ , R. Patidar ¹ , T. Chaudhuri ¹ , A. Kasturi ¹ ; ¹ IN, ² Karnatka/IN	
09:15 - 09:20	4220 - A prospective phase III randomized study to evaluate the efficacy of olanzapine for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC). <u>J. PEHALAJANI</u> ¹ , K. Govind Babu ¹ , D. Lokanatha ¹ , L. Jacob ¹ , M. Suresh Babu ¹ , K.N. Lokesh ² , A. Rudresha ² , L. Rajeev ¹ , S. Smitha ¹ , G. Giri ¹ ; ¹ IN, ² Karnatka/IN	
09:20 - 09:25	4230 - Study of Psycho-social Profile of Caregivers In Teenage and Young Adult (TYA) Cancer Patients: Indian Perspective <u>D. Yadlapalli</u> ¹ , P. Chitalkar ² , A. Punia ¹ , S. Runu ¹ , B. Ankit ¹ ; ¹ IN, ² MP/IN	
09:25 - 09:45	Discussion <u>K. Lee</u> ¹ , <u>C. Bokemeyer</u> ² ; ¹ NSW/HK, ² DE	

- 09:00 - 09:45** **Type: Mini Oral session** **Room 310**
Title: Mini Oral - Public policy
Chair: Deme Karikios, AU; Bishal Gyawali, US
- 09:00 - 09:05 **3960 - A multi-center, randomized, double-blind, parallel, two-group Phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer**
B. Han, K. Li, T. Chu, M. Bi, H. Zhang, Y. Yu, J. Shi, X. Zhang, Z. Chen, C. Han, T. Bai; CN
- 09:05 - 09:10 **3970 - Adolescents and Young Adults with Cancer Care in Asia: The Joint ESMO/SIOPE/SIOP ASIA survey**
R. Dalvi¹, C.-K. Li², K. Yonemori³, H. Ariffin⁴, C.J. Lyu⁵, M. Farid⁶, J.R.N. Gonzales-Santos⁷, Q. Zhou², S. Bielack⁸, L. Brugieres⁹, A. Blondeel¹⁰, S. Essiaf¹⁰, F. Peccatori¹¹, S. Jezdic¹², D. Stark¹³, J.-Y. Douillard¹², E. Saloustros¹⁴, G. Mountzios¹⁴; ¹IN, ²CN, ³JP, ⁴MY, ⁵KR, ⁶SG, ⁷PH, ⁸DE, ⁹FR, ¹⁰BE, ¹¹IT, ¹²CH, ¹³GB, ¹⁴GR
- 09:10 - 09:15 **3980 - The Prevalence of Breast Tumor: An Indonesia Non Communicable Disease Survey**
S. Idaiani, D. Delima; ID
- 09:15 - 09:20 **3990 - Analysis of the Current Status of Multidisciplinary Team (MDT) Care for Cancer Patients in Korea**
C.H. Maeng, H.K. Ahn, S.Y. Oh, B.-S. Kim, S. Lim, D.Y. Kim; KR
- 09:20 - 09:40 **Discussion**
D. Karikios¹, B. Gyawali²; ¹NSW/AU, ²Aichi/US

- 09:55 - 10:45** **Type: Mini Oral session** **Room 311**
Title: Mini Oral - Gastrointestinal tumours
Chair: David Goldstein, AU; Brigette Ma, HK
- 09:55 - 10:00 **870 - mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Analysis from two prospective trials**
J. Zhang, H. Hu, Z. Wu, Y. Cai, J. Ling, J. Xiao, Y.-H. Deng; CN
- 10:00 - 10:05 **880 - Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial**
R. Xu¹, K. Muro², T.W. Kim³, Y.S. Park³, W. Wang⁴, S.-W. Han³, M. Kotaka⁵, Y.-H. Deng⁴, J.B. Ahn³, M. Nakamura⁶, Y. Ba⁴, S.-H. Cho³, T. Kato⁶, T. Zhang⁴, K.-W. Lee³, H. Matsuoka⁶, W.-J. Fang⁴, S. Morita⁶, S. Iwasa⁶, S. Junichi⁶; ¹Guangdong/CN, ²Aichi/JP, ³KR, ⁴CN, ⁵Hyogo/JP, ⁶JP
- 10:05 - 10:15 **Discussion**
D. Goldstein, NSW/AU
- 10:15 - 10:20 **1530 - M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF- β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype**
C. Yoo¹, D.-Y. Oh², H.J. Choi², M. Kudo³, M. Ueno³, S. Kondo³, L.-T. Chen⁴, M. Osada³, C. Helwig⁵, I. Dussault⁶, M. Ikeda³; ¹Songpa-gu/KR, ²KR, ³JP, ⁴TW, ⁵DE, ⁶MA/US
- 10:20 - 10:25 **1540 - Atezolizumab monotherapy in Chinese patients with locally advanced or metastatic solid tumours**
L. Shen, L. Zhang, X. Hu, H. Pan, T. Liu, Y. Bai, Y.-C. Chen, J. Huang, T. Xu, W. Hsu, J. Shi; CN
- 10:25 - 10:30 **1550 - Efficacy of TAS-120, an Irreversible Fibroblast Growth Factor Receptor Inhibitor (FGFRi), in Patients With Cholangiocarcinoma and FGFR Pathway Alterations Previously Treated With Chemotherapy and Other FGFRi's**
B. Tran¹, F. Meric-Bernstam², H.-T. Arkenau³, R. Bahleda⁴, R. Kelley⁵, C. Hierro⁶, D. Ahn⁷, A. Zhu⁷, M. Javle², R. Winkler⁸, H. He⁹, J. Huang⁹, L. Goyal¹⁰; ¹AU, ²TX/US, ³GB, ⁴FR, ⁵CA/US, ⁶ES, ⁷US, ⁸AL/US, ⁹NJ/US, ¹⁰MA/US
- 10:30 - 10:45 **Discussion**
B. Ma, HK

09:55 - 10:50 **Type: Mini Oral session** **Room 310**

Title: Mini Oral - Developmental and precision medicine

Chair: Miguel Quintela-Fandino, ES; Daniel Shao Weng Tan, SG; Timothy Yap, US; Nicholas McGranahan, GB

- 09:55 - 10:00 **700 - Relationships between lenvatinib plasma concentration and toxicity in Japanese cancer patients**
R. Makihara, S. Narita, N. Yamamoto, J. Sato, S. Murakami, Y. Goto, S. Kanda, Y. Fujiwara, H. Horinouchi, T. Tsukamoto, H. Hashimoto, Y. Makino, Y. Ohe, M. Yamaguchi; JP
- 10:00 - 10:05 **710 - Phase 1 extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours.**
D. Tan¹, M. Ng¹, V. Subbiah², W. Messersmith³, V. Teneggi⁴, V. Diermayr¹, K. Ethirajulu¹, P. Yeo¹, B.H. Gan¹, L.H. Lee¹, S. Blanchard¹, R. Nellore¹, M. Yasin¹, D. Umrani¹, M.A. Lee¹, J. Hill¹, B. Madan¹, D. Virshup¹, A. Matter¹; ¹SG, ²TX/US, ³CO/US, ⁴Singapore/SG
- 10:05 - 10:10 **720 - Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): safety, efficacy and biomarkers.**
M. Quintela-Fandino¹, L. Manso Sánchez¹, E. Holgado Martín¹, M. Moreno¹, S. Morales Murillo², B. Bermejo De Las Heras³, D. Malon Gimenez¹, R. Colomer Bosch¹, L. Gonzalez Cortijo⁴, J. Hornedo¹, S. Mouron¹, M. Muñoz¹, S. Escudero¹, R. Blanco¹, S. Mañes¹; ¹ES, ²NA, ³Valencia/ES, ⁴Madrid/ES
- 10:10 - 10:20 **Discussion**
D.S.W. Tan¹, T. Yap²; ¹SG, ²Surrey/US
- 10:20 - 10:25 **3670 - Parallel identification and profiling of tumour antigen-specific T cells for biomarker discovery by mass cytometry**
F. Michael, E. Newell; SG
- 10:25 - 10:30 **3680 - Tumor mutation index as biomarker for responsive stratification on multi-targeted TKI Anlotinib: an ALTER-0303 companion diagnostic study**
J. Lu, W. Zhang, B. Yan, H. Li, L. Zhang, Y. Dong, J. Qian, S. Wang, B. Zhang, J. Wu, X. Zhao, Y. Zhao, B. Han; CN
- 10:30 - 10:35 **3690 - Biomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Ph2 umbrella trial in China (CTONG1505)**
Q. Zhou¹, X.-C. Zhang², H.-Y. Tu², B. Gan², B.-C. Wang², C.-R. Xu², H.-J. Chen², M.-Y. Zheng², Z. Wang², X.-Y. Bai², Y.-L. Sun², A. Myers², X. Lv², Y. Chakraborti³, S. Zhao², J.-J. Yang², Y.-L. Wu²; ¹Guangdong/CN, ²CN, ³IN
- 10:35 - 10:45 **Discussion**
M. Quintela-Fandino¹, N. McGranahan²; ¹ES, ²GB

10:30 - 11:00	Type: Young Oncologist session Title: Meet your mentor	Exhibition area
11:00 - 12:30	Type: Proffered Paper session Title: Presidential Symposium Chair: Josep Taberero, ES; Andrés Cervantes, ES	Hall 406
11:00 - 11:15	LBA1 - IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) <u>T.S.K. Mok</u> ¹ , M. Reck ² , L. Horn ³ , S. Lam ⁴ , D. Shames ⁴ , J. Liu ⁵ , F. Kabbinavar ⁴ , W. Lin ⁴ , A. Sandler ⁶ , S. Liu ⁷ ; ¹ HK, ² DE, ³ TN/US, ⁴ US, ⁵ CN, ⁶ OR/US, ⁷ DC/US	
11:15 - 11:30	Invited discussant <u>P. Garrido Lopez</u> , ES	
11:30 - 11:45	LBA2 - Primary results of ALESIA: phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC) <u>C. Zhou</u> ¹ , Y. Lu ² , S.-W. Kim ³ , T. Reungwetwattana ⁴ , J. Zhou ¹ , Y. Zhang ¹ , J. He ¹ , J.-J. Yang ¹ , Y. Cheng ⁵ , S.H. Lee ³ , L. Bu ¹ , T. Xu ¹ , L. Yang ¹ , C. Wang ¹ , P. Morcos ⁶ , E. Mitry ⁷ , Z. Li ⁸ ; ¹ CN, ² Sichuan/CN, ³ KR, ⁴ TH, ⁵ Jilin/CN, ⁶ NY/US, ⁷ CH, ⁸ Guangdong/CN	
11:45 - 12:00	Invited discussant <u>R. Soo</u> , SG	
12:00 - 12:15	LBA3 - Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial <u>M. Friedlander</u> ¹ , K. Moore ² , N. Colombo ³ , G. Scambia ³ , B.-G. Kim ⁴ , A. Oaknin ⁵ , A. Lisyanskaya ⁶ , A. Floquet ⁷ , A. Leary ⁸ , G. Sonke ⁹ , C. Gourley ¹⁰ , S. Banerjee ¹⁰ , A. Oza ¹¹ , A. González-Martín ⁵ , C. Aghajanian ¹² , W. Bradley ¹³ , E. Lowe ¹⁴ , R. Bloomfield ¹⁰ , P. Disilvestro ¹⁵ ; ¹ NSW/AU, ² US, ³ IT, ⁴ KR, ⁵ ES, ⁶ RU, ⁷ CEDEX/FR, ⁸ FR, ⁹ NL, ¹⁰ GB, ¹¹ Ontario/CA, ¹² NY/US, ¹³ WI/US, ¹⁴ MD/US, ¹⁵ RI/US	
12:15 - 12:30	Invited discussant <u>A.M. Poveda Velasco</u> , ES	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 405
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 404
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 407

12:45 - 14:15 **Type: ESMO Colloquium** **Room 324**
Title: ESMO COLLOQUIUM - Updated therapeutic approach of castration-resistant prostate cancer

12:45 - 12:50 **Welcome introduction**

R. de Wit, NL

12:50 - 13:05 **Definition and peculiarities of CRPC: M0 vs M1**

M. De Santis, DE

13:05 - 13:20 **Chemotherapy in mCRPC: Is it still relevant?**

B. Tran, AU

13:20 - 13:35 **Hormonal therapies in mCRPC: Where are we now?**

R. de Wit, NL

13:35 - 13:50 **Is there an optimal sequencing strategy in mCRPC?**

M. De Santis, DE

13:50 - 14:05 **Immunotherapy in mCRPC: Moving beyond Sip-T**

T. Powles, GB

14:05 - 14:15 **Conclusion and wrap up**

B. Tran, AU

12:45 - 14:15 **Type: Industry Satellite Symposium** **Room 311**
Title: Industry Satellite Symposium

14:30 - 16:00 **Type: Educational session** **Hall 405**
Title: Latest developments in urological cancers

Chair: Ronald de Wit, NL

14:30 - 14:55 **Metastatic prostate cancer: Optimal use of the currently available agents**

R. de Wit, NL

14:55 - 15:20 **Renal cell cancer: Optimising systemic treatment in an era of emerging treatment paradigms**

M. Lolkema, NL

15:20 - 15:45 **Integration of immunotherapy in bladder cancer: Who and when to treat?**

M. De Santis, DE

15:45 - 16:00 **Discussion**

14:30 - 16:00 **Type: Joint Symposium** **Hall 404**
Title: ESMO-AACR: PD1/PDL1: From discovery to clinical use
 Chair: Solange Peters, CH; Thomas Powles, GB

14:30 - 14:35 **Introduction**
T. Powles, GB

14:35 - 14:55 **Discovery of immune checkpoint as a mechanism of immune suppression**
P. Romero, CH

14:55 - 15:15 **Predictive biomarker of efficacy for the use of immune checkpoint inhibitors**
T. Powles, GB

15:15 - 15:35 **Development in the use of immune checkpoint inhibitors: Lung cancer as a paradigm shift**
S. Peters, CH

15:35 - 15:55 **Should immune checkpoint inhibitors be considered as agnostic drugs?**
J. Larkin, GB

15:55 - 16:00 **Conclusions**
S. Peters, CH

14:30 - 16:00 **Type: Multidisciplinary tumour board** **Hall 407**
Title: Multidisciplinary approach to resectable gastric cancer
 Chair: Florian Lordick, DE; Masanori Terashima, JP

14:30 - 14:35 **Presentation of case/condition**
F. Lordick, DE

14:35 - 14:55 **Surgical treatment perspectives**
M. Terashima, Shizuoka/JP

14:55 - 15:15 **Medical oncology perspectives**
S.P. Choo, SG

15:15 - 15:35 **Is there a role for radiotherapy?**
T. Leong, AU

15:35 - 16:00 **General discussion**

14:30 - 16:00 **Type: Multidisciplinary tumour board** **Room 324**
Title: Issues for cancer care in the elderly
Chair: Dorothy Keefe, AU; Christopher Steer, AU

14:30 - 14:40 **Case presentation**

U. Wedding, DE

14:40 - 15:00 **Assessment by onco-geriatrician**

U. Wedding, DE

15:00 - 15:20 **Balancing between treatment and toxicity**

C. Steer, VIC/AU

15:20 - 15:40 **Managing the financial implication**

D. Keefe, SA/AU

15:40 - 16:00 **Conclusions**

14:30 - 15:15 **Type: Mini Oral session** **Room 311**
Title: Mini Oral - Breast cancer
 Chair: Giuseppe Curigliano, IT; Binghe Xu, CN

14:30 - 14:35 **10 - Differences in Prognosis and Efficacy of Chemotherapy by p53 Expression in Triple Negative Breast Cancer**

S.Y. Bae, S.P. Jung, K.B.C.S. Korean Breast Cancer Society, S.J. Nam, Y. Jung, B.W. Park, W. Lim, S.H. Jung, H.K. Kim, J.-Y. You, S.B. Lee; KR

14:35 - 14:40 **230 - Implications of Plasma Deoxyribonucleic Acid Topoisomerase 2 Beta Level in Breast Cancer Patients receiving Doxorubicin-Based Chemotherapy**

T. Win, T.T. Naing, T.T. Win, K.K. Aung, Y.Y. Htun; MM

14:40 - 14:45 **400 - Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET)**

Y.S. Yap¹, N. Masuda², Y. Ito², T. Ishikawa², S.J. Kim², T. Aruga², T. Toyama², T. Saeki², T. Yamanaka², M. Saito², J. Watanabe², M. Takahashi², S. Nakamura², K. Inoue², J. Suarez-Vizcarra³, W. He³, N. Solovieff³, F. Su³, J. Chiu⁴; ¹SG, ²JP, ³NJ/US, ⁴HK

14:45 - 14:50 **410 - Decreased mortality strongly correlated with the upregulation of BCR in breast cancer metastasis to bone**

S.N. Mai¹, H. Vu¹, X.T. Hoang¹, V.T. Than¹, T. Nguyen², M.T. Le³, P.-L. Luu⁴, H. Tran¹, M.N. Nguyen⁵; ¹VN, ²WA/AU, ³KR, ⁴ACT/AU, ⁵US

14:50 - 15:15 **Discussion led by moderators**

14:30 - 16:00 **Type: Educational session** **Room 310**
Title: The reality of accessing cancer care in Asia and Asia/Pacific
 Chair: Sumittra Thongprasert, TH; Alexandru Eniu, RO

14:30 - 14:55 **Cancer medicines: What is available and is it effective enough?**

A. Eniu, RO

14:55 - 15:20 **Financial toxicity of cancer treatment in Asia and Asia-Pacific**

M. Bertram, CH

15:20 - 15:45 **Strategies to improve accessibility and availability of cancer medicines in LMICs**

S. Thongprasert, Muang/TH

15:45 - 16:00 **Discussion**

15:30 - 16:20	Type: Mini Oral session Title: Mini Oral - Head and neck cancers Chair: Anthony Chan, HK; Joseph Wee, SG	Room 311
15:30 - 15:35	3040 - Relationship of Circulating Tumor Cells to Progression-Free Survival and Tumor Response in Patients with Metastatic Nasopharyngeal Carcinoma: A Prospective Cohort Study R. You ¹ , M. Chen ² , Y.-P. Liu ¹ , Y.-N. Zhang ¹ , P.-Y. Huang ¹ ; ¹ CN, ² Guangdong/CN	
15:35 - 15:40	3050 - Surgery for Isolated Regional Failure in Nasopharyngeal Carcinoma after Radiation: Selective or Comprehensive Neck Dissection L. You-Ping ¹ , R. You ¹ , M. Chen ² , H. Li ¹ ; ¹ CN, ² Guangdong/CN	
15:40 - 15:50	Discussion	
15:50 - 15:55	3070 - Randomized, double-blind, placebo-controlled trial of probiotics to reduce radiation and chemotherapy induced oral mucositis for nasopharyngeal cancer patients C. Jiang, H. Xie, L. Zeng, T. Chen, J. Li; CN	
15:55 - 16:05	Discussion led by moderators	
16:00 - 16:30	Type: Young Oncologist session Title: Meet your mentor	Exhibition area

16:30 - 18:00 **Type: ESMO Clinical Practice Guidelines session** **Hall 405**
Title: Adaptation of ESMO guidelines in Asia
 Chair: Josep Tabernero, ES; Takayuki Yoshino, JP

16:30 - 16:40 **Welcome and Introduction**
T. Yoshino¹, J. Tabernero²; ¹JP, ²ES

16:40 - 16:55 **Case presentation: Metastatic oeso-gastric cancer**
T. Nakajima, JP

16:55 - 17:10 **Pan Asia Adapted metastatic Oeso-Gastric cancer Guidelines: results**
K. Muro, Aichi/JP

17:10 - 17:25 **Case presentation: Metastatic Non-Small Cell Lung Cancer**
H. Sun, CN

17:25 - 17:40 **Pan Asia Adapted metastatic NSCLC cancer Guidelines: results**
Y.-L. Wu, CN

17:40 - 18:00 **The way forward: other ESMO guidelines to adapt in 2019 Perspective and Challenges (panel), moderated by George Pentheroudakis**
G. Pentheroudakis, GR

16:30 - 18:00 **Type: Special Session** **Hall 404**
Title: In collaboration with ATEP: Pulmonary ground glass opacities (GGOs): Emerging challenge, evolving management
 Chair: Tetsuya Mitsudomi, JP

16:30 - 16:45 **GGO Management: Are current guidelines adequate?**
T. Mitsudomi, JP

16:45 - 17:05 **Advances in clinical and molecular profiling of GGOs**

17:05 - 17:25 **Resection of GGOs: Are surgeons being too aggressive ... or not aggressive enough?**
S. Cho, KR

17:25 - 17:45 **Advances in techniques and technologies for GGO surgery**
A.D.L. Sihoe, HK

17:45 - 18:00 **Discussion and Conclusions**

16:30 - 18:00 **Type: Educational session** **Hall 407**
Title: Neurotoxicity: A problem to remember
 Chair: Dorothy Keefe, AU; Kirsty Lee, HK

16:30 - 16:55 **Peripheral neuropathy**
G. Cavaletti, IT

16:55 - 17:20 **Lost in the fog: What is chemobrain?**
F. Boyle, AU

17:20 - 17:45 **Acute central neurotoxicity**
K.A. Griffith, US

17:45 - 18:00 **Discussion**

16:30 - 19:00 **Type: Special Session** **Room 324**
Title: Radiation oncology
 Chair: Françoise Mornex, FR; Suresh Senan, NL

16:30 - 16:42 **Stage III NSCLC and the immuno-oncology paradigm: Immunotherapy**
R. Soo, SG

16:42 - 16:54 **Stage III NSCLC and the immuno-oncology paradigm: Radiotherapy considerations**
F. Mornex, CEDEX/FR

16:54 - 17:00 **Q&A**

17:00 - 17:12 **Approaches towards inoperable HCC: Systemic treatment of HCC**
S.P. Choo, SG

17:12 - 17:24 **Approaches towards inoperable HCC: Role of external beam radiotherapy evidence and comparison with other local treatment**
J. Seong, KR

17:24 - 17:30 **Q&A**

17:30 - 17:42 **Evolving radiotherapy strategies in early-stage breast cancer: The role of surgery and new surgical approaches in early breast cancer**
C.W. Chan, SG

- 17:42 - 17:54 **Evolving radiotherapy strategies in early-stage breast cancer: The role of radiotherapy and new technical approaches**
F. Lim, SG
- 17:54 - 18:00 **Q&A**
- 18:00 - 18:12 **Oesophagus and Oeso-gastric junction carcinomas: Role of systemic treatment**
F. Lordick, DE
- 18:12 - 18:24 **Oesophagus and Oeso-gastric junction carcinomas: The radiation oncologist point of view**
T. Leong, AU
- 18:24 - 18:30 **Q&A**
- 18:30 - 18:42 **Oligometastatic prostate cancer - Management options: Initial neo-adjuvant systemic treatment**
R. Kanesvaran, SG
- 18:42 - 18:54 **Oligometastatic prostate cancer - Management options: The radiation oncologist point of view**
M.L.K. Chua, SG
- 18:54 - 19:00 **Q&A**

- 16:30 - 17:15** **Type: Mini Oral session** **Room 311**
Title: Mini Oral - Genitourinary tumours
Chair: Shigeo Horie, JP; James Larkin, GB
- 16:30 - 16:35 **2120 - United in Fight against prOstate cancer registry (UFO): treatment patterns and quality of life from a large, multi-center, longitudinal cohort study in Asia**
R. Kanavar¹, H. Uemura², D. Ye³, E. Chiong¹, B. Lojanapiwat⁴, Y.-S. Pu⁵, S. Kumar Rawal⁶, A.H.A. Razack⁷, H. Zeng³, B.H. Chung⁸, Y.-S. Tsai⁵, M.Y. Noor Ashani⁷, Y. Liu⁹, M. Asinas-Tan¹, W. Liu³, G.K.M. Low¹, M. van Kooten Losio¹⁰; ¹SG, ²JP, ³CN, ⁴TH, ⁵TW, ⁶IN, ⁷MY, ⁸KR, ⁹NJ/US, ¹⁰ACT/AU
- 16:35 - 16:40 **2130 - Efficacy and Safety of Apalutamide (APA) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN: Asian Subpopulation**
P. Mainwaring¹, E. Small², H. Uemura³, J.Y. Lee⁴, S.-T. Pang⁴, G. Marx¹, T.G. Kwon⁴, T. Satoh³, A. Bhaumik⁵, S. Cheng⁵, A. Londhe⁶, A. Lopez-Gitlitz², M. Smith⁷; ¹ACT/AU, ²CA/US, ³JP, ⁴KR, ⁵NJ/US, ⁶PA/US, ⁷US
- 16:40 - 16:45 **2140 - The change in expression of prostate-specific membrane antigen in circulating tumor cells during treatments for castration-resistant prostate cancer**
N. Nagaya, M. Kanayama, M. Nagata, S. Horie; JP
- 16:45 - 16:50 **2320 - Pharmacokinetics of Cabozantinib in Asian and Non-Asian Populations**
F. Benzagh¹, T.X.Q. Nguyen¹, S. Lacy²; ¹FR, ²CA/US
- 16:50 - 16:55 **2330 - Real World Practice and Outcomes for Metastatic Renal Cell Carcinoma: What Can We Learn from Real World Data Analysis in the US?**
F. Benzagh¹, A. Ren², M. del Pilar Schneider¹, J. Dinet¹, E. Pham¹; ¹FR, ²MA/US
- 16:55 - 17:15 **Discussion led by moderators**

16:30 - 17:30	Type: Special Session Title: Summary of the ESMO-ESGO consensus conference on ovarian cancer Chair: Jae-Weon Kim, KR	Room 310
16:30 - 16:45	The pathology, molecular biology and management of early ovarian cancer <u>S. Banerjee</u> , GB	
16:45 - 17:00	The management of advanced and recurrent ovarian cancer <u>J. Ledermann</u> , London/GB	
17:00 - 17:15	The Asian perspective <u>D. Tan</u> , SG	
17:15 - 17:30	Discussion / Q&A	
17:30 - 18:15	Type: Mini Oral session Title: Mini Oral - Gynaecological cancers Chair: Keiichi Fujiwara, JP; Sudeep Gupta, IN	Room 311
17:30 - 17:35	2530 - Long-term results of treatment of patients with locally advanced cervical cancer after pelvic exenteration <u>N. Zakhirova</u> , M. Tillashaykhov, O. Ahmedov, S. Djanklich, Y. Ten; UZ	
17:35 - 17:40	2540 - Dysgerminoma Ovary : Clinical Features and Treatment Outcome <u>P. Nair</u> , A. Kumar, S. Mathews, J. Joseph, S. Suchetha, J. Krishna, F. James; IN	
17:40 - 17:45	2550 - Achievement of complete response (CR) in metastatic or recurrent cervical cancer (MRCC): Does it matter? <u>J.F. Grau Béjar</u> , V. Rodriguez Freixinos, L. Fariñas Madrid, G. Villacampa, A. Gil, R. Verges, M.A. Perez Benavente, A. García, R. Dienstmann, A. Oaknin; ES	
17:45 - 17:50	2560 - Barriers to early diagnostics of cervical cancer in Uzbekistan <u>V. Saidakhmedova</u> , N. Zakhirova, E. Osmanova, O. Akhmedov, B. Yusupov, S. Djanklich, D. Egamberdiev; UZ	
17:50 - 18:10	Discussion led by moderators	
18:00 - 19:00	Type: Poster Display Title: Poster display - Cocktail	Exhibition area
18:00 - 18:00	Breast cancer, early stage	

- 18:00 - 18:00 **3P - HER2 positive rates in Invasive Lobular Breast Carcinoma : A study amongst 1,095 consecutive Asian patients**
G.J. Kee, R. Tan, R. Sultana, M.W.W. Zaw, W. Lian, K.T.B. Tan, R. Dent, F.Y. Wong, G.E. Lee; SG
- 18:00 - 18:00 **4P - CanAssist-breast -an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: a cost-effective and accurate solution for Asia**
M. Bakre, Karnataka/IN
- 18:00 - 18:00 **5P - Topical silymarin administration for prevention of radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial**
S. Elyasi¹, H. Karbasforushan¹, S. Hosseini², A. Fani Pakdel¹; ¹IR, ²Khorasan Razavi/IR
- 18:00 - 18:00 **6P - Comparison of interstitial brachytherapy with volumetric modulated arc therapy for tumour bed boost following breast conservative surgery**
K. Periasamy, S. Cholayil, G. Karunanithi, K. Dharanipragada, V. Neelakandan; IN
- 18:00 - 18:00 **7P - Triple Negative Breast Cancer and Platinum-based Systemic Treatment: Meta-analysis and Systematic Review**
J.G. Pandey, J. Balolong-Garcia, M.V. Cruz-Ordinario, F.V. Que; PH
- 18:00 - 18:00 **8P - Longitudinal study on incidences of obesity and weight changes in Chinese patients with early-stage breast cancer**
W. Yeo, Y. Lei, A. Cheng, C. Kwok, K. Cheung, R. Lee, I. Lee, Y. He, S. Ho; HK
- 18:00 - 18:00 **9P - Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome in breast cancer indicates endogenous and exogenous interplay**
H. Xie, J. Lövrot, J. Lindh, J. Bergh, S. Sim; SE
- 18:00 - 18:00 **10P - A novel nipple areolar complex involvement predictive index (NACPI) for indicating nipple sparing mastectomy in breast cancer**
H. Seki, T. Sakurai, K. Shimizu; JP
- 18:00 - 18:00 **11P - Multicenter Trial for Safety and Toxicity of Nanoxel®M in Breast Cancer**
T.H. Kim, G. Gwak, M.S. Chung, J.I. Kim, I. Park, E. Um, J.W. Han, A. Lee; KR
- 18:00 - 18:00 **12P - Implication of PET-CT to improve negative predictive value for axillary lymph node metastasis in early breast cancer**
O. Cho, Y.-T. Oh; KR
- 18:00 - 18:00 **13P - Upgrade of Low Grade Ductal Carcinoma in situ (DCIS): multimodality approach in a 10-year single institution study**
A. Chu, J.M. Chang, W.K. Moon; KR

- 18:00 - 18:00 **14P - Correlation between circulating tumor cells and the aromatase inhibitors therapy in postoperative patients with early breast cancer**
Y. Shi, G. Zhang, Y. Wang, C. Ren, L. Wen, L. Guo, N. Liao; CN
- 18:00 - 18:00 **15P - A Pilot Study of Single Pegfilgrastim Compared with Intermittent Every Other Days of 5 Shot-filgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) Chemotherapy (G-CSF 105 trial: NCT02685111)**
J. Jeong, B.S. Sohn, J.-H. Ahn, K.H. Jung, J.E. Kim, J. Oh, H. Lee, J.H. Sohn, S.-J. Koh, J.H. Seo, K.S. Lee, S.-B. Kim; KR
- 18:00 - 18:00 **17P - Painful scalp during chemotherapy induced hair loss is associated to permanent alopecia in breast cancer patients**
N. Mejri, M. Saadi, F. Guermazi, H. El Benna, N. Daoud, S. Labidi, H. Boussen; TN
- 18:00 - 18:00 **18P - Breast cancer survival analysis in East Azerbaijan: five years cancer registry data in Iran**
S. Pashaei¹, R. Dolatkhah¹, Z. Sanaat², P. Jabbaripour¹, G. de Bock³; ¹IR, ²East Azarbaijan/IR, ³NL
- 18:00 - 18:00 **19P - Is sarcopenia associated with increased toxicity of neoadjuvant/adjuvant chemotherapy for breast cancer?**
A. Ueno, K. Yamaguchi, M. Sudo, S. Imai; JP
- 18:00 - 18:00 **20P - A Study on possibility of High Sensitivity C - reactive protein (hs-CRP) and Circulating Interleukin-6 (IL-6) as biomarker in Breast Cancer Patients**
M.S.J.R. Shahi, M. Dey, A. Chowdhury; BD
- 18:00 - 18:00 **21P - Correlation Between Expression of Topoisomerase II Alpha with Ki-67 and Tumor Size in Luminal B-Like Indonesian Breast Cancer Patients**
H. Putri, M. Kristina, D. Widjaja, B. Baskoro, E. Kristiani; ID
- 18:00 - 18:00 **22P - Association of Serum Vitamin D Level and Vitamin D Receptor Polymorphism (Apa 1) And Breast Cancer**
S. Gohar¹, S. Al-Hassanin², B. Montaser², S. Soliman²; ¹Menoufia Governorate/EG, ²EG
- 18:00 - 18:00 **Breast cancer, locally advanced**
- 18:00 - 18:00 **24P - Prognostic Nomograms for Predicting Overall and Cancer-Specific Survival in Breast Cancer Patients Not Achieving Pathological Complete Response After Neoadjuvant Chemotherapy**
J. Lai, Z. Pan, H. Deng, J. Peng, P. Chen, G. Ye, F. Yu, K. Chen, F. Su; CN
- 18:00 - 18:00 **25P - Prognostic Nomogram Based on Lymph Node Ratio to Predict Survival in Node-Positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy**
J. Lai, J. Peng, H. Deng, P. Chen, G. Ye, F. Yu, F. Su, K. Chen, Z. Pan; CN

- 18:00 - 18:00 **26P - Breast tumor associated exosomes mediate loss of antitumor immune response by arresting cytotoxic T cell functions in the tumor microenvironment**
S. Chatterjee, A. Chatterjee, S. Jana, H. Roy, N. Nargis, A. Bhattacharyya; IN
- 18:00 - 18:00 **27P - Hormonal therapy confers clinically relevant benefit in women with low estrogen receptor-positive breast tumor**
T. Zhang, B. Ho, P. Chan, E.Y. Tan; SG
- 18:00 - 18:00 **28P - Breast board comined with a thermoplastic head mask immobilization can improve the reproducibility of the treatment setup for breast cancer patients who received whole breast and supraclavicular nodal region irradiation**
M.W. Ma, S. Wang, S. Qin; CN
- 18:00 - 18:00 **29P - Imaging-proven Venous Thromboembolism Breast Cancer in a Tertiary Hospital in the Philippines**
A.T. Gerona, PH
- 18:00 - 18:00 **30P - Tumor-infiltrating lymphocytes and pathologic complete response among the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) : Single center experience**
J. Ha, J.E. Kim, J.H. Jeong, J.-H. Ahn, K.H. Jung, H.J. Lee, G. Gong, E.Y. Chae, H.H. Kim, I.Y. Chung, B.S. Ko, S.-B. Kim; KR
- 18:00 - 18:00 **31P - PD-L1 expression on circulating monocytes in patients with breast cancer**
M. Nagano, K. Saito, Y. Kozuka, M. Shibusawa, N. Imai, A. Noro, Y. Kageyama, T. Mizuno, T. Ogawa, N. Katayama; JP
- 18:00 - 18:00 **32P - Dosimetric plan evaluation of hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT) and 2-Dimensional (2D) simulator planning in whole breast irradiation after breast conserving surgery**
M. Roy, B. Goswami, S. Goswami, A. Jadhav, S. Agarwal; IN
- 18:00 - 18:00 **33P - IQGAP3 Overexpression Correlates with Poor Prognosis and Radiation Therapy Resistance in Breast Cancer**
H. Lin, X. Hua, Z. Long, W. Zhang, C. Lin, X. Sun, W. Wen, Z. Lu, N. Guo, Z. He, L. Song, L. Guo; CN
- 18:00 - 18:00 **34P - A reliable nomogram for predicting overall survival in patients with triple-negative breast cancer**
M.W. Ma, N. Jing, S. Gao; CN
- 18:00 - 18:00 **35P - Dose distribution in coronary arteries in left-sided breast cancer treated with Radiotherapy**
U. Velu, P. Alurkar; IN

- 18:00 - 18:00 **36P - Metabolic Syndrome in Luminal-Type Non-Metastatic Breast Cancer during Hormonal Treatment Does it really have impact on prognosis?**
K. Taroeno-Hariadi, M. Hardianti, J. Kurnianda, Y. Putra, T. Aryandono; ID
- 18:00 - 18:00 **37P - High Eosinophils Lymphocyte Ratio (ELR) Related With Subtype of Breast Cancer in Sanglah General Hospital, Bali**
A.A. Lestari, I.P. Prabawa, S. Wiranata, I.G.P. Supadmanaba; ID
- 18:00 - 18:00 **YO4 - Breast ecchymotic purpura: a rare presentation of a locally advanced breast carcinoma**
C. Dabiri, K. Wehbe, O. Hu, P. Soibinet Oudot; FR
- 18:00 - 18:00 **Breast cancer, metastatic**
- 18:00 - 18:00 **42P - Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)**
N. Masuda¹, S. Noguchi¹, T. Ishikawa¹, T. Aruga¹, S.J. Kim¹, T. Toyama¹, T. Saeki¹, M. Saito¹, T. Yamanaka¹, J. Watanabe¹, S. Nakamura¹, M. Takahashi¹, K. Inoue¹, I. Gounaris², Y. Han², T. Samant², M. Gazdciu², Y. Ito¹; ¹JP, ²NJ/US
- 18:00 - 18:00 **43P - Osteopontin Level and Promoter Polymorphism is Associated with Aggressiveness in Breast Cancer**
M. Elbaiomy¹, M. El-Ghonemy², R. Elhelaly², R. Elzehery²; ¹Mansura/EG, ²EG
- 18:00 - 18:00 **44P - Global Clinical Trials Validating Bioequivalence with China-Manufactured Trastuzumab Biosimilar, HLX02, and Herceptin®**
Q. Zhang¹, B. Xu¹, Q. Zhang¹, T. Sun¹, W. Li¹, Y. Teng¹, X. Hu¹, I. Bondarenko², H. Adamchuk², L. Zhang¹, D. Trukhin², S. Wang¹, H. Zheng¹, Z. Tong¹, X. Zhang¹, E. Liu¹, W. Jiang¹, S. Liu¹, A. LUK¹; ¹CN, ²UA
- 18:00 - 18:00 **45P - Circular RNA NCAPG promotes breast cancer metastasis through acting as the sponge of miR-200s**
Y. He, J. Tang; CN
- 18:00 - 18:00 **46P - Repeat biopsy a must in recurrent breast cancer: A study from tertiary cancer centre in India.**
A. Anand¹, L. Jacob¹, K.C. Lakshmaiah¹, K. Govind Babu¹, D. Lokanatha¹, M. Suresh Babu¹, K.N. Lokesh², A.H. Rudresha¹, L. Rajeev¹, S. Saldanha¹, G. Giri¹, R. Patidar¹, V. Asati¹, R. Chethan¹, T. Chaudhuri¹, D. Koppaka¹, D. Panwar¹, R. Kumar¹; ¹IN, ²Karnatka/IN
- 18:00 - 18:00 **47P - Meta-analysis of four Phase 3 RCTs of tamoxifen, versus 3rd generation aromatase inhibitors as 1st Line Endocrine Therapy for HR+ Advanced Breast Cancer**

J. Robertson¹, C. Campbell¹, J. Bogaerts², R. Parideans², J. Lichfield¹; 1GB, 2BE

- 18:00 - 18:00 **48P - Estimation of efficacy and safety of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in recurrent or metastatic breast cancer patients**
S.S. Kang, KR
- 18:00 - 18:00 **49P - The adipocyte suppresses the inhibitory role of hsa_circ_0000190 in the metastasis of breast cancer cells**
X. Chen, J. Tang; CN
- 18:00 - 18:00 **50P - CircASS1 suppressed the invasion and metastasis ability of breast cancer cell line by targeting gene ASS1 and harboring miR-4443**
J. Hou, J. Tang; CN
- 18:00 - 18:00 **51P - Ex-vivo drug sensitivity of primary breast cancer stems cell populations to potentiate therapeutic strategy for treatment resistant breast cancer**
S. Nandi, R. Bhattacharya, T. Roychowdhury, U. Roy, S. Chattopadhyay, A. Mukhopadhyay; IN
- 18:00 - 18:00 **52P - Molecular Tumor Board (MTB): development of clinical pathways for precision medicine. Experiences of Center for Breast cancer at National cancer center, Korea**
I.H. Park, C. Park, W. Jang, H. Yang, K. An, Y. Kwon, K.S. Lee, S.H. Sim, S.Y. Kong; KR
- 18:00 - 18:00 **53P - MicroRNA based immune response signature identifies poor prognostic subgroup within ER negative breast cancers**
S. Rajarajan, J. Prabhu, A. Korlimarla, M. Nair, A. Alexander, R. Kaluve, H. Ps, U. Raja, R. Ramesh, S. Patil, S. Bs, S. Ts; IN
- 18:00 - 18:00 **54P - The clinical efficacy of apatinib combined with Xeloda in advanced triple negative breast cancer**
Y. Li, Y. Wang; CN
- 18:00 - 18:00 **55P - Quality of life and psychosocial needs of metastatic breast cancer patients**
T. Mehmood, PK
- 18:00 - 18:00 **56P - TC-1 mediate the TBC1D3 oncogene induced migration of MCF-7 breast cancer cells**
Y. Shen, L. Zhang, H. Zhao, C.-L. Shen; CN
- 18:00 - 18:00 **57P - RelB facilitates cell migration and invasion in breast cancer via MMP1 upregulation**
M. Wang, J. Tang; CN
- 18:00 - 18:00 **58P - Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience**

J. Watanabe¹, S. Nakamoto²; ¹Shizuoka/JP, ²JP

- 18:00 - 18:00 **59P - Proteolysis-Targeting Chimera (PROTAC) Compounds to Degrade S100A4 and Inhibit Breast Cancer Metastasis**
M. Du, G. Wang, T. Ismail, R. Crick, R. Barraclough, B. Daimark, G. Nixon, P. Rudland; GB
- 18:00 - 18:00 **CNS tumours**
- 18:00 - 18:00 **60P - Most clinically approved anti-EGFR antibodies fail to neutralize EGFRvIII, leading to lack of anti-tumour efficacy in high grade glioma**
S. Greenall¹, T. Adams², T. Johns³; ¹AU, ²VIC/AU, ³WA/AU
- 18:00 - 18:00 **61P - Regulation of Programmed cell death 10 (PDCD10) by FAT1 gene in human glioblastoma**
N. Malik, P. Chattopadhyay, C. Sarkar, A. Suri, S. Sinha, K. Chosdol; IN
- 18:00 - 18:00 **62P - Overall survival of elderly glioblastoma patient treated with concurrent chemoradiotherapy: A retrospective review with comparison to non-elderly counterpart**
A. Das, BD
- 18:00 - 18:00 **64P - Association of MTHFR gene polymorphisms with glioma and meningioma patients in Indian population**
R. Kumawat, S. Gowda, E. Debnath, S. Rashid, R. Niwas, A. Suri, C. Sarkar, S. Sinha, K. Chosdol; IN
- 18:00 - 18:00 **66P - A phase II trial of response adapted whole brain radiotherapy after high dose Methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma**
N. Adhikari, A. Biswas; IN
- 18:00 - 18:00 **67P - Association between altered expression of key enzymes involved in kynurenine pathway with clinical outcome in patients with different grades of astrocytoma**
D. Mohania¹, P. Kumar², D. Goyal¹, R. Acharya¹, S. Kalra¹, S. Jain¹, S. Bhalla¹, S. Misra¹, A. Kumar¹; ¹IN, ²AL/US
- 18:00 - 18:00 **68P - Triple intrathecal chemotherapy for leptomeningeal carcinomatosis in solid tumours**
V. Srinivasalu¹, N. Subramaniam¹, A. Philip², W. Jose³, K. Pavithran³; ¹IN, ²Tamil Nadu/IN, ³Kerala/IN
- 18:00 - 18:00 **YO5 - Pleural metastasis from anaplastic meningioma**
T. Patimarattananan, T. Ativitavas; TH

- 18:00 - 18:00 **YO6 - Pituitary and pineal germinoma with peritoneal metastasis**
C. Ngokngarm, C. Bandidwattanawong, A. Suthepwanon, K. Runglodvatana; TH
- 18:00 - 18:00 **YO7 - Pulmonary metastases in recurrent intracranial meningioma: Case Report**
A.A. Sulaiman Shah, F. Ismail; MY
- 18:00 - 18:00 **Developmental therapeutics**
- 18:00 - 18:00 **73P - Ganoderic acids BT-01, a galectin-1 inhibitor, suppresses ovarian cancer growth in humanized mouse xenograft model.**
C.-P. Huang, S.-Y. Chen, H.-H. Lai, Y.-H. Lin, C.-T. Su, S.-J. Wu, C.-H. Chang, C.-C. Tsao, Y.-C. Chen, S.-C. Wang, Y.-H. Liu, S.-B. Lin, T.-H. Chen; TW
- 18:00 - 18:00 **77P - SMA-tDodSNO improves the potency of doxorubicin in breast cancer evidence for the involvement of oxidative stress**
H. Alimoradi¹, A. Barzegarfallah¹, K. Gireshe²; ¹NZ, ²BH
- 18:00 - 18:00 **78P - Selective killing of circulating tumor cells prevents metastasis and extends survival**
Y.R. Kim, J.W. Choi; KR
- 18:00 - 18:00 **79P - CXCR4 antagonist mediated targeting of cancer cells using nanoparticles**
S. Ansari, M. Mudassir, B. Vijayalekshmi, P. Chattopadhyay; IN
- 18:00 - 18:00 **80P - Emodin Sensitizes Ovarian Cancer Cells to Carboplatin through Suppression of Mitochondrial Respiration**
Y. Ge, Y. Chen, W. Wang, D. Wu, F. Cao, X. Zhou, J. Gao, Z. Cao, X. Zheng, W. Li, J. Li; CN
- 18:00 - 18:00 **81P - NKG2D enhances chemosensitivity to cisplatin in patients with extensive small cell lung cancer by up-regulating NF- κ B2**
R. Si, G. Yang, X. Tang; CN
- 18:00 - 18:00 **82P - Anticancer activity of Moringa Oliefera mediated Silver Nanoparticles (AgNps) on Human Lymphocyte Cells**
S. Mahalakshmi, IN
- 18:00 - 18:00 **83P - Phase 1 Investigator's Perceptions to 'Supersized Seamless Trials in Oncology'**
B. Ma¹, N. van der Velden², F. Mo¹, H. Loong¹, L. Siu³, B. Goh⁴, Y.-J. Bang⁵, C.-C. Lin⁶, J. Desai⁷, M. Lolkema²; ¹HK, ²NL, ³Ontario/CA, ⁴SG, ⁵KR, ⁶TW, ⁷VIC/AU
- 18:00 - 18:00 **84P - Real World Experience of adverse events with immunotherapy using PD1 inhibitors- Single center experience from India**
A. Rauthan¹, P. Patil¹, S.P. Somashekhar¹, S. Zaveri²; ¹IN, ²Karnataka/IN

- 18:00 - 18:00 **85TiP - A Phase 1 trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with advanced malignancies, including expansion cohorts for patients with non-small-cell lung cancer**
S. Kitano¹, T. Shimizu¹, T. Koyama¹, T. Ebata¹, S. Iwasa¹, S. Kondo¹, A. Shimomura¹, Y. Fujiwara¹, N. Yamamoto¹, C. Baum², S. Li³, P. Rietschel², T. Sims²; ¹JP, ²NY/US, ³NJ/US
- 18:00 - 18:00 **Gastrointestinal tumours, colorectal**
D. Goldstein, NSW/AU
- 18:00 - 18:00 **89P - Prevention and Management of Low Rectal Anastomotic Leakage in The Robotic Era: A Propensity Score Matched Study**
J. Xu, W. Chang, Y. Wei, T. Liu; CN
- 18:00 - 18:00 **90P - Robot-assisted versus laparoscopic surgery for colorectal Cancer: short-term outcome of a retrospective comparative study**
L. li, X. Yang, X. Zhu, W. Zhang, L. Feng, B. Du; CN
- 18:00 - 18:00 **91P - Surgery versus Combined Surgery and Chemotherapy: Survival Patterns among Patients with Stage II Colorectal Adenocarcinoma**
A. Shaltout, N. Sayed, A. Abobakr, R. Elemam, I. Uthman; EG
- 18:00 - 18:00 **92P - NORTH/HGCSG1003 : A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer : Comparison with medical oncologists and surgeons.**
I. Iwanaga¹, S. Yuki², Y. Kawamoto¹, H. Nakatsumi¹, N. Takahashi¹, T. Shichinohe¹, H. Okuda², A. Ishiguro¹, K. Harada¹, K. Hatanaka², K. Oomori¹, M. Nakamura¹, N. Senmaru¹, K. Iwai¹, M. Koike¹, Y. Ito¹, A. Taketomi¹, S. Hirano¹, N. Sakamoto¹, Y. Komatsu²; ¹JP, ²Hokkaido/JP
- 18:00 - 18:00 **93P - Maintenance therapy with monthly tegafur-uracil for improving disease-free survival of patients with ypStage III rectal cancer**
Y.H. Kuo, TW
- 18:00 - 18:00 **94P - Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer**
J. Hasegawa, T. Kato, J. Nishimura, S. Yoshioka, S. Noura, Y. Kagawa, M. Yasui, M. Ikenaga, K. Murata, T. Hata, C. Matsuda, T. Mizushima, H. Yamamoto, Y. Doki, M. Mori; JP
- 18:00 - 18:00 **95P - Long term outcomes of preoperative concurrent CapeOx/RT in locally advanced rectal cancer**
E. Sirachainan, C. Sitathanee, W. Suwanthanma, N. Larbcharoensub, S. Lukrak, N. Sripaiboonkit Thokanit, S. Phongkitkarun, K. Sumboonnanonda; TH

- 18:00 - 18:00 **96P - Efficacy and safety of S-1-based chemotherapy as first-line treatment in colorectal cancer: a meta-analysis of randomized controlled trials**
Z. Wang, Y. Zang, X. Liu, G. Zhang, G. Cheng; CN
- 18:00 - 18:00 **97P - Is right-sided (sRt) BRAF mutated (mBRAF) metastatic colorectal cancer (mCRC) unresponsive to the 1st-line antiEGFR antibody treatment?**
R. Kudo, JP
- 18:00 - 18:00 **98P - The role of perioperative radiotherapy for patients with local recurrence of rectal cancer**
H. Karasawa¹, S. Ohnuma¹, H. Suzuki¹, A. Kohyama¹, K. Watanabe¹, T. Kamei¹, T. Naitoh¹, M. Unno²; ¹JP, ²Miyagi/JP
- 18:00 - 18:00 **99P - Comparative study: Side effects of Folfox4 and Folfiri for Colorectal Cancer Chemotherapy regiment in Margono Soekarjo Hospital, Purwokerto**
I.N.A. Wiratama, W. Djatmiko, I. Ardiansyah, M. Salipi, A. Ilmi, N. Maharani; ID
- 18:00 - 18:00 **100P - Phase 2 KEYNOTE-164 Study of Pembrolizumab (pembro) Monotherapy for Patients (pts) With Previously Treated, Mismatch Repair-Deficient (dMMR) Advanced Colorectal Cancer (CRC): Primary and Japan Subgroup Analyses**
H. Hara¹, T. Yoshino¹, H. Taniguchi², K. Akagi¹, K. Shitara¹, T. Masuishi², Y. Kuboki¹, T. Shimamoto¹, K. Ueki¹, S.R. Han¹, K. Noguchi³, L. Diaz⁴; ¹JP, ²Aichi/JP, ³Chiyoda-ku/JP, ⁴MD/US
- 18:00 - 18:00 **101P - Effect On Oxaliplatin-Free Interval For Successful Rechallenge Of Oxaliplatin In Colorectal Cancer Patients Who Had Experienced An Oxaliplatin-Related Hypersensitivity Reaction.**
S. Horasawa¹, A. Kaneko¹, D. Kotani², S. Nakashima¹, H. Bando¹, T. Yoshino¹; ¹JP, ²Chiba/JP
- 18:00 - 18:00 **102P - HGCSG1503 : A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer : Analysis of GERCOR index.**
K. Suzuki¹, S. Yuki², S. Nakano¹, Y. Kawamoto¹, H. Nakatsumi¹, K. Hatanaka², T. Ando¹, K. Furukawa¹, A. Ishiguro¹, T. Ohta¹, K. Eto¹, J. Nakajima¹, M. Nakamura¹, S. Sogabe¹, K. Kato¹, M. Tateyama¹, S. Kato¹, M. Sekiguchi¹, Y. Sakata³, Y. Komatsu²; ¹JP, ²Hokkaido/JP, ³Aomori/JP
- 18:00 - 18:00 **103P - HGCSG1503 : A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer : Analysis of cases of prior regorafenib.**
Y. Tsuji¹, S. Yuki¹, K. Sawada², T. Muranaka¹, Y. Kobayashi¹, H. Okuda¹, K. Ogawa², S. Minami², T. Honda², M. Dazai¹, T. Kato², T. Sasaki², Y. Shindo², S. Ota², A. Sato², A. Ueda², S. Saitoh², H. Nagai², Y. Sakata³, Y. Komatsu¹; ¹Hokkaido/JP, ²JP, ³Aomori/JP
- 18:00 - 18:00 **104P - Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer.**

Y. Katata, T. Nagasaka, H. Tanioka, A. Nyuya, T. Toshima, Y. Mori, K. Shigeyasu, M. Okawaki, M. Yamamura, A. Tsuruta, T. Ueno, Y. Yamaguchi; JP

- 18:00 - 18:00 **105P - A China-Manufactured Bevacizumab Biosimilar, HLX04, Matches Avastin® Sourced from China, USA and European Union**
Y. Ding, T. Yu, J. Sun, M. Wu, Q. Chen, H. Qian, L. Xie, X. Zhang, E. Liu, W. Jiang, S. Liu, A. LUK; CN
- 18:00 - 18:00 **106P - Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer**
D. Kotani¹, Y. Kuboki², K. Yasuda², Y. Nakamura², A. Kawazoe², H. Bando², H. Taniguchi², K. Shitara², T. Yoshino²; ¹Chiba/JP, ²JP
- 18:00 - 18:00 **107P - Phase Ib/ II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): phase Ib results**
Y. Kagawa¹, H. Satake², T. Kato¹, K. Oba¹, H. Yasui¹, M. Nakamura¹, T. Watanabe¹, K. Hirata¹, K. Muro³, Y. Komatsu⁴, T. Yoshino¹, K. Yamazaki⁵, H. Mishima³, M. Kotaka², A. Tsuji¹, Y. Kakeji¹, E. Oki⁶, N. Nagata⁷, S. Junichi¹; ¹JP, ²Hyogo/JP, ³Aichi/JP, ⁴Hokkaido/JP, ⁵Shizuoka/JP, ⁶Fukuoka/JP, ⁷Hukuoka/JP
- 18:00 - 18:00 **108P - A pilot case-control study of second or third line treatment with cetuximab-containing chemotherapy (Cetux-chemo) in patients (pts) with metastatic colorectal cancer (mCRC) who were previously treated with Cetux-chemo**
C.S. Ho, A. Cheng, L. Li, W. Ho, E. Hui, K.F. To, J. Tong, B. Ma; HK
- 18:00 - 18:00 **109P - Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study**
K.-H. Yeh¹, T.-S. Yang¹, T.-C. Hsu¹, W.T.-L. Chen¹, H.-H. Chen¹, H.-W. Teng¹, B.-W. Lin¹, F.-C. Kuan¹, F.-F. Chiang¹, C.-W. Duann¹, Y.-S. Li¹, S. Fiala-Buskies², M. Ducreux³, J.-Y. Wang¹; ¹TW, ²DE, ³FR
- 18:00 - 18:00 **110P - HGCSG1401 : A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer : Analysis of risk factors for liver dysfunction.**
A. Ishiguro¹, S. Yuki², S. Nakano¹, Y. Kawamoto¹, K. Sawada¹, Y. Tsuji², T. Honda¹, T. Miyagishima¹, S. Yoshida¹, K. Hatanaka², T. Sasaki¹, O. Muto¹, H. Ohnuma¹, S. Kato¹, A. Sato¹, M. Abe¹, K. Kato¹, T. Amano², Y. Sakata³, Y. Komatsu²; ¹JP, ²Hokkaido/JP, ³Aomori/JP
- 18:00 - 18:00 **111P - TAS-102 Followed by Regorafenib or the Reverse Sequence in Advanced Colorectal Cancer**
Y. NAKATANI¹, S. Ueda¹, Y. Tsuboguchi¹, Y. Yoshii¹, K. Akiyoshi¹, A. Tsuya¹, S. Okazaki², S. Tokunaga¹, H. Daga¹; ¹JP, ²Fushimi-ku/JP

- 18:00 - 18:00 **112P - Efficacy of regorafenib in metastatic colorectal cancer: a multi-institutional retrospective study**
M.S. Bazarbashi¹, M. Elshenawy², M. Kandil¹, M. Zahir¹, A. Shaheen¹, A. Gad³, O. Alshaer¹, A. Alzahrani¹, A. Eldali¹, A. Aljubran¹; ¹SA, ²Menoufia Governorate/EG, ³EG
- 18:00 - 18:00 **113P - Real world experience with Regorafenib in dose escalation schedule in metastatic colorectal cancer in Indian patients**
A. Rauthan¹, P. Patil¹, S.P. Somashekhar¹, S. Zaveri²; ¹IN, ²Karnataka/IN
- 18:00 - 18:00 **114P - Role of consolidative radiation therapy after surgery in patients with stage IV rectal cancer**
T. Mehmood, PK
- 18:00 - 18:00 **115P - HGCSG1301 : A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment.**
M. Dazai¹, S. Yuki¹, K. Sawada², T. Muranaka¹, Y. Kawamoto², H. Nakatsumi², S. Nakano², A. Ishiguro², M. Tateyama², A. Sato², Y. Kobayashi¹, M. Nakamura², H. Okuda¹, Y. Takahashi¹, K. Eto², S. Muto², K. Hatanaka¹, T. Amano¹, Y. Sakata³, Y. Komatsu¹; ¹Hokkaido/JP, ²JP, ³Aomori/JP
- 18:00 - 18:00 **116P - Retrospective Analysis of Outcome in GIST patients on Imatinib in Sarawak General Hospital: A Single Institution Experience**
Y.Y. Sum, U. Nagaswara, S.K. Kho, C.J. Lim, Y.-Y. Junie Khoo; MY
- 18:00 - 18:00 **117P - Immunoscore feasibility study in routine postsurgical pathologic review for early-stage colon cancer (CC) cases risk-assessment**
K. Belaloui¹, E. Malifarge¹, J. Bohm², C. Bossard¹, R. Dienstmann³, S. Garcia⁴, C. Geppert⁵, I. Gogenur⁶, A. Hartmann⁵, D. Hatzibougias⁷, S. Landolfi³, M. Mishaeli⁸, D. Paez³, P. Patel⁹, M. Rodriguez-Justo¹⁰, J. Szafranska³, M. van den Eynde¹¹, E. Zavadova¹², S. Turcan¹, F. Hermitte¹; ¹FR, ²FI, ³ES, ⁴CEDEX 20/FR, ⁵DE, ⁶DK, ⁷GR, ⁸IL, ⁹IN, ¹⁰GB, ¹¹BE, ¹²CZ
- 18:00 - 18:00 **118P - The Impact of Universal Immunohistochemistry on Lynch Syndrome Diagnosis in an Australian Colorectal Cancer Cohort**
Z. Loh¹, D. Williams², L. Salmon², E. Dow², T. John²; ¹AU, ²VIC/AU
- 18:00 - 18:00 **119P - Poor-prognosis Locally Advanced Rectal Cancer is Defined by a Molecularly Distinct Subtype**
J. Zhang, L. Shen, Y. Wang, Y. Deng, L. Yang, J. Wan, Z. Zhang; CN
- 18:00 - 18:00 **120P - Comparison of incidence and survival outcomes in mucinous and signet-ring cell colorectal cancers with classical adenocarcinoma: A SEER analysis**
T. Mehmood, PK

- 18:00 - 18:00 **121P - Prognosis of Three Histological Subtypes of Colorectal Adenocarcinoma: A Retrospective Analysis of 8005 Chinese Patients**
C. Li, H. Zheng, D. Huang, S. Cai, J. Zhu; CN
- 18:00 - 18:00 **122P - Impact of tumor regression grade as a major prognostic factor in pathological stage II and III rectal cancer after neoadjuvant chemoradiotherapy**
J.-S. Kim¹, C. Song², S.-B. Kang², H.S. Lee², K.-W. Lee²; ¹Gyeonggi-do/KR, ²KR
- 18:00 - 18:00 **123P - Development of a Nomogram for Predicting Survival in Microsatellite Stable Patients with Resected Colorectal Cancer**
Y. Li, J. Peng, D. Huang, X. Ma, S. Cai; CN
- 18:00 - 18:00 **124P - Targeted sequencing of germline colorectal cancer predisposition genes in young Asians**
J. Chiang, M.R. Toh, J. Ngeow; SG
- 18:00 - 18:00 **125P - A SEER analysis of increasing disparities in age-related cause specific survival (CSS) among patients with colorectal cancer**
T. Mehmood, PK
- 18:00 - 18:00 **126P - STING, an immune biomarker for colorectal cancer**
H. Chon, D. Kim, C. Kim; KR
- 18:00 - 18:00 **127P - A model based on a new inflammation-nutrition score and TNM stage for predicting overall survival of patients with colorectal cancer**
S. Fujino, N. Miyoshi, K. Saso, M. Sasaki, S. Ishikawa, Y. Takahashi, M. Yasui, M. Ohue, T. Hata, C. Matsuda, T. Mizushima, Y. Doki, M. Mori; JP
- 18:00 - 18:00 **129P - Prevalence of Vitamin D deficiency in Chinese Patients with Early Stage Colorectal Cancer**
D. Ng, R. Tan, R. Sultana, M. Ang, W. Lim, D. Chong, C. Cwl, S.-L. Koo, S. Seet, Z. Tan, I. Tan; SG
- 18:00 - 18:00 **130P - Liquid Biopsy has a potential to predict the colorectal cancer patients with destiny for recurrence after curative surgery**
T. Toshima¹, A. Nyuya¹, U. Umeda¹, K. Yasui¹, K. Yoshida¹, T. Fujiwara¹, A. Goel², T. Nagasaka¹; ¹JP, ²US
- 18:00 - 18:00 **131P - Novel drug discovery for cancer invasion and metastasis**
H.J. Na, S.Y. Park, S.J. Lee, Y.R. Kim, J.W. Choi; KR
- 18:00 - 18:00 **133P - Molecular characterization of cancer associated fibroblasts in colorectal cancer**
T. Aizawa¹, H. Karasawa¹, H. Suzuki¹, A. Yamamura¹, S. Ohnuma¹, T. Kamei¹, T. Naitoh¹, M. Unno²; ¹JP, ²Miyagi/JP

- 18:00 - 18:00 **134P - A retrospective analysis of the association between perioperative carcinoembryonic antigen level and prognosis in stage III colorectal cancer**
R. Kozuki¹, E. Shinozaki¹, H. Osumi¹, T. Wakatsuki¹, M. Suenaga¹, T. Ichimura¹, M. Ogura¹, T. Suzuki¹, Y. Ota¹, I. Nakayama¹, D. Takahari², K. Chin¹, T. Nagasaki¹, T. Akiyoshi¹, T. Konishi¹, Y. Fujimoto¹, S. Nagayama¹, Y. Fukunaga¹, M. Ueno¹, K. Yamaguchi¹; ¹JP, ²Aichi/JP
- 18:00 - 18:00 **135P - Association of preoperative CEA with recurrence in high risk of recurrence groups with Stage2 and 3 colorectal cancer patients received by CapeOX adjuvant chemotherapy**
H. Osawa, JP
- 18:00 - 18:00 **137P - Prognostic value of staging FDG PET/CT in patients with metastatic colorectal cancer**
E.K. Choi, J.K. Oh, Y.-A. Chung; KR
- 18:00 - 18:00 **138P - Natural killer NKG2A and NKG2D serum levels in patients with colorectal cancer**
G. Refaat, A. Mohamed, W. Zaki, M. Adel, M. Amin, M. Deeb, M. Rushdy, N. Safwat; EG
- 18:00 - 18:00 **139P - Prognostic value of high EZH2 expression in patients with colorectal cancer in East Azerbaijan, Iran**
Z. Sanaat¹, R. Dolatkhah², N. Gholami²; ¹East Azarbaijan/IR, ²IR
- 18:00 - 18:00 **140P - DCLK1 as part of EMT feedback-loop promotes colorectal cancer cell proliferation, invasion, and 5-Fu resistance**
Y. Ge¹, N. Weygant², D. Qu², C.W. Houchen³; ¹CN, ²OK/US, ³AL/US
- 18:00 - 18:00 **141P - Tumor-Associated Carbohydrate Antigens - Tn Antigen Expression and Contribution in Human Colorectal Cancer**
Y. Jiang, T. Wen; CN
- 18:00 - 18:00 **142P - Biological characteristics predict outcome of rectal cancer patients: Data from tertiary care hospital in a low economic country**
A. zaki, S. Hirani, S. Sawani, S. Sarwar, M. Moosajee; PK
- 18:00 - 18:00 **143P - The role of molecular biomarker CDKN-2A in early diagnosis of colorectal cancer**
Y. Ten, M. Tiilashaykhov, S. Abdujapparov, H. Islamov, Y. Ziyaev; UZ
- 18:00 - 18:00 **144P - The Impact of Bone Fracture on Prognosis of Colorectal Cancer Patients Receiving Chemotherapy.**
Y. Sakai, T. Sone, T. Murai, K. Itaya, Y. Ono, M. Nakamura; JP
- 18:00 - 18:00 **145P - pregnancy had no significant impact on young colorectal cancer patients**
J. Zhu, J. Wang; CN

- 18:00 - 18:00 **146TiP - A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer**
T. Yoshino¹, S. Siena², R. Dalal³, Y. Okuda¹, E. Yamamoto¹, A. Grothey⁴; ¹JP, ²IT, ³US, ⁴TN/US
- 18:00 - 18:00 **147TiP - Impact of the Immunoscore® assay on adjuvant chemotherapy decision making in patients with resected stage II-III colon cancer: A prospective, multicenter study (PROSCORE)**
D. Malka, C. Mollevi, F. Hermitte, A. Catteau, N. LACHAUX, C. Jouffroy; FR
- 18:00 - 18:00 **YO8 - Delayed perforation after stent placement for sigmoid colon cancer obstruction**
S. Fukai, K. Mizokami; JP
- 18:00 - 18:00 **YO9 - Durable response to cetuximab plus FOXFOX in metastatic unresectable sigmoid colon cancer**
D. Ratanapichayachai, TH
- 18:00 - 18:00 **YO10 - Rectal Adenocarcinoma and Ileocecal Tuberculosis: a simple coincidence or a pathologic co-existence?**
J.M.J. Lomanta, C.D. Uy, J. Ignacio, R. Berba; PH
- 18:00 - 18:00 **Gastrointestinal tumours, non-colorectal**
- 18:00 - 18:00 **156P - TCOG T1308 Study: The Final Results of a Phase II Trial of modified Gemcitabine plus S-1 combination as the First-line Treatment in Patients with Advanced Biliary Tract Cancer**
N.-J. Chiang¹, L.-T. Chen¹, J.-S. Chen¹, S.-H. Yang¹, C. Hsu¹, Y.-S. Shan¹, C.-J. Yen², M.-H. Chen¹, H.-H. Tsou¹; ¹TW, ²CN
- 18:00 - 18:00 **157P - Epidemiological parameters and survival outcome of Gall bladder cancer: An North West India based institution study**
S. Narayan¹, P. Pareek²; ¹Rajasthan/IN, ²IN
- 18:00 - 18:00 **158P - Impact on gemcitabine plus cisplatin in unresectable hilar cholangiocarcinoma patients according to effective bile drainage**
K. Min Jae, J.-H. Hwang, J.-C. Lee, D.W. Shin, S.Y. Yang; KR
- 18:00 - 18:00 **159P - Clinical prognostic factors and treatment outcomes for survival of patients with cholangiocarcinoma**
C. Charonpongsuntorn, P. Piyasatit, P. Chonmaitree, P. Muangnoi, D. Muntham; TH
- 18:00 - 18:00 **160P - Common Chromosomal Abnormalities in Gastric Cancer Cell Lines and Ascetic Fluids of Metastatic Gastric Cancer Patients**

M. Yaghmaie, T. Nayebbagher, H. Pashaiefar, K. Alimoghaddam, M. Jalili, M. Esfandbod, M. Saberian, H. Behroozi, M. Izadifard, A. Ghavamzadeh; IR

- 18:00 - 18:00 **161P - Efficacy and safety of modified ECF regimen as first-line chemotherapy in metastatic gastric adenocarcinoma: A phase II study**
T. Chaudhuri, K.G. Babu, K.C. Lakshmaiah, L. Dasappa, L. Jacob, M.C.S. Babu, K.N. Lokesh, A.H. Rudresha, L.K. Rajeev, R. Patidar, V. Asati, R. Chethan, D. Koppaka, A. Anand; IN
- 18:00 - 18:00 **162P - A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study**
K.-W. Lee¹, I.S. Choi², J.H. Kim¹; ¹Gyeonggi-do/KR, ²KR
- 18:00 - 18:00 **163P - mFLOT versus EOX in first line treatment of metastatic carcinoma of stomach**
V. Srinivasalu¹, N. Subramaniam¹, W. Jose², A. Philip³, K. Pavithran²; ¹IN, ²Kerala/IN, ³Tamil Nadu/IN
- 18:00 - 18:00 **164P - Gastric Adenocarcinoma Incidence And Mortality Trends In Asian-American Population**
M. Gad, A. Saad, M. Al-Husseini; EG
- 18:00 - 18:00 **165P - Prognostic Significance of CT-determined Sarcopenia in Patients with Advanced Gastric Cancer Treated with Chemotherapy**
Y.S. Kim, E.Y. Kim, H.K. Ahn, I. Park, S.-C. Lee, I.G. Hwang, S.J. Sym, D.B. Shin; KR
- 18:00 - 18:00 **166P - Assessment of molecular classification of gastric cancer by immunohistochemistry and in situ hybridization: a validation study in the chinese population**
Y. Sun, W. Yu, W. Guan, M. Qiao, L. Zheng, R. Jiang, R. Wang, L. Wang; CN
- 18:00 - 18:00 **167P - Pattern of gastric cancer in young(GCY) : A retrospective study from a tertiary cancer care centre in Indian subcontinent.**
S. Kumar, K. Gupta, T. Murali, K. Dharma, A. Anand, M. Bhandare, V. Chaudhary, S. Shrikhande; IN
- 18:00 - 18:00 **168P - Optimal time interval between surgery and adjuvant chemotherapy of gastric cancer**
G.T. Ahn, S.K. Baek, S.-Y. Kim, J.J. Han, H.-J. Yoon, C.H. Maeng; KR
- 18:00 - 18:00 **169P - Apatinib reverses resistance of paclitaxel-containing regimens in advanced gastric cancer: a phase II study**
R. Lin, N. Fan, H. Li, J. Liu, S. Zhao, J. Yu; CN

- 18:00 - 18:00 **170P - Early Results of Pegvorhyaluronidase Alfa (PEGPH20; PVHA) + Pembrolizumab Therapy in Patients (Pts) with Relapsed/Refractory Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma**
R.D. Harvey¹, A. Murphy², E. Kim³, M. Tejani⁴, W. Wu³, E. Pham⁵, M. Muhsin⁵; ¹AL/US, ²MD/US, ³CA/US, ⁴NY/US, ⁵US
- 18:00 - 18:00 **171P - A novel method of measuring exosomal HER2 to assist in selecting advanced gastric cancer patients benefiting from anti-HER2 therapy**
Q. Li¹, X. Xu¹, Y. Yu¹, W. Li¹, L. Liang¹, J. Song¹, X. Zhao¹, S. Cai¹, T. Liu²; ¹CN, ²Changning/CN
- 18:00 - 18:00 **172P - CT image features of peritoneal metastasis and outcomes of the advanced gastric cancer patients receiving 2nd-line chemotherapy**
S. Kita, A. Takashima, H. Hirano, M. Aoki, H. Imazeki, M. Ishikawa, H. Shoji, Y. Honma, S. Iwasa, N. Okita, K. Kato, K. Nagashima, N. Boku; JP
- 18:00 - 18:00 **173P - How can we predict the possibility of advanced gastric cancer patients to receive third-line chemotherapy in the real-world setting?**
M. Ueno, A. Doi, H. Mouri, M. Mizuno; JP
- 18:00 - 18:00 **174P - EMT markers gene expression in BPIFB2 overexpressed gastric cancer cell lines**
Z. Karim, N.A. Zulkifli, S.H. Sheikh Abdul Kadir, K. Abd Khalil, M. Musa; MY
- 18:00 - 18:00 **175P - Overall Survival Results From a Phase 3 Trial of Trifluridine/Tipiracil (FTD/TPI) vs Placebo in Patients (Pts) with Metastatic Gastric Cancer Refractory to Standard Therapies (TAGS)**
K. Shitara¹, J. Tabernero², M. Dvorkin³, W. Mansoor⁴, H.-T. Arkenau⁴, A. Prokharau⁵, M. Alsina², M. Ghidini⁶, C. Faustino⁷, V. Gorbunova³, E. Zhavrid⁵, K. Nishikawa¹, A. Hosokawa¹, D. Ganea⁸, Ş. Yalçın⁹, K. Fujitani¹, G. Beretta⁶, R. Winkler¹⁰, T. Doi¹, D. Ilson¹⁰; ¹JP, ²ES, ³RU, ⁴GB, ⁵BY, ⁶IT, ⁷PT, ⁸RO, ⁹TR, ¹⁰AL/US
- 18:00 - 18:00 **176P - Superior antitumor efficacy of interferon incorporated hydrogels combined with CIK and radiation against gastric cancer**
Q. Liu, D. Zhang, H. Qian, B. Liu; CN
- 18:00 - 18:00 **177P - Long-term results of conversion therapy for initially unresectable gastric cancer: analysis of 122 patients at the National Cancer Center in China**
T. Wang, N. Wang, H. Ren, H. Zhou, A. Zhou, J. Jin, Y. Chen, D. Zhao; CN
- 18:00 - 18:00 **178P - FOXO3 inhibits human gastric adenocarcinoma (AGS) cell growth by promoting autophagy in an acidic microenvironment**
Y. Gao, CN
- 18:00 - 18:00 **179P - Efficacy and Safety of Regorafenib after Progression on Sorafenib in Korean Patients with Advanced Hepatocellular Carcinoma (HCC)**

C. Yoo¹, J.-W. Park², Y.J. Kim², D.Y. Kim², S.J. Yu², T.S. Lim², B.-Y. Ryoo², S.J. Lee², H.-Y. Lim²; ¹Songpa-gu/KR, ²KR

- 18:00 - 18:00 **180P - Prognostic Factors affecting the survival of hepatocellular carcinoma patients undergoing different surgical techniques**
S. Ahmed, M. Morsi, I. Uthman; EG
- 18:00 - 18:00 **181P - GNMT negatively regulates MAPK Pathway and suppresses the growth and metastasis of Hepatocellular cancer cells**
S. Jiang, F. Jingyuan; CN
- 18:00 - 18:00 **182P - Lenvatinib acts as the salvage therapy for advanced hepatocellular carcinoma**
M.-C. Hsieh, Y.-L. Su, Y.-Y. Chen, C.-T. Liu, Y.-H. Chen, T.-J. Chiu, S.-N. Pei, C.-C. Wu, K.-M. Rau; TW
- 18:00 - 18:00 **183P - Response to Multi-Targeted Kinase Inhibitor (MKI) after Immune Checkpoint Inhibitor (ICI) in Patients with Hepatocellular Carcinoma (HCC)**
S. Chng, S. Tan, J. Lee, S.P. Choo; SG
- 18:00 - 18:00 **184P - Continued Value of the Serum Alpha-Fetoprotein in Surveilling At-Risk Populations for Hepatocellular Carcinoma**
J.H. Shim, J. An, B. Oh, J. Song, Y.J. Oh; KR
- 18:00 - 18:00 **185P - Role of Tie2, CD14, angiopoietin as angiogenetic markers in hepatocellular carcinoma complicating hepatitis C virus infection in Egyptian patients**
E.-Z. Meghezel, H. Abdelhfez Ahmed, A. Askar, E.E. Hassan, A. Elyamany; EG
- 18:00 - 18:00 **186P - Phase 2 trial of tepotinib vs sorafenib for treatment-naïve advanced hepatocellular carcinoma (HCC) in Asian patients**
B.-Y. Ryoo¹, Z. Ren², T.-Y. Kim¹, H. Pan³, K.-M. Rau², H.J. Choi¹, J.-W. Park¹, J.H. Kim⁴, C.-J. Yen², B.-H. Kim¹, D. Zhou², J. Straub⁵, C. Zhao⁶, S. Qin²; ¹KR, ²CN, ³Zhejiang/CN, ⁴Gyeonggi-do/KR, ⁵DE, ⁶MA/US
- 18:00 - 18:00 **187P - Outcome of induction chemotherapy consisting of docetaxel, cisplatin, and S-1 (DCS) followed by esophagectomy for cT4 esophageal cancer in comparison with chemoradiotherapy**
H. Shimoji, T. Nishimaki, H. Karimata, Y. Nakamura; JP
- 18:00 - 18:00 **188P - Outcome of Small Cell Carcinoma of Esophagus: An Institutional Experience from North-East India**
P. Roy¹, B. Saikia², M. Hazarika², C. Bhuyan², G. Kumar², R. Mishra², C.W. Nyuthe²; ¹Assam/IN, ²IN

- 18:00 - 18:00 **189P - Efficacy of palliative chemotherapy (CTx) by lines of treatment in patients (pts) with recurrent/metastatic esophageal squamous cell cancer (SCC): Retrospective analysis of 103 patients in single center**
E. Kim, S.R. Park, J.H. Kim, Y.-H. Kim, H.R. Kim, S.-B. Kim; KR
- 18:00 - 18:00 **190P - Metastatic to negative lymph node ratio - can it used as a prognostic indicator in squamous cell carcinoma esophagus**
G. M.s, IN
- 18:00 - 18:00 **191P - Nomogram to predict cancer-specific survival in patients with pancreatic acinar cell carcinoma: A competing risk analysis**
C. He, S. Li; CN
- 18:00 - 18:00 **192P - Use of FOLFIRINOX chemotherapy in an Australasian population of pancreatic cancer**
A. Jalali¹, M. Lee², C. Semira³, S. Banks³, H.-L. Wong¹, S. Ananda¹, L. Lipton¹, J. Shapiro¹, P. Cooray¹, K. Clarke⁴, M. Burge⁵, R. Wong¹, J. Shapiro³, S.-A. McLachlan³, M. Harris¹, D. Croagh³, N. Tebbutt¹, P. Gibbs¹, B. Lee¹; ¹VIC/AU, ²ACT/AU, ³AU, ⁴NZ, ⁵QLD/AU
- 18:00 - 18:00 **193P - Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)**
H.N.N. Ip¹, I. Hwang², J. Kang², K.-P. Kim², J.H. Jeong², H.-M. Chang², B.-Y. Ryoo², C. Yoo²; ¹HK, ²KR
- 18:00 - 18:00 **194P - Runx1 enhancer element marks stem/ progenitor cells in pancreas and can be an origin of cancer**
H. Sato¹, A. Yamamura¹, J. Matsuo², Z. Hossain², M. Osato², T. Naitoh¹, T. Kamei¹, M. Unno³, Y. Ito²; ¹JP, ²SG, ³Miyagi/JP
- 18:00 - 18:00 **195P - Symptoms at diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine practice and frequency variation across Europe**
A. Carrato Mena¹, D. Melisi², B. Westphalen³, Å. Mellbring⁴, J. Taieb⁵, G. Prager⁶, T. Macarulla Mercadé¹, N. D'esquermes⁵, A. Ferreras⁵, F. de Jong⁷; ¹ES, ²IT, ³DE, ⁴SE, ⁵FR, ⁶AT, ⁷CH
- 18:00 - 18:00 **196P - HGCSG1403 : Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer.**
A. Yoshikawa¹, Y. Kawamoto¹, S. Yuki², S. Nakano¹, K. Sawada¹, T. Muranaka², H. Nakatsumi¹, K. Harada¹, Y. Kobayashi², T. Miyagishima¹, T. Saiki¹, A. Ishiguro¹, R. Saito¹, N. Ehira¹, I. Iwanaga¹, K. Hatanaka², N. Abe¹, N. Sakamoto¹, Y. Sakata³, Y. Komatsu²; ¹JP, ²Hokkaido/JP, ³Aomori/JP
- 18:00 - 18:00 **197P - Expression of p16 and KRAS in periampullary cancers**
J. swain, M.T. Tewari; IN

- 18:00 - 18:00 **199P - Incidence, risk factors, and outcomes of arterial thromboembolism in patients with pancreatic cancer following palliative chemotherapy**
W.-C. Chou, Y.-Y. Chen, J.-S. Chen, C.-H. Lu, P.-H. Chang, C.-Y. Hung; TW
- 18:00 - 18:00 **200P - Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: further subgroup analyses of the pivotal NAPOLI-1 study**
L.-T. Chen¹, T. Macarulla Mercadé², K.-H. Lee³, G. Lakatos⁴, A. Wang-Gillam⁵, B. Mirakhur⁶, F. de Jong⁷; ¹TW, ²ES, ³KR, ⁴HU, ⁵MO/US, ⁶US, ⁷CH
- 18:00 - 18:00 **201P - Three-dimensional remnant pancreatic volumetry as an indicator of poor prognosis in pancreatic cancer patients after pancreatoduodenectomy**
R. Miyamoto, N. Sano, M. Maeda, S. Inagawa; JP
- 18:00 - 18:00 **202P - GLRLM feature by using CT texture analysis is prognostic factor , Evaluation of pancreatic cancer heterogeneity**
H.S. Kim, J.S. Park, Y.J. Kim, K.G. Kim; KR
- 18:00 - 18:00 **204P - Prognostic impact of progression type by RECIST criteria in patients with metastatic pancreatic cancer who received 1st line gemcitabine based chemotherapy**
J. Lee, M.A. Lee, I.-H. Kim; KR
- 18:00 - 18:00 **205P - Trends in the Incidence, Prevalence, and Survival Outcomes of Appendiceal Adenocarcinoma**
W. Xiang, G. Cai; CN
- 18:00 - 18:00 **206P - Incidence of catheter-related thrombosis in patients with long-term indwelling central venous catheter who received chemotherapies for unresectable advanced digestive cancers**
H. Tanioka, M. Asano, K. Kawasaki, R. Yoshida, N. Waki, F. Uno, M. Ishizaki, K. Yamashita, Y. Morishita, Y. Katata, T. Nagasaka; JP
- 18:00 - 18:00 **207TiP - A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr Virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies**
B. Liu¹, J. Yan¹, S. Su¹, J. Shao¹, Y. Zhao¹, Q. Xu¹, Y. Yang¹, Z. Zou¹, X. Huang¹, J. Wei²; ¹CN, ²Jiangsu Province/CN
- 18:00 - 18:00 **208TiP - A randomized, phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer**
K. Shitara¹, Y.-J. Bang², D. Sakai³, H. Yasui³, Y. Kawaguchi³, M. Sugihara³, K. Saito³, R. Dalal⁴, K. Yamaguchi³; ¹Chiba/JP, ²KR, ³JP, ⁴US

- 18:00 - 18:00 **209TiP - CA209-9DX: Phase 3, Randomized, Double-Blind Study of Adjuvant Nivolumab vs Placebo for Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence after Curative Resection or Ablation**
M.J. Jimenez Exposito¹, M. Akce², J. Alvarez³, E. Assenat⁴, L. Balart⁵, A. Baron⁶, T. Decaens⁴, A. Heurgue-Berlot⁴, A. Martin³, S. Paik⁷, V. Poulart⁸, A. Sehbai⁹, M. Shimada¹⁰, N. Takemura¹⁰, J.-H. Yoon⁷; ¹US, ²GA/US, ³ES, ⁴FR, ⁵LA/US, ⁶CA/US, ⁷KR, ⁸BE, ⁹AL/US, ¹⁰JP
- 18:00 - 18:00 **210TiP - IMbrave150: a randomised Phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma**
S. Qin¹, A.-L. Cheng², M. Ducreux³, P. Galle⁴, A. Zhu⁵, T.-Y. Kim⁶, D.-Z. Xu¹, W. Verret⁷, J. Liu¹, R. Finn⁸, M. Ikeda⁹; ¹CN, ²TW, ³CEDEX/FR, ⁴DE, ⁵US, ⁶KR, ⁷AL/US, ⁸CA/US, ⁹Chiba/JP
- 18:00 - 18:00 **211TiP - HALO 110-101: Phase 1b Study of PEGPH20 in Combination with Cisplatin + Gemcitabine (PEGCISGEM) or Atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in Patients with Locally Advanced/Metastatic Cholangiocarcinoma and Gallbladder Cancer**
D.-Y. Oh¹, J.-O. Park¹, C. Charoentum², S. Stein³, M. Noel⁴, V. Chung⁵, W. Wu⁵, R. Alton⁵, M. Muhsin⁶, M. Javle⁷, G. Abou-Alfa⁴, M. Borad⁸; ¹KP, ²TH, ³CT/US, ⁴NY/US, ⁵CA/US, ⁶US, ⁷TX/US, ⁸AZ/US
- 18:00 - 18:00 **YO11 - Hepatocellular carcinoma responding to sequential radioembolization and external radiotherapy: A successful salvage?**
A. Ahmed, QA
- 18:00 - 18:00 **YO12 - Solid Pseudopapillary Tumor of Pancreas: A Case Report**
S. m, G. Ushashree, N. Rao, R. Reddy; IN
- 18:00 - 18:00 **YO13 - Synchronous adenocarcinoma and gastrointestinal stromal tumors in the stomach**
H. Ubaydullaeva, UZ
- 18:00 - 18:00 **YO14 - Gastrointestinal perforation caused from colonofiberscopy to lung adenocarcinoma with metastasises small intestine ; a case report**
N. Haruta, Y. Haruta, M. Matsuo, K. Murase; JP
- 18:00 - 18:00 **YO15 - A case of Obstructive Jaundice in Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy**
A. Giselvania, A. Munandar, G.B. Prajogi, S.M. Sekarutami, S. Gondhowiardjo; ID
- 18:00 - 18:00 **Genitourinary tumours, prostate**

- 18:00 - 18:00 **215P - Comparison between robot-assisted radical prostatectomy and minimum incision endoscopic radical prostatectomy for high-risk prostate cancer following neoadjuvant therapy : A propensity score-matched analysis**
A. Imai, H. Yamamoto, S. Hatakeyama, T. Yoneyama, Y. Hashimoto, C. Ohyama; JP
- 18:00 - 18:00 **216P - The impact of different treatment modalities on toxicity and quality of life for prostate cancer - a real-world study based on WeChat in China**
X. Qi, H. Li, S. Gao; CN
- 18:00 - 18:00 **217P - HoxB13 expression in prostate cancer: clinicopathologic characteristics and role as potential diagnostic marker**
Y.A. Cho, C.K. Park, N.H. Cho; KR
- 18:00 - 18:00 **218P - Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for Asian patients with early-stage localized prostate cancer: acute toxicity results from a prospective randomized phase II study**
D. Poon¹, D. Lam¹, K. Wong¹, F. Mok², F. Mo¹, C.M. Chu¹, A.C.F. Ng¹, J. Suen¹, A. Chan¹; ¹HK, ²Kowloon/HK
- 18:00 - 18:00 **219P - The linear-quadratic (LQ) model is inappropriate for high doses per fraction owing to α/β ratio is not a constant: evidence deduced from radiotherapy outcomes of 16367 prostate cancer patients.**
M. Cui, S. Gao; CN
- 18:00 - 18:00 **220P - Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC)**
A. Anton¹, S. Wong², P. Parente², A. Azad², J. Shapiro¹, A. Weickhardt², J. Torres², F. Parnis³, J. Goh⁴, C. Semira¹, P. Gibbs², B. Tran¹, C. Pezaro²; ¹AU, ²VIC/AU, ³SA/AU, ⁴QLD/AU
- 18:00 - 18:00 **221P - Prognostic impact of pT3a subclassification based on extent of extraprostatic extension after robot-assisted radical prostatectomy.**
K. Kanao, M. Sugie, S. Morinaga, H. Muramatsu, K. Kajikawa, I. Kobayashi, G. Nishikawa, M. Watanabe, K. Zennami, K. Nakamura, M. Sumitomo; JP
- 18:00 - 18:00 **222P - Immunotherapy with dendritic cells derived from bone marrow hematopoietic stems cells inhibited tumor growth on a TRAMP-C1 syngeneic mouse model of prostate cancer**
Y. Kim, B.-M. Kim, C.-S. Kim, H. Kim, S.Y. Choi, H. Lee; KR
- 18:00 - 18:00 **223P - Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy.**
A. Anton¹, Z. Ballok¹, P. Bowden², T. Costello³, L. Harewood³, N. Corcoran³, P. Dundee³, J. Peters³, N. Lawrentschuk³, A. Troy³, D. Webb³, Y. Chan³, A. See³, S. Siva³, D. Murphy³, M. Hofman³, B. Tran¹; ¹AU, ²ACT/AU, ³VIC/AU

- 18:00 - 18:00 **224P - A new novel gene ABCC5 promotes castration-resistant prostate cancer progression through ERK carcinogenic pathway**
G. Ji, CN
- 18:00 - 18:00 **225P - Docetaxel versus Abiraterone in Newly Diagnosed Metastatic Prostate Cancer : Study from Tertiary Care Cancer Centre in a Developing Country**
S. Hussain, G. Gautam, P. Ahluwalia, A. Punnakal, H. Chaturvedi, A. Gupta; IN
- 18:00 - 18:00 **226P - Aldo-keto-reductase 1C3 expression in prostate cancer**
Y. Hashimoto, A. Imai, H. Yamamoto, S. Hatakeyama, T. Yoneyama, C. Ohyama; JP
- 18:00 - 18:00 **227P - LOCALISED CARCINOMA PROSTATE: Intensity Modulated Radiotherapy (IMRT) Followed By Stereotactic Body Radiotherapy (SBRT) Boost: A Feasibility Study For Acute Toxicity.**
G. Deepthi, N. Kumar, S. Kumar, B. Yadav, P. Gupta; IN
- 18:00 - 18:00 **228P - Upfront Chemotherapy for High Volume HSPC, Single Institute Experience of Southern Taiwan**
C.-M. Tsai, J.-T. Lin, C.-C. Yu, T. Wu, I.-H. Cheng, M.-X. He; TW
- 18:00 - 18:00 **229P - Predictability of intra-fractional prostate motion**
K. Perumal, M. Potharaju; IN
- 18:00 - 18:00 **230P - Utility of Gallium-68 PSMA PET/CT Scan for Staging and Treatment of Prostate Cancer in Contemporary Era: Study from Tertiary Care Cancer Centre in a Developing Country**
A. Gupta, S. Hussain, P. Ahluwalia, G. Gautam, A. Punnakal, H. Chaturvedi, A. Rajput, J. Bal, P. Dougall; IN
- 18:00 - 18:00 **231P - Prognostic and predictive clinical factors for progression to castration refractory prostate cancer in patients with hormone sensitive prostate cancer.**
M. Watanabe, K. Kanao, M. Sugie, S. Morinaga, H. Muramatsu, I. Kobayashi, K. Kajikawa, G. Nishikawa, K. Zennami, K. Nakamura, M. Sumitomo; JP
- 18:00 - 18:00 **Genitourinary tumours, non-prostate**
- 18:00 - 18:00 **234P - Quantitative proteomic analysis identifies AHNAK as a novel candidate biomarker for bladder urothelial carcinoma diagnosis**
C. hyun, M.S. Park; KR
- 18:00 - 18:00 **235P - Comparison of Cisplatin versus Carboplatin Chemotherapy for Metastatic Urothelial Carcinoma in Patients with Stage 3 Chronic Kidney Disease**
C.-C. Wu, K.-M. Rau, M.-C. Hsieh, Y.-L. Su; TW

- 18:00 - 18:00 **236P - The relationship between preoperative stage 3B chronic kidney disease and post-surgical oncological outcomes in patients with urothelial carcinoma**
S. Hatakeyama, H. Yamamoto, A. Imai, T. Yoneyama, Y. Hashimoto, T. Koie, C. Ohyama; JP
- 18:00 - 18:00 **237P - High expression of sushi domain containing 2 (SUSD2) promote cell proliferation in bladder cancer and was associated poor survival outcome.**
C. Wang, TW
- 18:00 - 18:00 **238P - Role of Post Lasix FDG PETCT in Recurrent Carcinoma Bladder**
S. Malapure, R. Kumar, P. Sharma; IN
- 18:00 - 18:00 **239P - Correlation of DNA damage and urinary cotinine levels in cases of carcinoma urinary bladder.**
T. Singh, S. Gupta, P. Garg; IN
- 18:00 - 18:00 **240P - Determine cisplatin or carboplatin in first-line chemotherapy for elderly patients with metastatic urothelial carcinoma: Does age preclude cisplatin eligibility?**
S.Y. Huang, Y.-L. Su, M.-C. Hsieh, K.-M. Rau; TW
- 18:00 - 18:00 **241P - Does neoadjuvant chemotherapy promote chemoresistance after recurrence in patients with muscle-invasive bladder cancer?**
S. Hatakeyama, H. Kodama, S. Konishi, K. Okita, H. Yamamoto, A. Imai, T. Yoneyama, Y. Hashimoto, T. Koie, C. Ohyama; JP
- 18:00 - 18:00 **242P - A Novel Cost-effective Method for Diagnosis of Bladder Cancer by Detecting ErbB3 Expression in Urine**
X. Chen, S. Wang, C. Liu, J. Chen, D. Wang, M. Huang, J. Song, S. Cai, S. Qiu; CN
- 18:00 - 18:00 **243P - Node-positive bladder cancer after neoadjuvant chemotherapy followed by radical cystectomy: a single-center retrospective study**
J.H. Cho, J. Lee, Y. Kim, S. Park, S.E. Yoon, K.K. Lee, J.Y. Hur, S.J. Lee, S.H. Park; KR
- 18:00 - 18:00 **244P - Lipid cell change in urothelial carcinoma - Signs of tumor aggression and the worst prognosis among the variants -**
T. Hayashi, G. Kimura, Y. Kondo; JP
- 18:00 - 18:00 **245P - comparison of partial nephrectomy and percutaneous radiofrequency ablation for small renal mass in the manner of PADUA classification**
W.-T. Kuo, TW
- 18:00 - 18:00 **246P - Patient characteristics, patterns of care and survival outcome in patients with Adult testicular granulosa cell tumor: an individual patient data meta-analysis**
S. Thambi¹, R. Benson², L. Haridas¹; ¹IN, ²Delhi/IN

- 18:00 - 18:00 **247P - Clinicopathological and survival analysis of endometrial carcinoma: a single center experience in Pakistan**
Z. Samoon, S. Ahmed, S. Jehangir, S. Rizvi, S. Sawani; PK
- 18:00 - 18:00 **249P - The gap of frailty value from a community-dwelling population predict oncological outcomes in patients with urological cancers**
S. Hatakeyama, S. Konishi, K. Okita, O. Soma, T. Matsumoto, T. Yoneyama, Y. Hashimoto, T. Koie, C. Ohyama; JP
- 18:00 - 18:20 **YO16 - Urothelial carcinoma of the kidney in a patient with ovarian and breast cancer**
F.V. Que, PH
- 18:20 - 18:20 **YO17 - Induction Chemoradiation Therapy in Recurrent Locally Advanced Urachal Cancer**
T. Dajsakdipon, S. Worawichawong, C. Leenanupunth, P. Phichai Chansriwong; TH
- 18:20 - 18:20 **Gynaecological cancers**
A.M. Poveda Velasco¹, J.-W. Kim², E. Pujade-Lauraine³, H.Y.-S. Ngan⁴, C. Scott⁵; ¹ES, ²KR, ³CEDEX 4/FR, ⁴HK, ⁵AU
- 18:20 - 18:20 **257P - Correlation between Knowledge and Attitudes of Female High School Students Regarding Cervical Cancer in Denpasar, Bali**
R. Martianus, R. Putri, A. Satyarsa, Y. Brahmantya, A. Abdulhadi; ID
- 18:20 - 18:20 **258P - Screening Program for cervical cancer among rural women by Visual Inspection with Acetic Acid (VIA): A Camp approach in Eastern India**
I. Mandal, J. Basak, A. Mukhopadhyay, C. Bose; IN
- 18:20 - 18:20 **259P - Neoadjuvant chemotherapy in locally advanced cervical cancer: two randomized studies**
Z. Olimova, UZ
- 18:20 - 18:20 **260P - Neoadjuvant intraarterial chemotherapy and chemoembolization in locally advanced cervix cancer**
O. Akhmedov, N. Zakhirova, N. Umarova; UZ
- 18:20 - 18:20 **261P - Concurrent Chemoradiation with Nano- Paclitaxel and Carboplatin in Locally Advanced Cervical cancer - A Study at Quaternary Care Medical Center**
P. Eswaran¹, S. Kalyan², J. Crystal²; ¹Tamil Nadu/IN, ²IN
- 18:20 - 18:20 **262P - Is Bone Marrow sparing Intensity modulated radiotherapy better than 3-Dimensional Conformal radiotherapy in reducing haematological toxicities during pelvic irradiation in locally advanced carcinoma cervix?: A prospective study.**
A. Elangovan, A. Bahl, F. Patel, C.B. DRACHAM, B. Rai, G. Trivedi; IN

- 18:20 - 18:20 **263P - Pelvic plastic reconstruction results after small pelvis exenteration**
M. Tillashaykhov, N. Zakhirova, O. Ahmedov, Y. Ten, S. Djanklich; UZ
- 18:20 - 18:20 **264P - Development of the surgery method of pelvic floor reconstruction in locally advanced cervical cancer after exenteration**
N. Zakhirova, M. Tillyashaykhov, O. Akhmedov, S. Djanklich, Y. Ten; UZ
- 18:20 - 18:20 **265P - Life after cervical cancer: Bowel dysfunction , Urinary dysfunction and quality of life in long-term survivors of carcinoma uterine cervix among Indian women.**
N. Sethi, A. Shankar, J. Patil, K. Mandrelle, A. Luther; IN
- 18:20 - 18:20 **266P - Efficacy of Multimodality Treatment in Survival Patterns among Patients with Endometrial Carcinoma Stage III**
R. Elemam, I. Uthman, A. Yahya, N. Mohamed, A. Shaltout; EG
- 18:20 - 18:20 **267P - HPV E6/E7 oncoprotein promotes cervical cancer by promoting miR-466 expression via P53 pathway**
Y. Shen, Q.-X. Xu; CN
- 18:20 - 18:20 **269P - miRNA-96 might serve as potential biomarkers for cervical cancer**
J.-M. Gong, CN
- 18:20 - 18:20 **271P - Prevalence of BRCA and VUS Mutations in Patients with Ovarian Cancer Treated at Oncosalud - AUNA**
C. Flores, P. Carrion Calderon; PE
- 18:20 - 18:20 **272P - Clinical background and outcomes of risk-reducing salpingo-oophorectomy for patients with hereditary breast and ovarian cancer in Japan**
H. Nomura, M. Sekine, S. Yokoyama, N. Takeshima, M. Arai, S. Nakamura; JP
- 18:20 - 18:20 **273P - Olaparib maintenance treatment, the Royal Marsden experience**
C. Orbegoso Aguilar, L. Dumas, E. Davies, M. Gore, A. George, S. Banerjee; GB
- 18:20 - 18:20 **274P - Real-world experience of olaparib maintenance in high grade serous recurrent ovarian cancer patients with BRCA 1/2 mutation**
E.S. Paik, J. Kim, T.-J. Kim, C.H. Choi, J.-W. Lee, D.-S. Bae, B.-G. Kim; KR
- 18:20 - 18:20 **275P - Efficacy and tolerability of Olaparib in Asian patients with recurrent ovarian, primary peritoneal or fallopian tube carcinoma: the National University Cancer Institute, Singapore experience.**
V. Heong, Y.W. Lim, S.C. Lee, S. Ow, S.E. Lim, P.Y. Ong, J. Low, J. Ng, A. Ilancheran, P. Tong, D. Lim, D. Tan; SG
- 18:20 - 18:20 **276P - Overexpression of HER3 and the survival of ovarian cancer**

S. Kim, J.Y. Song; KR

- 18:20 - 18:20 **277P - Investigation of the role of transforming growth factor beta in the development and progression of granulosa cell tumours of the ovary**
A. Muthukaruppan, S.K. Arora, C. Blenkiron, A. Shelling; NZ
- 18:20 - 18:20 **278P - Predicting CA-125 Status and Ovarian Cancer Survival Using Artificial Neural Networks**
M. Osman, EG
- 18:20 - 18:20 **279P - PET/CT in recurrent carcinoma ovary: Contrast enhanced CT (CECT) versus non enhanced low-dose CT (NECT)**
A. Vyas, A. Tiwary, A. Aggarwal; IN
- 18:20 - 18:20 **280TiP - GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ 2 line recurrent or metastatic cervical cancer**
K. Tewari¹, I. Vergote², A. Oaknin³, E. Alvarez¹, S. Gaillard⁴, S. Lheureux⁵, D. Rischin⁶, A. Santin⁷, M. Feng⁴, M. Mathias⁸, M. Fury⁸, I. Lowy⁸, B. Monk⁹; ¹US, ²BE, ³ES, ⁴AL/US, ⁵AB/CA, ⁶ACT/AU, ⁷CT/US, ⁸NY/US, ⁹AZ/US
- 18:20 - 18:20 **YO18 - Ototesticular mixed germ cell tumor in a 46,XY/46,XX hermaphrodite: a case report**
R. So, I. Orolfo-Real, J.A. Toral, S. Paloyo, E.M. Cutiongco-Dela Paz; PH
- 18:20 - 18:20 **YO19 - Recurrent Intracranial Hemorrhage in a Patient with Metastatic Choriocarcinoma to the Brain Mimicking as Vasculitis**
A. Gerodias, E. Esposito, J. Datukan; PH
- 18:20 - 18:20 **Haematological malignancies**
- 18:20 - 18:20 **281P - Significance of PARP1 Expression levels in patients with Acute Myeloid Leukemia**
H. Pashaiefar, M. Yaghmaie, J. Tavakkoly-Bazzaz, S.H. Ghaffari, K. Alimoghaddam, M. Momeny, M. Izadifard, A. Kasaeian, A. Ghavamzadeh; IR
- 18:20 - 18:20 **282P - Efficacy and safety of Single-agent Arsenic trioxide (ATO) as an Induction regimen in the treatment of newly diagnosed Acute promyelocytic leukemia (APL): A prospective single arm phase II study from South India.**
P. simha¹, D. Lokanatha¹, K. Govind Babu¹, L. Jacob¹, M. Suresh Babu¹, K.N. Lokesh², A. Rudresha², L. Rajeev¹, S. Smitha¹, G. Giri¹; ¹IN, ²Karnatka/IN
- 18:20 - 18:20 **283P - High Dose Methotrexate in Acute Lymphoblastic Leukemia without monitoring drug levels: Indain Experience**

D. Yadlapalli¹, P. Ankur¹, V. Gumdal², M. Renu¹, S. Runu¹, B. Ankit¹, P. Chitalkar²; ¹IN, ²MP/IN

- 18:20 - 18:20 **285P - Karyotype Complexity and characterization of childhood acute myeloid leukemia (AML) in Pakistan**
Z. Ahmed¹, M. Shaiakh², T. Moatter², A. Nasir²; ¹Sindh/PK, ²PK
- 18:20 - 18:20 **286P - First China-Manufactured Proposed MabThera® Biosimilar Met Primary Efficacy and Safety Endpoints in CD20-Positive Diffuse Large B-Cell Lymphoma**
Y. Shi, Q. Zhang, X. Han, Y. Song, Y. Qin, X. Hong, X. Ke, J. Feng, D. Wang, W. Li, H. Su, Y. Zhang, H. Zhang, J. Yang, L. Liu, X. Zhang, E. Liu, W. Jiang, S. Liu, A. LUK; CN
- 18:20 - 18:20 **287P - Peripheral blood neutrophil-to-lymphocyte ratio in NK/T-cell lymphoma - prognostic significance and correlation with tumor transcriptomic profiles**
T. Khee Ming¹, B. Chia¹, J.Q. Lim¹, L.P. Khoo¹, C.L. Cheng¹, L. Tan¹, J.Y. Chan¹, E.Y.L. Poon¹, N. Somasundaram¹, M. Farid¹, T.P.L. Tang¹, M. Tao¹, D.M.Z. Cheah¹, Y. Laurensia¹, J.W.L. Pang¹, S.J. Kim², W.S. Kim², C.K. Ong¹, S.T. Lim¹, T. Song¹; ¹SG, ²KR
- 18:20 - 18:20 **288P - Combination of chemotherapy and radiation improve the prognosis of primary diffuse large B-cell lymphoma of the tonsil.**
S. Ko, S.-N. Lim, B.S. Sohn; KR
- 18:20 - 18:20 **289P - Safety and efficacy of pralatrexate in patients with relapsed or refractory peripheral t-cell lymphoma from China**
Y. Song¹, X. Hong¹, H. Huang¹, B. Bai¹, H. Zhang¹, X. Ke¹, Y. Shi¹, J. Zhu¹, G. Lu¹, S. Liebscher², C. Cai¹; ¹CN, ²DE
- 18:20 - 18:20 **290P - Extranodal NK/T Cell Lymphoma- Nasal type: Experience from an Indian regional cancer centre**
S. Saldanha¹, K. Govind Babu², D. Lokanatha², L. Jacob², M. Suresh Babu², K.N. Lokesh¹, A. Rudresha¹, L. Rajeev², G. Giri², P. Khandare²; ¹Karnatka/IN, ²IN
- 18:20 - 18:20 **291P - Clinicopathologic features of breast lymphoma in core needle biopsy**
R. Shui, J. Rao, X. Li, W. Yang; CN
- 18:20 - 18:20 **292P - Erectile dysfunction among male lymphoma survivors in a developing country**
G. Gan, D. Ng, Y. Leong; MY
- 18:20 - 18:20 **293P - An Attempt to Predict Double Expresser DLBCL Based on Cell of origin and Proliferative Index (Ki-67): A Prospective Study from India**
V. Asati¹, C. Premalata¹, K. Govind Babu¹, K. Lakshmaiah¹, D. Lokanath¹, L. Jacob¹, M. Suresh Babu¹, K.N. Lokesh², A. Rudresha², L. Rajeev¹, S. Smitha¹, G. Giri¹, D. Koppaka¹, T. Chaudhuri¹, A. Anand¹, R. Chethan¹, A. Goyal¹, R. Patidar¹; ¹IN, ²Karnatka/IN

- 18:20 - 18:20 **294P - A Prospective Study to Determine Survival Outcome to CHOP-based therapy in patients with Double Expresser DLBCL: Single Centre Experience from India**
V. Asati¹, K. Lakshmaiah¹, K. Govind Babu¹, D. Lokanath¹, L. Jacob¹, M. Suresh Babu¹, K.N. Lokesh², L. Rajeev¹, A. Rudresha², S. Smitha¹, G. Giri¹, D. Koppaka¹, A. Anand¹, R. Chethan¹, T. Chaudhuri¹, R. Patidar¹, A. Goyal¹, C. Premalata¹; ¹IN, ²Karnataka/IN
- 18:20 - 18:20 **295P - A Strategy of Stringent Control of Side-effects prevent the incidence of methotrexate related lymphoproliferative disorders in rheumatoid arthritis**
Y. URATA, JP
- 18:20 - 18:20 **296P - Is fusion of a baseline PET really necessary in radiation treatment planning of early stage Lymphomas?? Or will a baseline CT suffices??**
M. Muddabhaktuni, B. Yadav, N. Kumar, G. Prakash, B. Mittal, S. Goshal; IN
- 18:20 - 18:20 **297P - Chemotherapy versus Combined Chemoradiotherapy: Survival Patterns among Patients with early stage classical Hodgkin lymphoma**
L. Omar, E. Ali, A. Abd Elbaset; EG
- 18:20 - 18:20 **298P - The prognostic significance of baseline serum Ferritin in patients with malignant Lymphoma**
D. El-Habashy, E. Tawfik, S. Alhassanin, A. El-Desoky, A. Shehata; EG
- 18:20 - 18:20 **299P - Efficacy of salvage therapy of Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma**
S.-N. Lim, S. Ko, B.S. Sohn, S.Y. Oh; KR
- 18:20 - 18:20 **301TiP - A phase 3 randomized study of gilteritinib versus salvage chemotherapy in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia**
J. Wang¹, J. Li¹, A. Tantiworawit², S. Izuka³, S. Yamada³, J. Hill⁴, E. Shima Rich⁵, E. Bahceci⁴; ¹CN, ²TH, ³JP, ⁴IL/US, ⁵AL/US
- 18:20 - 18:20 **302TiP - Safety and Efficacy of Midostaurin in Patients With Newly Diagnosed FLT3-Mutated AML**
P.-N. Wang¹, A.Y.H. Leung², J.H. Jang³, S. Voloshin⁴, L. O'Sullivan-Djentuh⁵, K. Suzuki⁶, S. Ifrah⁷, G. Le Gouadec⁷, T. Kakizume⁶, H. Kitagawa⁶, K. Malek⁵, Y. Miyazaki⁶; ¹TW, ²CN, ³KR, ⁴RU, ⁵CH, ⁶JP, ⁷FR
- 18:20 - 18:20 **YO20 - Dyspnoea on Anti CD 38 directed IgG1k monoclonal Antibody - A Case Report**
R. Arora, IN
- 18:20 - 18:20 **YO21 - NK/T Cell Lymphoma, Nasal Type in a Filipino Male**
A.T. Gerona, PH

- 18:20 - 18:20 **YO22 - Chemotherapy in Bulky Neck Mass DLBCL with Massive Gastrointestinal Bleeding Due to Erosive Gastritis and Myelodysplasia Syndrome : A Case Report**
Y. Putra, M. Hardianti; ID
- 18:20 - 18:20 **Head and neck cancer, excluding thyroid**
- 18:20 - 18:20 **308P - Prophylactic percutaneous endoscopic gastrostomy in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy**
T. Dechaphunkul, N. Ngamphaiboon, P. Danchaivijitr, R. Jiratrachu, A. Dechaphunkul; TH
- 18:20 - 18:20 **309P - To evaluate Oncological and Quality of life outcomes between Robotic and open neck dissection for oral cavity cancers: A prospective trial.**
K. Gupta, S. Dabas; IN
- 18:20 - 18:20 **310P - Analgesic efficacy in Head and neck cancer patients using tapentadol vs. tramadol plus paracetamol**
R. Narayanasamy, S. Thiagarajan, K. Perumal; IN
- 18:20 - 18:20 **311P - Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial.**
X. Hua¹, L. Chen¹, Q. Zhu¹, W. Hu¹, C. Lin¹, Z. Long¹, W. Wen¹, X. Sun¹, Z. Lu¹, Q. Chen¹, D. Luo¹, R. Sun¹, H. Mo¹, L. Tang¹, W. Zhang¹, Z. He¹, H. Mai¹, H. Lin¹, L. Guo²; ¹CN, ²Guangdong/CN
- 18:20 - 18:20 **312P - Weight loss during Radiation Therapy in Patients of Head &&**
S. Das, D. Lahiri, S. Mandal, P. Biswas; IN
- 18:20 - 18:20 **313P - Study of the cellular immunity in children and adolescents with nasopharyngeal cancer**
N. Karimova, D. Polatova, A. Ismailova, I. Iskandarova, M. Boboev; UZ
- 18:20 - 18:20 **314P - Association of immune-related adverse events and efficacy in Japanese patients with squamous cell carcinoma of the head and neck treated with nivolumab**
T. Otsuka, K. Fujiishi, K. Matsumoto, T. Kimura, R. Koike, H. Cho, A. Hasegawa, M. Nishio, S. Otozai, T. Yoshii, T. Kudo, F. Fujisawa, N. Sugimoto, T. Yagi, F. Imamura, T. Fujii; JP
- 18:20 - 18:20 **315P - Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma in adults: Results from a non-endemic cohort of South India**
T. Chaudhuri, K.C. Lakshmaiah, K.G. Babu, L. Dasappa, L. Jacob, M.C.S. Babu, K.N. Lokesh, A.H. Rudresha, L.K. Rajeev, R. Patidar, V. Asati, R. Chethan, D. Koppaka, A. Anand; IN

- 18:20 - 18:20 **317P - Nasopharyngeal carcinoma in children and adolescent: A 10-year review in Sarawak General Hospital, Malaysia.**
N.I. Mohd Naseri, R.-Y. Lee, U. Nagaswara, C.K. Tan, V. Pei Jye; MY
- 18:20 - 18:20 **318P - Induction chemotherapy with docetaxel plus cisplatin followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma:8-year follow-up**
A. Al-Humigani, A. Maklad,, A. Alyamany, K. Taher, R. Akasha, M. Alsenosy, M. Omran, H. Alhussain, H. Bakhribah, A. Alzahrani, A. Marie, S. Aldahri, K. Al-Qahtani, R. Mohamed, Y. Bayoumi,; SA
- 18:20 - 18:20 **319P - Oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in non-distant metastatic stage IV of nasopharyngeal carcinoma**
J.-H. Chen, TW
- 18:20 - 18:20 **320P - Weekly Docetaxel Concurrent Chemoradiotherapy Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis**
J. Liao, CN
- 18:20 - 18:20 **321P - The Efficacy of Induction Chemotherapy in Stage II Nasopharyngeal Carcinoma in IMRT Era**
P.-J. Li, CN
- 18:20 - 18:20 **322P - Gender differences in risk of developing Nasopharyngeal Cancer (NPC) in one of the highest NPC ethnic in the world.**
C.K. Tan, S.P. Beh, R.-Y. Lee, V. Pei Jye, S. Damoderam, N.I. Mohd Naseri, U. Nagaswara, G.G. Yeo; MY
- 18:20 - 18:20 **323P - Strong family history of nasopharyngeal carcinoma (NPC) in Bidayuh, a local native group in Sarawak, Malaysia.**
G.G. Yeo, S.P. Beh, C.K. Tan, V. Pei Jye; MY
- 18:20 - 18:20 **324P - Neoadjuvant Chemotherapy + Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy ± Adjuvant Chemotherapy for Locoregionally Advanced NPC: an Update Meta-analysis and Efficacy-toxicity Joint Analysis.**
S. LIU, D. Xie, S. Zhou, C. Xu, Z. Ye, S. Liu, G. Wang, S. Ding, Y. Xia; CN
- 18:20 - 18:20 **325P - Comparing different normal tissue complication probability (NTCP) models of radiation-induced temporal lobe injury after intensity-modulated radiation therapy for nasopharyngeal carcinoma**
L. Zeng, CN
- 18:20 - 18:20 **326P - A curative-intent endoscopic surgery for postradiation nasopharyngeal necrosis in patients with nasopharyngeal carcinoma**
X. Zou¹, M. Chen², Y.-P. Liu¹, S.-L. Wang¹; ¹CN, ²Guangdong/CN

- 18:20 - 18:20 **327P - Two miRNA signatures for identifying nasopharyngeal carcinoma from head-neck tumors and the normal**
W. Wen, CN
- 18:20 - 18:20 **328P - Unlocking the potential of saliva-based test to detect HPV-driven oropharyngeal cancer.**
K.D. Tang¹, C. Punyadeera²; ¹AU, ²QLD/AU
- 18:20 - 18:20 **329P - Function Preservation with Trimodality Therapy in Locally Advanced Oral Tongue Squamous Cell Carcinoma**
U. Khaleeq¹, A. Rashid¹, T. Abbas¹, S. Rasheed¹, A. Raza¹, M. Khan¹, H. Mahmood¹, Y. Hameed², R. Hussain¹, A. Jamshed³; ¹PK, ²TN/US, ³Punjab/PK
- 18:20 - 18:20 **330P - Outcomes in T4 Oral cancers undergoing upfront surgery compared to Neo-Adjuvant Chemotherapy followed by surgery: A Matched Pair analysis.**
H. Dhar, S. Thiagarajan; IN
- 18:20 - 18:20 **331P - The role of ultrasound and ultrasound guided Fine needle aspiration cytology in detection and management of neck node metastases in clinically N0 patients with carcinoma of upper aero-digestive tract in remote part of underdeveloped country.**
M. Gubhaju, A. Bajracharya; NP
- 18:20 - 18:20 **332P - A study to assess the supportive care needs of post operative patients with oral cancer in B.R.A I.R.C.H, AIIMS, New Delhi.**
N. Paulose, IN
- 18:20 - 18:20 **333P - Different treatment response in several head and neck squamous cell carcinoma cell lines possibly reflecting underlying molecular signatures**
J.P. Chen, J.-Y. Chang, R.-L. Hong; TW
- 18:20 - 18:20 **334P - Surgery versus combined radiotherapy and chemotherapy: survival patterns among patients with laryngeal squamous cell carcinoma stage III and IV**
A. Abobkr, A. Shaltout, R. Elghareeb, N. Mohamed, I. Uthman; EG
- 18:20 - 18:20 **335P - Safety and efficacy of Carboplatin, Capecitabine plus Cetuximab biweekly regimen in the first-line treatment of patients with recurrent/metastatic head and neck cancer (R/MSCHN)**
R.R. Ganta, S. Nasaka; Andhra Pradesh/IN
- 18:20 - 18:20 **336P - Cys144Arg &&**
S. Yadav¹, D. Parmar²; ¹Uttar Pradesh/IN, ²IN
- 18:20 - 18:20 **338P - Palliative Chemotherapy (CT) with or without Cetuximab (CTX) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): An Indian Retrospective Analysis**

A. Bahl, K. Bhatia, P. Choudhary, S. Singhla, G. Shrivastava, J. Bal, A.K. Anand, H. Chaturvedi; IN

- 18:20 - 18:20 **339P - Decreased expression of NDRG2 predicts poor clinical outcome in patients with oral squamous cell carcinoma.**
H.-J. Yoon, H.-W. Shim, W.-J. Shin, J.-H. Kim; KR
- 18:20 - 18:20 **340P - Differential approach to the bone tumors of the maxillofacial region according to computed tomography signs**
A. Almanova, M. Khodjibekov; UZ
- 18:20 - 18:20 **341P - Human Papillomavirus (HPV) associated oral cavity and oropharyngeal cancers: cross-sectional follow-up study in south Asian country, Sri Lanka.**
P.K.D.P. Alahakoon, K.A. Perera, W.S. Pannala; LK
- 18:20 - 18:20 **342P - Survival predictors of Major Salivary Gland Cancer**
K.M. Elhusseiny¹, F.A.-E. Abd-Elhay¹, M.G. Kamel¹, H.H. Abd El Hamid Hassan¹, H.H. Muhammad El Tanany¹, H.T. Hong², T.M. Tieu³, S.K. Low⁴, V. Hou³, M. Dibas⁵, N.T. Huy⁶; ¹EG, ²VN, ³CA, ⁴MY, ⁵SA, ⁶JP
- 18:20 - 18:20 **343P - Histopathologic diagnosis of tumors in the external auditory canal: Recent 7-year experience from a single center in Daegu, Korea**
Y.-H. Kim, KR
- 18:20 - 18:20 **344P - Evaluation of oral cancer trends in Pakistan during the period 2010 to 2016.**
N. Malkani, A. Mahmood; PK
- 18:20 - 18:20 **YO23 - Nivolumab Induced Immune Thrombocytopenia in a patient with Relapsed Carcinoma of Tongue**
A. Sreevatsa, M. Kamath; IN
- 18:20 - 18:20 **YO24 - Extra Skeletal Myxoid Chondrosarcoma of Buccal Mucosa - A Case Report.**
S. m, H. Manchala, S. Kumari; IN
- 18:20 - 18:20 **YO25 - Primary Neuroendocrine Tumor of the Maxilla: A Case Report**
C.D. Uy, C.C. Esplana, G. Fernando; PH
- 18:20 - 18:20 **Melanoma and other skin tumours**
C. Robert, FR
- 18:20 - 18:20 **348P - Interim analysis of prospective observational study on the efficacy of nivolumab for Japanese advanced melanoma patients (CREATIVE study)**
Y. Nakamura, A. Takahashi, K. Namikawa, T. Takenouchi, S. Kitano, T. Fujita, K. Kubota, T. Yamanaka, Y. Kawakami, N. Yamazaki; JP

- 18:20 - 18:40 **349P - Dynamics of clinical biomarkers as predictors of immunotherapy (IT) benefit in metastatic melanoma (MM) patients (pts) treated in reference institution.**
A. Hernando, R. Dienstmann, C. Ortiz Velez, G. Villacampa, F.J. Ros Montaña, J.F. Grau Béjar, A. Garcia-Alvarez, P. Nuciforo, A. Gros, V. Garcia-Patos, D. Bodet, B. Ferrer Fabrega, J. Recio, E. Muñoz-Couselo; ES
- 18:40 - 18:40 **350P - Single-institute, retrospective study of metastatic uveal melanoma in the immune check point inhibitor era**
S. Kazuhiro, K. Sugiyama, K. Nozawa, Y. Funahashi, Y. Kogure, C. Kitagawa, S. Ichihara, R. Nishimura, T. Kubota, H. Saka; JP
- 18:40 - 18:40 **351P - Clinicopathological and prognostic significance of Programmed death ligand 1 expression in Korean melanoma patients**
S. Yun, K. Lee, Y. Park, S. Moon, H.S. Lee, G. Choe, K.S. Lee; KR
- 18:40 - 18:40 **352P - Early safety from a phase 1, multicenter, open-label, dose de-escalation study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with unresectable stage IIIB-IV melanoma (MEL)**
N. Yamazaki¹, H. Koga¹, T. Kojima¹, A. Tsutsumida¹, K. Namikawa¹, M. Yi², K. Mera¹, C. Pickett-Gies²; ¹JP, ²CA/US
- 18:40 - 18:40 **353P - Clinical and laboratory markers as predictors of Time to Treatment Failure (TTF) and Overall Survival (OS) in patients (pts) with mucosal melanoma (MM).**
F.J. Ros Montaña, I. Baraibar Argota, C. Ortiz Velez, J.F. Grau Béjar, G. Villacampa, V. Garcia-Patos, D. Bodet, C. Fernandez-Pulido, R. Dienstmann, E. Muñoz-Couselo; ES
- 18:40 - 18:40 **354P - 5HT3 receptor antagonists selectively kill melanoma cells**
A. Barzegar Fallah, H. Alimoradi, S. Baird; NZ
- 18:40 - 18:40 **355P - Efficacy and safety of weekly docetaxel regimen for advanced extramammary Paget's disease: retrospective single institute analysis.**
Y. Nakamura, I. Hirai, M. Ishii, Y. Kawakami, K. Tanese, T. Funakoshi; JP
- 18:40 - 18:40 **356P - Knowledge, attitudes, and behaviors toward skin cancer among Marine Fisheries students of Udayana University, Bali**
S.A. Suryantari, A. Satyarsa, I.G.A. Indriani, P. Sudarsa, L.M. Rusyati, M. Adiguna; ID
- 18:40 - 18:40 **357P - Location of malignant melanoma in distal extremity draining to popliteal or epitrochlear sentinel lymph nodes**
S. jinnai, K. Namikawa, E. Nakano, A. Takahashi, N. Yamazaki; JP
- 18:40 - 18:40 **YO26 - Local disease control of nasal malignant melanoma achieved by administration of nivolumab followed by palliative radiation: a case report**
T. Yamazaki, JP

- 18:40 - 18:40 **YO27 - Complete response of BRAF-mutated metastatic melanoma treated with dabrafenib and trametinib in a super-elderly patient: a case report**
S.B. Oh, K.-O. Park, J.-J. Kim, S.-Y. Oh; KR
- 18:40 - 18:40 **YO28 - Malignant Melanoma of the Palate: Report of a Metastatic Case**
M.V. Cruz-Ordinario, C.A. Boado, A. Gorospe; PH
- 18:40 - 18:40 **YO29 - Excellent response of nivolumab in patient with metastatic malignant melanoma of vagina: a case report**
A. Maisrikrod, A. Dechaphunkul; TH
- 18:40 - 18:40 **Palliative care**
- 18:40 - 18:40 **359P - A prospective study about the nutritional status of cancer patients in the southern of Tunisia**
W. Ben Kridis, W. Karray, G. Marrekechi, A. Khanfir, M. Frikha; TN
- 18:40 - 18:40 **360P - Patterns of practice for bone metastases in Japan - use of questionnaires to promote a multidisciplinary approach**
N. Nakamura¹, Y. Sakai¹, N. Matsubara², K. Kakutani¹, T. Akisue¹, N. Kiyota³, H. Minami³; ¹JP, ²Chiba/JP, ³Hyogo/JP
- 18:40 - 18:40 **361P - Aloe Vera: A multifaceted Ayurvedic herb use in palliative care of oral cancer patients**
J. Acharya, S. Beniwal, S. Jakhar, N. Mohta; IN
- 18:40 - 18:40 **362P - Retrospective analysis of efficacy and safety of Cell-free and Concentrated Ascites Reinfusion Therapy in pancreatic cancer patients with malignant ascites**
K. Harada¹, Y. Kobayashi², S. Nozawa¹, K. Sakurai¹, K. Suto¹, A. Yoshikawa¹, R. Sasaki¹, R. Abiko¹, H. Ebata¹, I. Sano¹, H. Oda¹, T. Miyagishima¹; ¹JP, ²Hokkaido/JP
- 18:40 - 18:40 **363P - A Randomized Controlled Trial of Mindfulness Breathing Exercise in Patients with Advanced Lung Cancer**
C.S. Chai, S.-B. Tan, D. Ng, C.K. Liam, Y.K. Pang; MY
- 18:40 - 18:40 **364P - An Estimation of the Population-based Survival Benefit of First-course Chemotherapy for Advanced Incurable Cancer**
V. Do, W. Ng, S. Jacob, G. Delaney, M. Barton; NSW/AU
- 18:40 - 18:40 **365P - Palliative care as a part of national cancer control plan in Uzbekistan - first steps towards the solution**
Y. Ziyaev, M. Tillyashaykhov, A. Yusupbekov, S. Abdujapparov, D. Egamberdiev, Y. Ten, H. Islamov; UZ

- 18:40 - 18:40 **366P - Socioeconomic status and demographic assessment of advanced cancer patients in Palliative care department of a tertiary care centre : Observational study**
G. Kumar, West Bengal/IN
- 18:40 - 18:40 **Precision medicine**
- 18:40 - 18:40 **370P - Shaheenah Dawood MD1, Maroun Khoury2, Faraz Khan2, Falah Khatib1, Milicent Bello3, Annette Hamadi3, Houriya Kazim3, Rania Khoury4, Georges Nasioulas5, Aparna Dhar6**
R. Khoury¹, S. Dawood², M. Khoury², F. Khan², F. Al Khatib², M. Bello², A. Hamadi², H. Kazim², A. Dhar³, G. Nasioulas⁴; ¹LB, ²AE, ³IN, ⁴GR
- 18:40 - 18:40 **371P - Clinical and molecular characteristics of ALK-rearranged Chinese lung cancer patients**
Y. Fang, J. Shou, W. Han, H. Li, X. Zhou, D. Li, H. Cheng, H. Wang, F. Lou, S. Cao, H. Pan; CN
- 18:40 - 18:40 **372P - Identification and validation of a Prognostic Signature in Malignant Pleural Mesothelioma**
J.-G. Zhou, H. Ma; CN
- 18:40 - 18:40 **373P - Cell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian cancer patient population**
J. Lee¹, A. Franovic², T. Rich², Y. Shiotsu², V. Raymond², R. Lanman²; ¹KR, ²US
- 18:40 - 18:40 **374P - Are We There Yet? A Critical Reflection of Asian Medical Oncologists on NGS-guided Precision Treatment in Asia 2018**
A. Lai¹, W.S. Seo Tho¹, S.L. Poon¹, K.T. Tan², K. Tung², J. Lee²; ¹SG, ²TW
- 18:40 - 18:40 **375P - Concordance study of between IBM Watson for oncology and real clinical practice for gastric, breast and ovarian cancer**
J.G. Choi, KR
- 18:40 - 18:40 **376P - Impact of single-gene and co-occurring mutations on TMB with potential implications for immunotherapy**
T. Shou, H. Ma, F. Lan, W. Gu, W. Cui, B. Zhang, Y.-A. Dong; CN
- 18:40 - 18:40 **377P - Application of a comprehensive platform technology for detection of cancer-associated genomic alterations and viral DNA in liquid biopsies**
Y. Choudhury, H. Chen, F. Fadhlullah, D. Tan, K. Ng, W. Phyo, M.H. Tan; SG
- 18:40 - 18:40 **378P - Circulating cell-free DNA molecular profiling among East Asian patients reveals activating MET alterations are common in diverse advanced cancer types**

S. Ikeda¹, Y. Kumaki¹, T. Rich², Y. Shiotsu², A. Franovic², V. Raymond², R. Kurzrock³, R. Lanman², J. Lee⁴, T.S.K. Mok⁵; ¹JP, ²US, ³AL/US, ⁴KR, ⁵HK

- 18:40 - 18:40 **379P - Prevalence of pathogenic mutations in Korean hereditary breast-ovarian cancer**
G. Lee, J.H. Kim, S.N. Lee, H. Chae, J. Yoo, E. Han, W. Jang, M. KIM, Y. Kim; KR
- 18:40 - 18:40 **380P - Establishment of a patient-derived xenograft (PDX) model with malignant pleural effusion and its application**
S. Chen, C.-P. Huang, H.-H. Lai, Y.-H. Lin, C.-T. Su, S.-J. Wu, C.-H. Chang, C.-C. Tsao, Y.-C. Chen, S.-C. Wang, Y.-H. Liu, S.-B. Lin, T.-H. Chen; TW
- 18:40 - 18:40 **381P - The study of RET rearrangement in advanced primary non-small cell lung cancer and associated metastatic lesions**
W.-X. Wang, C. Xu, Q.-X. Zhang, W. Zhuang, Y.-W. Tian, J. Zhang, M.-Y. Fang, Y.-P. Chen, G. Chen, T.-F. Lv, Y. Song; CN
- 18:40 - 18:40 **382P - comparison of tumor mutational burden and pd-11 between 2797 primary and metastatic breast cancer samples**
S. Dawood¹, K. Schuster², R. Fedlman³; ¹AE, ²CH, ³US
- 18:40 - 18:40 **383P - Whether pericarcinomatous tissue of non-small cell lung cancer can serve as genetic background filter in next-generation sequencing analysis**
Y. Zhang, L. Zhang, L. Chang, Y. Yang, W. Fang, Y. Guan, X. Xia, X. Yi; CN
- 18:40 - 18:40 **384P - Incidence of Germline BRCA1 and BRCA2 mutations among Filipinos**
F.V. Que, D. Ang, J.J. Andal, M. Madrid, R. Lo, M.S. Imasa, M.L. Enriquez, F. Tria Iv, L.K. Cabral, R. Dimalibot, R. Li; PH
- 18:40 - 18:40 **385P - Clinical feasibility of pancreaticoduodenectomy in different ages**
Z. Wei, T. Qing, D. Wei; CN
- 18:40 - 18:40 **386P - TP53 GOF mutations predict good response and prolonged survival to bevacizumab treatment in metastatic colorectal cancer**
Y.-L. Hsieh, Y. Liu, N. Lapke, H.-C. Hsu, H.-C. Chen, S.-J. Chen, K.T. Tan; TW
- 18:40 - 18:40 **387P - Radiation dose to contralateral parotid during treatment of carcinoma buccal mucosa**
R. Narayanasamy, S. Thiagarajan, S. P. K. Perumal; IN
- 18:40 - 18:40 **388P - ALK rearrangment in pulmonary sarcomatoid carcinoma: a retrospective study of the real world**
Y.-C. Zhu, C. Xu, W.-X. Wang, M.-Y. Fang, W. Zhuang, Q.-X. Zhang, Z. Gong, Y.-P. Chen, G. Chen, T.-F. Lv, Y. Song; CN

- 18:40 - 18:40 **389P - Risk factors of nivolumab-induced pneumonitis in patients with solid tumors**
T. Yamaguchi¹, T. Hasegawa¹, N. Hanai¹, Y. Inaba¹, K. Muro², T. Hida¹; ¹JP, ²Aichi/JP
- 18:40 - 18:40 **390P - Analysis of RET rearrangement non-small cell lung cancer cell blocks from pleural effusion**
C. Xu, W.-X. Wang, Q.-X. Zhang, W. Zhuang, Y.-W. Tian, J.-P. Xu, M.-Y. Fang, Y.-P. Chen, G. Chen, T.-F. Lv, Y. Song; CN
- 18:40 - 18:40 **391P - Mismatch repair deficiency testing for immunotherapy in metastatic cancers: a single centre study from India**
T. Sood¹, A. Rauthan¹, P. Patil¹, S. Kulkarni¹, S.P. Somashekhar¹, S. Zaveri²; ¹IN, ²Karnataka/IN
- 18:40 - 18:40 **392P - Candidate markers of homologous recombination deficiency for triple negative breast cancer**
K. Havrysh¹, G. Mukhametshina², S. Petrov², S. Safina², R. Kiyamova²; ¹UA, ²RU
- 18:40 - 18:40 **393P - The landscape and genomic characteristics in BRAF V600E wild type papillary thyroid carcinoma**
M.-Y. Fang, C. Xu, W.-X. Wang, M.-J. Wu, G. Chen, M.-H. Ge; CN
- 18:40 - 18:40 **394P - Development of the immuno-wall device for rapid detection of ALK and ROS1 fusions in lung cancer.**
N. Yogo, T. Hase, T. Kasama, T. Hatta, N. OZAWA, M. Sato, N. Kaji, M. Tokeshi, Y. Baba, Y. Hasegawa; JP
- 18:40 - 18:40 **395P - A study of efficacy and safety with apatinib therapy in advanced neuroendocrine carcinoma patients**
C. Chen, X. Liu, C. Han; CN
- 18:40 - 18:40 **Public policy**
- 18:40 - 18:40 **400P - Do Time, distance and economic factors influence stage of presentation of malignancies?? Experience from a Regional cancer center in India**
N. Ballari, T. Jindia, L. Annam, R. Miriyala, S. Ghoshal; IN
- 18:40 - 18:40 **401P - Survey of Diet and Physical Activity in New Cases of Young Breast Cancer Patients in Taiwan**
H. Feng, H.-C. Chen, I.-C. Chen, C.-H. Lin, Y.-S. Lu, W.-H. Kuo, M.-Y. Wang, C.-S. Huang, A.-L. Cheng, W.-W. Chen, P.-R. Chen; TW
- 18:40 - 18:40 **402P - Retrospective analysis of risk factor of injection site reaction induced by infusion of cisplatin plus vinorelbine**

N. OZAWA, T. Hase, T. Hatta, A. Sagara, K. Ichikawa, M. Miyazaki, M. Ando, K. Yamada, Y. Hasegawa; JP

- 18:40 - 18:40 **403P - Knowledge and Attitudes of Productive Age Women About Visual Inspection with Acetic Acid (VIA) Test in Early Screening of Cervical Cancer in Tihingan village, Klungkung, Bali**
R. Putri, A. Satyarsa, L. Marina Wirahartato, L.P. Virayanti, K. Wiswa Mitra Kenwa, P. Adiputra, I.W. Sudarsa; ID
- 18:40 - 18:40 **404P - Clinical spectrum and treatment outcomes of HIV associated cancers in a tertiary care center in South India**
S. Elumalai, K. Kannan, R. Gopal, S. Sundararajan; IN
- 18:40 - 18:40 **405P - The Impact of Awareness Program on the Knowledge, Attitude and Practice of Breast self examination among Female Healthcare workers in a Tertiary Hospital: An Interventional Study**
S.R.A. Kwak, PH
- 18:40 - 18:40 **Sarcoma**
R. Quek¹, H. Loong²; ¹SG, ²HK
- 18:40 - 18:40 **409P - Prognostic factors for post-progression survival after trabectedin treatment in patients with advanced soft tissue sarcoma**
S. Iwata, K. Yonemori, A. Arakawa, A. Maejima, F. Nakatani, E. Kobayashi, T. Mori, K. Sudo, E. Noguchi, T. Hirose, S. Komatsubara, H. Fujimoto, C. Ogawa, K. Tamura, A. Kawai; JP
- 18:40 - 18:40 **410P - FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive behavior: clinical and molecular pathology findings of two cases**
M. Lacambra¹, H. Loong¹, K.F. To¹, X. Feng², G. Taylor², E. Pleasance², J. Laskin², M. Marra², J. Griffith¹, H.Y.M. Yeung¹, K.-C. Wong¹, C. Chow¹, S. Kumta¹, W.H.A. Ng¹, T. Tse¹, C. Tong¹, T. Ng²; ¹HK, ²BC/CA
- 18:40 - 18:40 **411P - Molecular-genetic markers and remote results in osteosarcoma treatment**
D. Polatova, M. Gafur-Akhunov, K. Abdikarimov, U. Islamov, S. Urunbaev, B. Sultonov, R. Davletov; UZ
- 18:40 - 18:40 **412P - Comprehensive mRNA-based screen for tyrosine kinase fusions and a de novo alternative transcription initiation site in soft tissue sarcomas**
Y. Suehara, S. Kohsaka, A. Kurisaki, K. Akaike, T. Hayashi, K. Mogushi, T. Okubo, Y. Kim, S. Sato, E. Kobayashi, K. Kaneko, H. Mano, T. Saito; JP
- 18:40 - 18:40 **413P - Clinical benefits of later line trabectedin and eribulin treatment for soft tissue sarcoma (STS) after pazopanib treatment from Nishinomiya Sarcoma Cohort Study (NSCS)**
H. Narahara¹, M. Morimoto², E. Tanaka², S. Ueda², Y. Yasunaga², Y. Inui², K. Takahashi², S. Kawata²; ¹Hyogo/JP, ²JP

- 18:40 - 18:40 **414P - Treatment outcomes of adult osteosarcoma in Srinagarind Hospital**
P. Eiamprapaporn¹, A. Sookprasert², K. Wirasorn², P. Ungarereevittaya¹, J. Chindaprasirt²; ¹TH, ²Mueang Khon Kaen District/TH
- 18:40 - 18:40 **415P - A clinical outcome of dedifferentiated Low-grade osteosarcoma based on molecular pathological confirmation**
E. Kobayashi, S. Toki, A. Yoshida, A. Kawai; JP
- 18:40 - 18:40 **416P - Ewing Sarcoma in Adults: Demystifying Experience from a Developing Nation**
R. Ambalathandi¹, S. Gundeti¹, B. Stalin², M. Konatam¹, N. Palukuri¹, R. Yedla¹; ¹IN, ²Andhra Pradesh/IN
- 18:40 - 18:40 **417P - Oncological outcome of extremity synovial sarcomas treated with multimodality management**
A. Gulia, A. Puri, S. Laskar, B. Rekhi; IN
- 18:40 - 18:40 **418P - Oxidized low density lipoprotein receptor 1 promotes lung metastases in osteosarcoma through regulating the epithelial-to-mesenchymal transition**
J. Dylan¹, S. Jiang², H. Long², Q. Luo²; ¹Guangdong/CN, ²CN
- 18:40 - 18:40 **419P - Outcomes of gemcitabine-docetaxel as second-line chemotherapy in patients of advanced soft tissue sarcoma: a retrospective analysis**
K. Gupta, S. Parthiban, S. Kumar, S. Srinivas, D. Vallathol, R. Chanana, G. Grewal, N. Rathnasamy, A. Goel, J. Bajpai; IN
- 18:40 - 18:40 **YO30 - Extra-Gastrointestinal stromal tumor and tumor lysis syndrome, A case-report**
T. Sanlung¹, K. Wirasorn²; ¹TH, ²Mueang Khon Kaen District/TH
- 18:40 - 18:40 **YO31 - Reduced and re-escalated dose of sunitinib was adequately effective against gastrointestinal stromal tumor of the small intestine: a case report**
M. Ogata¹, H. Satake², T. Ogata¹, Y. Hatachi¹, H. Yasui¹; ¹JP, ²Hyogo/JP
- 18:40 - 18:40 **YO32 - A Case Report: Life-threatening giant cell tumor of bone with coexisting primary hyperparathyroidism initially misdiagnosed as brown tumor treated with denosumab.**
A. Phongphithakchai, S. Sakdejayont; TH
- 18:40 - 18:40 **YO33 - Dermatofibrosarcoma Protuberans of Thigh: A Case Report**
S. m., G. Usha Shree, N. Rao, R. Reddy; IN
- 18:40 - 18:40 **Supportive care**
D. Keefe¹, K. Lee², C. Steer³; ¹SA/AU, ²NSW/HK, ³VIC/AU

- 18:40 - 18:40 **424P - Clinical Factors associated with satisfaction of cancer patients for the treatment of opioid-induced constipation: A post hoc analysis utilizing outcomes of naldemedine Phase 3 study**
H. Ishiki, E. Satomi, Y. Tada, T. Yokota, H. Sato, M. Okamoto, I. Osaka; JP
- 18:40 - 18:40 **425P - Opioid-induced Constipation in Patients with Cancer Pain in Japan (OIC-J Study): Patients' Self-Assessment of the Symptoms and the Impact**
T. Noriyuki¹, H. Imai¹, S. Fumita¹, T. Harada¹, M. Gamoh², Y. Akashi¹, H. Sato¹, Y. Kizawa¹, A. Tokoro¹; ¹JP, ²Miyagi/JP
- 18:40 - 18:40 **426P - Nutritional supplement ONCOXIN to maintain appetite, body mass and quality of life in patients with advanced cancer on chemotherapy**
M. Kopp¹, I. Koroleva¹, E. Bilan¹, E. Sanz², F. Petrovskiy¹; ¹RU, ²ES
- 18:40 - 18:40 **427P - Association between dietary patterns with disease recurrence in Thai colorectal cancer patients**
V. Kunnavuttivanich, P. Pramyothin, S. Ithimakin; TH
- 18:40 - 18:40 **428P - Efficacy of single dose NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetrone (APR/GRAN) for prevention of nausea in patients receiving high dose cisplatin**
A. Dechaphunkul¹, S. Lu², S. Olivari³, L. Zhang²; ¹TH, ²CN, ³CH
- 18:40 - 18:40 **429P - A Randomized, Double Blind, Placebo-Controlled Study Evaluating Efficacy of Combination Olanzapine, Ondansetron and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Doxorubicin plus Cyclophosphamide**
W. Nipondhkit, TH
- 18:40 - 18:40 **430P - The Prospective Multicenter Study of Relation between 5-HIAA / Substance P plasma Concentration Transition and Nausea / Vomiting in Patients with Gastrointestinal Cancer Receiving Moderately Emetogenic Chemotherapy (MEC).**
K. Sawada¹, Y. Komatsu², T. Muranaka², S. Nakano¹, Y. Kawamoto¹, H. Nakatsumi¹, S. Yuki², M. Dazai², T. Saiki¹, A. Ishiguro¹, M. Tateyama¹, K. Ono¹, S. Ohnishi¹, N. Sakamoto¹; ¹JP, ²Hokkaido/JP
- 18:40 - 18:40 **431P - A randomized study comparing two different training programs**
A. Bellens, B. Sabbe, P. van Dam; BE
- 18:40 - 18:40 **432P - Resilience in adult cancer care: A review and concept analysis**
D. Luo¹, M. Eicher², K. White³; ¹AU, ²CH, ³ACT/AU
- 18:40 - 18:40 **433P - A pilot study of exercise intervention during chemotherapy in patients with metastatic cancer**

H.K. Ahn, Y.S. Kim, E.Y. Kim, K.D. Park, I. Park, S.J. Sym, S.H. Park, D.B. Shin; KR

- 18:40 - 18:40 **434P - A phase II study to assess the immunogenicity and optimal timing of 13-valent pneumococcal conjugated vaccination during adjuvant chemotherapy**
W.K. Bae, KR
- 18:40 - 18:40 **435P - Title: Primary Prophylaxis For Febrile Neutropenia - Is It Really Required For AC Chemoregimen In Breast Cancer Patients?**
N. Palukuri, IN
- 18:40 - 18:40 **436P - Identifying predictive factors for severe anemia in cancer patients treated with cytotoxic chemotherapy**
B. Mofid, A. Razzaghdoust, P. Peyghambarlou; IR
- 18:40 - 18:40 **437P - Cost simulation for the US of febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim in lung cancer**
A. McBride¹, A. Krendyukov², N. Mathieson², K. Campbell³, S. Balu³, K. MacDonald⁴, I. Abraham⁵; ¹AL/US, ²DE, ³NJ/US, ⁴US, ⁵AZ/US
- 18:40 - 18:40 **438P - Preventive Role of Beta Blockers and Renin-Angiotensin Inhibitors in Anthracycline-induced Cardiotoxicity among Adult Cancer Patients: A Meta-Analysis**
D.B. Sacdalan, M.D. Tiongson, K.A. Mondragon, L. Abrahan, Iv, J. Añonuevo, G. Fernando, F.E. Punzalan; PH
- 18:40 - 18:40 **439P - Pain control among cancer patients receiving strong opioids and their perspective towards opioids in a developing country with a diverse multicultural background**
D. Lee, D. Kiu, V. Pei Jye; MY
- 18:40 - 18:40 **440P - A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting. (ESPRESSO-02/HGCSG1602)**
M. Nakamura¹, T. Muranaka², M. Yagisawa¹, Y. Kawamoto¹, S. Yuki², A. Ishiguro¹, M. Dazai², S. Sogabe¹, K. Harada¹, Y. Kobayashi², T. Miyagishima¹, N. Okamura¹, Y. Tsuji², S. Terae¹, K. Ono¹, Y. Komatsu²; ¹JP, ²Hokkaido/JP
- 18:40 - 18:40 **441P - The Efficacy of Scalp-Cooling System for the Prevention of Chemotherapy-induced Hair Loss in Metastatic Breast Cancer Patients Treated with Erubrin.**
M. Kato, JP
- 18:40 - 18:40 **442P - CGA directed interventions in Asian geriatric oncology patients**
M. Wang, F. Ho, Y.S. Ng, B.C. Tai, W.C. Yong, S.L.A. Pang; SG

- 18:40 - 18:40 **443P - Safety and efficacy of direct oral anticoagulants vs. warfarin for Japanese lung cancer patients with thromboembolism in real world settings.**
T. Oguri¹, M. Hiraide², T. Shiga², C. Yasuda², M. Nishio², S. Takahashi²; ¹Aichi/JP, ²JP
- 18:40 - 18:40 **444P - Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma**
S. Nakamura, H. Miki, Y. Okamoto, K. Sogabe, M. Oura, M. Takahashi, M. Iwasa, T. Harada, S. Fujii, K. Kagawa, M. Abe; JP
- 18:40 - 18:40 **445P - Correlation between Lymphocyte-Monocyte Ratio and Hand Grip Strength in Breast Cancer Patients before Chemotherapy**
A. Kurniawan, R. Hatma, A. Adisasmita, N. Soetandyo, F. Witjaksono, H. Putri, D. Widjaja; ID
- 18:40 - 18:40 **446P - What do oncologists think patients with incurable cancer should be told about their prognosis?**
A. Vasista¹, M. Stockler², A. Martin², N. Lawrence², B. Kiely²; ¹AU, ²NSW/AU
- 18:40 - 18:40 **447P - Herbal product and dietary supplement intake among patients at the Philippine General Hospital (PGH) medical oncology clinic: a cross-sectional survey.**
R.E. King, D. Sacdalan, R.R. Angeles; PH
- 18:40 - 18:40 **448P - Can we estimate the risk of chemotherapy toxicity in Indian Geriatric patient population and utility of CRASH (Chemotherapy risk assessment scale for high age patients) score?**
A. Mittal, A. Agarwal, R. Rangaraju, S. Batra, C. Gouda D, S. Qureshi; IN
- 18:40 - 18:40 **449P - A Study of Adherence to oral temozolomide chemotherapy in central nervous system tumors**
S. VALLATHOL, IN
- 18:40 - 18:40 **450P - Prescreening of immune-related adverse events in our institute**
T. Sone, T. Murai, K. Itaya, Y. Koike, Y. Ono, M. Nakamura; JP
- 18:40 - 18:40 **451P - Epidemiology of AYA(adolescents and young adults) cancer in National Institute of Cancer Research and Hospital(NICRH), Dhaka, Bangladesh.**
A.A.M. Khan, P.S. Akthar; BD
- 18:40 - 18:40 **452TiP - A feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy. (ExCAVE study)**
M. Nakamura¹, M. Yagisawa¹, T. Saiki¹, A. Ishiguro¹, K. Sawada¹, S. Yuki², T. Sasaki¹, T. Ando¹, H. Ohori³, M. Kotaka⁴, O. Muto¹, Y. Shindo¹, K. Nakashima¹, A. Hosokawa¹, A. Doi⁵, N. Izawa¹, Y. Sunakawa¹, A. Satoh¹, K. Ono¹, Y. Komatsu²; ¹JP, ²Hokkaido/JP, ³Miyagi/JP, ⁴Hyogo/JP, ⁵Chiba/JP

- 18:40 - 18:40 **Thoracic tumours, early stage**
- 18:40 - 18:40 **454P - The PD-L1 expression in surgically resected lung adenocarcinoma: Its correlations with the prognosis, driver oncogene alterations and clinicopathological features**
K. Takamochi, T. Hayashi, K. Hara, K. Suzuki; JP
- 18:40 - 18:40 **455P - Association Between Pre-Existing Conditions and Driver Gene Profiles/Immune Contextures in NSCLC: A Large-Sample Analysis**
W. Liang, C.C. Li, Z. Wang, Y. He, J. He; CN
- 18:40 - 18:40 **456P - Optimal Starting Age for Lung Cancer Screening with Low-dose CT: A Population Level Analysis**
C.C. Li, H. Liang, Y. Zhao, Y. Wen, G. Qiu, N. Zhong, J. He, W. Liang; CN
- 18:40 - 18:40 **457P - Impact of FDG PET/CT in selection of patients for adjuvant chemotherapy in resection margin negative stage IB and IIA (T2bN0) non-small cell lung cancer**
H.L. Park, I.R. Yoo, S. Park, S.H. Boo; KR
- 18:40 - 18:40 **458P - Rate of pathological N2 nodes among patients of NSCLC with cN0/cN1 nodal status on CECT scan - A study from tertiary care hospital in India**
B. Bansal, M. Gowda, V. Kumar, S. Deo, S. Bhorawal, D. Jain, P. Malik, S. Jee Bharati, M. Yadav, S. Kumar; IN
- 18:40 - 18:40 **459P - Clinical outcomes and treatment strategies of sarcomatoid carcinoma of the lung**
Y. Wang, CN
- 18:40 - 18:40 **460P - Chemotherapy versus Combined Chemoradiotherapy: Survival Patterns among Elderly Patients with Limited Stage Small Cell Lung Cancer**
S. Abdulaziz, EG
- 18:40 - 18:40 **461P - Clinical courses of patients with small cell lung cancer after complete resection followed by adjuvant chemotherapy**
Y. Shinno, S. Kanda, J. Sato, R. Morita, Y. Matsumoto, S. Murakami, Y. Goto, H. Horinouchi, Y. Fujiwara, N. Yamamoto, Y. Ohe; JP
- 18:40 - 18:40 **462P - Circular RNA Profiling and Its Potential for Esophageal Squamous Cell Cancer Diagnosis and Prognosis**
Q. Cao, L. Fan, J. Zhu, J. Zhang, B. Li; CN
- 18:40 - 18:40 **463P - Asthma and Risk of Lung Cancer: A Mendelian Randomization Study**
H. Zhou¹, Y. Zhang¹, W. Fang¹, Y. Huang¹, Y. Yang¹, S. Hong¹, G. Chen¹, S. Zhao¹, J. Liu¹, H. Zhao¹, Z. Li²; ¹CN, ²Guangdong/CN

- 18:40 - 18:40 **YO35 - Thymic large cell neuroendocrine carcinoma- a rare and aggressive tumor: case report**
W. laosuangkool, E. Sirachainan; TH
- 18:40 - 18:40 **YO36 - A Case of Good Syndrome: A Rare Acquired Immunodeficiency Associated with Thymoma**
S. Sakchinabut, C. Sookthon, P. Phichai Chansriwong; TH
- 18:40 - 18:40 **Thoracic tumours, locally advanced**
- 18:40 - 18:40 **467P - Correlation between PD-L1 expression and clinicopathological characterization in NSCLC**
Y. Jin, CN
- 18:40 - 18:40 **468P - Relationship of the level of soluble PD-L1 and its relevant proteins in peripheral blood with the prognosis of patients with NSCLC**
G. Bai, Y. Xu, M. Wang; CN
- 18:40 - 18:40 **469P - Application of Next Generation Sequencing in Pleural Effusion Molecular Profiling Using Oncomine™ Lung Cell-Free Total Nucleic Acid Research Assay**
C. Xiang, R. Zhao, S. Ma, L. Guo, Y. Han; CN
- 18:40 - 18:40 **470P - Clinical and Pathological Characteristics and Survival Analysis of NSCLC Patients with Skip Metastasis in Stage pN2/III**
L. Zhang, CN
- 18:40 - 18:40 **471P - Effect of second-line ramucirumab in East Asian patients with refractory and aggressive disease: Subgroup analysis from REVEL and JVCG trials in non-small cell lung cancer**
K. Yoh¹, K. Nakagawa¹, G.-C. Chang², Y. Hosomi¹, T.-C. Hsia², T. Tamura¹, R. Cheng², R. Varea³, S. Enatsu¹, A. Hayden Zimmermann⁴, J.-Y. Shih²; ¹JP, ²TW, ³ES, ⁴AL/US
- 18:40 - 18:40 **472P - Plasma KRAS Mutation in Indonesian Lung Cancer Patients with Smoking History, Treated with Chemotherapy**
N. Masykura¹, S. Andarini², E. Syahrudin Spp K¹, J. Zaini¹, A. Hudoyo¹, Y. Santoso¹, A. Mirandari³, A.R. Utomo¹; ¹ID, ²DKI Jakarta/ID, ³GB
- 18:40 - 18:40 **473P - ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): subpopulation analyses by poor performance status (PS), elderly, uncommon EGFR mutations**
M. Provencio¹, P. Cheema², J. Vansteenkiste³, B.C. Cho⁴, C. Zhou⁵, J. Yu⁵, C. Martin⁶, K. Park⁴, Y. He⁵, Y. Hu⁵, D. Vicente¹, M. Miranda⁷, J. Rigas⁸, F. de Marinis⁹; ¹ES, ²CA, ³BE, ⁴KR, ⁵CN, ⁶AR, ⁷GB, ⁸MD/US, ⁹IT

- 18:40 - 18:40 **474P - Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC**
S. Thongprasert¹, S. Geater¹, D. Clement², A. Abdelaziz³, J. Reyes-Igama⁴, D. Jovanovic⁵, A. Alexandru², M. Schenker², V. Sriuranpong¹, P. Serwatowski⁶, S. Suresh⁷, A. Cseh⁸, R. Gaafar³; ¹TH, ²RO, ³EG, ⁴PH, ⁵RS, ⁶PL, ⁷SG, ⁸AT
- 18:40 - 18:40 **475P - Radiotherapy With Continued EGFR-TKIs for Oligoprogressive Disease in Non-Small Cell Lung Cancer: A Real-World Study**
F. Wu¹, S. Wu², H. Hu²; ¹Hunan/CN, ²CN
- 18:40 - 18:40 **476P - Clinicopathological Features of ALK Protein in 9889 Non-small-cell Lung Cancer Specimens and Genomic Rearrangement Identified by Capture-based Next-generation Sequencing: a Chinese Retrospective Analysis**
R. Zhao, J. Zhang, Y. Han, J. Shao, L. Zhu, C. Xiang, Q. Zhang, H. Teng, G. Qin, L. Zhao, M. Ye, J. Zhao, W. Ding; CN
- 18:40 - 18:40 **477P - Meta-analysis comparing incidence of Grade 3/4 neutropenia with ALK inhibitors and chemotherapy, in patients with NSCLC**
A. Krendyukov¹, R. Arani², N. Mathieson¹, B. Rapoport³; ¹DE, ²NJ/US, ³ZA
- 18:40 - 18:40 **478P - A Large-scale Retrospective Study on ROS1 Fusion in Lung Carcinoma in Chinese Population.**
Q. Zhang, Y. Han, J. Zhang, J. Shao, L. Zhu, R. Zhao; CN
- 18:40 - 18:40 **479P - Bevacizumab-Induced Radiosensitization in Small Cell Lung Cancer**
J. Bonner¹, H. Trummell²; ¹US, ²AL/US
- 18:40 - 18:40 **480P - Tracheal adenoid cystic carcinoma: A systematic review and Meta-analysis**
S. Mallick, P. Giridhar, G. Rath; IN
- 18:40 - 18:40 **481P - The effectiveness of CRT combined with esophagectomy for cT4b esophageal SCC**
S. Hamasu, D. Manaka; JP
- 18:40 - 18:40 **482P - treatment experience of thymoma & thymic carcinoma in tertiary cancer institute in india**
V. Tirumala¹, M. Suresh Babu¹, K. Govind Babu¹, D. Lokanatha¹, L. Jacob¹, K.N. Lokesh², A. Rudresha², L. Rajeev¹, S. Saldanha², G. Giri¹; ¹IN, ²Karnatka/IN
- 18:40 - 18:40 **YO37 - The usefulness of radiotherapy for intubated patients with squamous cell carcinoma of the lung.**
S. Hiraoka, K. Ogura, Y. Kosaka, T. Imagumbai, T. Hattori, T. Ogata, M. Kokubo; JP
- 18:40 - 18:40 **Thoracic tumours, metastatic**

- 18:40 - 18:40 **494P - Hippo-YAP Pathway Mediated Resistance to Crizotinib in ROS1-Positive Lung Cancer**
P. Sun, H. Gao; CN
- 18:40 - 18:40 **495P - Serum EGFR1 and EGFR2 expression in Non Small Cell Lung Cancer patients.**
M.M.A. Beg, IN
- 18:40 - 18:40 **496P - Clinical application of plasma mitochondrial DNA content in lung cancer patients**
L. Zhang, CN
- 18:40 - 18:40 **497P - Neutrophil Extracellular Traps Promote Lung Cancer Invasion and Migration In Response to Severe Infection**
L. Zhang, CN
- 18:40 - 18:40 **498P - Retrospective evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with clinical and demographical data from a tertiary care institute of northern India.**
K. Domadia, U. Batra, P. Jain, M. Sharma, S. Gupta, S. Bothra, S. Pasricha, K. Chaudhari, G. Vishwakarma; IN
- 18:40 - 18:40 **499P - Mutation status and targeted therapeutic efficacy of advanced non-small cell lung cancer: A real-world study of NSCLC in China (preCAPTRA-LUNG)**
H. Liang, X. Song, Y. Zhang, S. Zhang, F. li, J. Fang, J. li, L. Liang, L. Nie, K. Ma, L. Zhang, X. Wang, W. Zhong, J. Zhao, Y. Xu, M. Chen, M. Wang; CN
- 18:40 - 18:40 **500P - Efficacy of Icotinib in Advanced Lung Squamous Cell Carcinoma**
S. Liang, M. Wang, Y. Xu, F. Tan, L. Ding, Y. Ma; CN
- 18:40 - 18:40 **501P - Phase II study of Nedaplatin plus Amrubicin in patients with untreated, advanced or relapsed Squamous cell lung cancer**
T. Suyama, H. Taniguchi, T. Ikeda, H. Yamaguchi, T. Kitazaki, H. Soda, K. Nakatomi, A. Kinoshita, M. Fukuda, H. Mukae; JP
- 18:40 - 18:40 **502P - Apatinib plus S-1 as Second-Line or Laterline Treatment for Advanced Squamous Cell Lung Carcinoma**
Q. Shi¹, L. Xia¹, J. Zhou¹, Z. Wang¹, L. Sheng¹, G. Wang¹, L. Wang¹, X. Cheng¹, F. Wang¹, F. Kong², F. Zhao¹, X. Li¹, B. Ye¹, L. Mei¹, Y. Liu¹, L. Pan¹, J. Xie¹, G. Cheng¹, X. Li¹; ¹CN, ²CX
- 18:40 - 18:40 **503P - Clinical experiences of cytotoxic chemotherapy in patients with lung cancer complicated by interstitial pneumonia who were treated with pirfenidone simultaneously: A retrospective observational study in single institution**
Y. Yanq, K. Nishida, M. Ishijima, T. Uenami, Y. Akazawa, T. Yamaguchi, M. Mori; JP

- 18:40 - 18:40 **504P - Association of Systemic Inflammation With Survival in EGFR wild-type lung cancer**
X. Chen, L. Zhang, X. Liu; CN
- 18:40 - 18:40 **505P - Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT02780778)**
Z. Pan, C. Wang, G. Xie, D. Liu, Z. Yan, Y. Li, Z. Jiang, B. Wang, L. Li; CN
- 18:40 - 18:40 **506P - Efficacy of local therapy for patients with oligometastatic non-small cell lung cancer**
Y. Sato, D. Fujimoto, K. Hosoya, H. Kawachi, H. Hamakawa, Y. Takahashi, M. Kokubo, S. Hara, K. Tomii; JP
- 18:40 - 18:40 **507P - Investigating Tumour Evolution in a Single Patient with Disseminated Cancer**
T. Robb, C. Blenkiron, P. Tsai, K. Parker, A. Drummond, M. Black, A. Gavryushkin, B. Woodhouse, P. Houseman, E. Coats, P. Shields, S. Fitzgerald, D. Wright, R. Tse, N. Kramer, C. Barker, Y. Triggs, S. Stables, B. Lawrence, C. Print; NZ
- 18:40 - 18:40 **508P - Oncogenic driver mutation analysis in lung adenocarcinoma: a single center study in India**
S. Kulkarni¹, A. Rauthan¹, P. Patil¹, T. Sood¹, S. Somashekhar¹, S. Zaveri²; ¹IN, ²Karnataka/IN
- 18:40 - 18:40 **509P - Treatment (Tx) patterns in patients (pts) with lung cancer starting 1st or 2nd generation (1G/2G) EGFR-TKI: a US insurance claims database analysis**
J. Gray¹, B. Thakrar², P. Sun², S. Maclachlan², N. Chehab³, D. Potter²; ¹FL/US, ²GB, ³US
- 18:40 - 18:40 **510P - Characteristics and outcome of small cell lung cancer patients (SCLC) transformed from adenocarcinoma after tyrosine kinase inhibitors treatment**
B. Zhang, J. Xu, S. Wang, Y. Zhang, J. Qian, R. Qiao, J. Lu, L. Zhang, Y. Zhao, B. Han; CN
- 18:40 - 18:40 **511P - AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): updated PhII results including overall survival (OS)**
C. Zhou¹, M. Wang¹, Y. Cheng², Y. Chen³, Y. Zhao¹, Y.-K. Shi¹, M.-J. Ahn⁴, Y. Lu⁵, M. Shi¹, J.-Y. Han⁴, S.-W. Kim⁴, H.-L. Zhang¹, G. Chen¹, H. Li¹, J. Wang¹, Y.-L. Wu¹; ¹CN, ²Jilin/CN, ³Hubei/CN, ⁴KR, ⁵Sichuan/CN
- 18:40 - 18:40 **512P - Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study**
Q. Zhou, H. Zhang, L. Jiang, Y. Shi, Y. Chen, J. Yu, C. Zhou, Y. He, Y. Hu, Z.-A. Liang, Y. Pan, W. Zhuo, Y. Song, G. Wu, G. Chen, Y. Lu, Y. Cheng, S. Lu, J. Wang, Y. Wu; CN

- 18:40 - 18:40 **513P - Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer**
P.-L. Su, Y.-L. Wu, W.-Y. Chang, W.-C. Su, S.-C. Yang, C.-C. Lin; TW
- 18:40 - 18:40 **514P - Co-occurring Alterations in Driver Genes Impact on EGFR-Targeted Therapy Among Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer**
C. Lu, J. Kang, H.-J. Chen, H.-Y. Tu, Q. Zhou, J.-Y. Ye, Y.-L. Wu, J.-J. Yang; CN
- 18:40 - 18:40 **515P - Tepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): phase 2 data**
Y.-L. Wu¹, J. Zhou², S. Lu², Y. Zhang³, J. Zhao², H. Pan², Y.-M. Chen⁴, C.-F. Chian⁵, R. Bruns⁶, A. Johne⁶, J. Scheele⁶, Y. Cheng⁷; ¹Guangdong/CN, ²CN, ³Zhejiang/CN, ⁴TW, ⁵, ⁶DE, ⁷Jilin/CN
- 18:40 - 18:40 **516P - Phase II Trial of Afatinib in Elderly Patients over 75 Years of Age with EGFR mutation positive NSCLC**
Y. Nakahara, S. Oizumi, H. Mizugaki, Y. Fujita, T. Harada, T. Takashina, R. Ko, K. Watanabe, T. Hotta, H. Minemura, S. Saeki, S. Yagishita, A. Hamada; JP
- 18:40 - 18:40 **517P - A real world study of osimertinib: ASTRIS 2nd DCO Korean subgroup analysis**
J.-S. Lee¹, B.C. Cho², D.-W. Kim², K. Park², J.H. Kang², S.S. Yoo², S.Y. Lee², C.H. Kim², S.H. Jang², Y.C. Kim², H.-K. Yoon², S.-W. Kim²; ¹Gyeonggi-do/KR, ²KR
- 18:40 - 18:40 **518P - Outcomes of EGFR-TKIs for patients with non-small cell lung cancer harboring EGFR mutations with poor performance status**
K. Hashimoto, Y. Okuma, T. Hakozaki, K. Watanabe, Y. Hosomi; JP
- 18:40 - 18:40 **519P - Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) - Tyrosine Kinase Inhibitors (TKI) in Elderly Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)**
Y. Takeyasu, Y. Goto, R. Morita, J. Sato, S. Murakami, H. Horinouchi, Y. Fujiwara, S. Kanda, N. Yamamoto, Y. Ohe; JP
- 18:40 - 18:40 **520P - Brain surgery for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases**
H.H. Lee, M.-Y. Huang; TW
- 18:40 - 18:40 **521P - Real World Data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation.**
K. Tanaka¹, N. Inui¹, K. Asada¹, T. Abe¹, O. Hataji¹, S. Hayai¹, K. Ito¹, K. Imaizumi¹, T. Kimura², A. Kubo¹, E. Kunii¹, K. Murotani¹, M. Okuno¹, Y. Oya¹, J. Shindoh¹, H. Taniguchi¹, T. Tsuda¹, T. Yamaguchi¹, T. Hida¹, T. Suda¹; ¹JP, ²Aichi Prefecture/JP

- 18:40 - 18:40 **523P - Real World Data on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKI) use in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR mutations in Singapore**
B. Chua, E.H. Tan, D. Lim, M.-K. Ang, D.S.W. Tan, Q.-S. Ng, R. Kanesvaran, A. Jain, W.-L. Tan, C.K. Toh, T. Rajasekaran; SG
- 18:40 - 18:40 **524P - EGFR mutation in Middle East and Africa is it really lower than in asiatic NSCLC ?**
Z. Benbrahim, H. Bedoudou, N. Mellas; MA
- 18:40 - 18:40 **525P - Management of Brain Metastases in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis**
C.H. Chen, M.-Y. Huang, I.-W. Chong; TW
- 18:40 - 18:40 **526P - Correlation between the response to crizotinib and concomitant genetic alterations in advanced lung cancer patients with ALK rearrangement**
X. Liu, M. Chen, Y. Xu, J. Zhao, W. Zhong, M. Wang; CN
- 18:40 - 18:40 **527P - Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong**
H. Loong¹, C. Wong¹, L. Leung¹, C.P.K. Chan¹, A. Chang¹, M. Gibbs²; ¹HK, ²AE
- 18:40 - 18:40 **528P - The impact of continuing ALK inhibitors beyond initial disease progression on clinical outcome in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter retrospective analysis**
S. Sakata, S. Saeki, Y. Sakata, K. Kawamura, K. Ichikado, M. Inaba, S. Ushijima, K. Imamura, K. Iyonaga, T. Kumabe, R. Fujita, K. Kashiwabara, S. Fujii, T. Komatsu, O. Sakamoto, H. Okabayashi, K. Saruwatari, Y. Tomita, T. Sakagami; JP
- 18:40 - 18:40 **529P - The management and outcome of crizotinib resistant patients: comparison of patients who received ceritinib to those treated with chemotherapy or other oral TKI.**
S. Majumdar, A. Agarwal, V. Noronha, A. Joshi, V. Patil, R. Kumar, K. Prabhash; IN
- 18:40 - 18:40 **530P - Comparative efficacy of first-line ceritinib and alectinib in advanced ALK+ NSCLC: a cross-study indirect comparison**
C.P.K. Chan¹, J. Li², S. Knoll³, W. Tang⁴, I. Bocharova², J. Signorovitch²; ¹HK, ²MA/US, ³NJ/US, ⁴US
- 18:40 - 18:40 **531P - Clinical Experience in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases in China**
Y. Han, K. Ren, H. Zhang, L. Sun, X. Ren; CN
- 18:40 - 18:40 **532P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: does choice of platinum affect outcomes?**

D. Rodriguez Abreu¹, M. Garassino², E. Esteban³, G. Speranza⁴, E. Felip³, M. Domine³, M. Hochmair⁵, S. Powell⁶, S. Cheng⁷, H. Bischoff⁸, N. Peled⁹, R. Hui¹⁰, M. Reck⁸, E. Garon¹¹, M. Boyer¹², F. Grossi², R. Jennens¹³, J. Yang¹⁴, M.C. Pietanza¹⁴, S. Gadgeel¹⁵; ¹Canary Islands/ES, ²IT, ³ES, ⁴AB/CA, ⁵AT, ⁶SD/US, ⁷ON/CA, ⁸DE, ⁹IL, ¹⁰NSW/AU, ¹¹CA/US, ¹²ACT/AU, ¹³VIC/AU, ¹⁴NJ/US, ¹⁵MI/US

- 18:40 - 18:40 **533P - PD-(L)1 Inhibitors VS. Chemotherapy VS. Their Combination in Front-line Treatment of NSCLC**
H. Liang, D. Chen, Z. Liu, J. He, W. Liang; CN
- 18:40 - 18:40 **534P - Pre-existing antibody profiles related to immune-related adverse events in advanced non-small-cell lung cancer patients treated with anti PD-1 antibody**
Y. Toi, S. Sugawara, J. Sugisaka, H. Ono, M. Asou, K. Tsurumi, K. Suzuki, H. Shimizu, Y. Domeki, T. Aiba, S. Kawana, R. Saito, K. Terayama, Y. Kawashima, A. Nakamura, S. Yamanda, Y. Kimura, Y. Honda; JP
- 18:40 - 18:40 **535P - Association of immune-related pneumonitis with the phenotypic appearance of concurrent ILD in patients treated with anti-PD-1 antibody**
R. Shibaki, S. Murakami, Y. Matsumoto, Y. Goto, S. Kanda, H. Horinouchi, Y. Fujiwara, N. Yamamoto, Y. Ohe; JP
- 18:40 - 18:40 **536P - Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild type advanced NSCLC**
P. Xiao¹, R. Yu², X. Wu³, Y. Shao², Y.-L. Wu¹, Q. Zhou¹; ¹CN, ²CA, ³ON/CA
- 18:40 - 18:40 **537P - The financial toxicity of non-small lung cancer treatment: the optimization of first and second-line therapy with immune check point inhibitors**
J. Giuliani, A. Bonetti; IT
- 18:40 - 18:40 **538P - Lung cancer vaccine - Experiences in Serbia**
Z. Andric, RS
- 18:40 - 18:40 **539P - Profiling of Immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small-cell lung cancer in real world.**
M. Aso, S. Sugawara, Y. Toi, J. Sugisaka, H. Ono, K. Tsurumi, K. Suzuki, H. Shimizu, Y. Domeki, T. Aiba, S. Kawana, R. Saito, K. Terayama, Y. Kawashima, A. Nakamura, S. Yamanda, Y. Kimura, Y. Honda; JP
- 18:40 - 18:40 **540P - Clinical Outcomes in Non-Small Cell Lung Cancer Patients with Ultra-high Expression of Programmed Death Ligand-1 Treated with Pembrolizumab as First-line Therapy: A Retrospective Multicenter Cohort Study**
H. Kurebe, R. Edahiro, M. Kanazu, D. Fujimoto, M. Tamiya, A. Tamiya, H. Suzuki, K. Hirano, T. Yokoyama, M. Morita, Y. Fukuda, J. Uchida, T. Makio; JP
- 18:40 - 18:40 **541P - Gold fiducial tracking using Cyberknife in adrenal metastasis from Small cell lung cancers**
G. Lohith, B.S. Ajai Kumar; IN

- 18:40 - 18:40 **542P - Prophylactic cranial irradiation in patients with extensive-stage small-cell lung cancer (ES-SCLC): an updated tertiary cancer centre experience**
M. Naidoo, F. Lin, M. Jameson, K. Shelly, A. Srivastava; NZ
- 18:40 - 18:40 **543P - Investigation and Analysis of Nutritional Status of Patients With Lung Cancer**
X. Chen, L. Zhang, X. Liu; CN
- 18:40 - 18:40 **544P - Lung Cancer in Adolescent & Young Adults: Single Center Experience from Eastern India**
B. Biswas, D. Dabkara, S. Ganguly, J. Ghosh; IN
- 18:40 - 18:40 **545TiP - Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study)**
Y. Xu, L. Zhang, J. Fang, Z. Wang, J. li, L. Li, B. Ai, L. Nie, X. Mu, L. Liang, S. Zhang, Y. Zhang, Y. Song, X. Song, Y. Wang, T. Xin, B. Jin, X. Wang, C. Ding, M. Wang; CN
- 18:40 - 18:40 **546TiP - Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); a phase 2 trial in progress**
P. Paik¹, H. Sakai², R. Bruns³, J. Scheele³, J. Straub³, E. Felip⁴; ¹NY/US, ²JP, ³DE, ⁴ES
- 18:40 - 18:40 **YO38 - Concurrent nivolumab and radiotherapy in treatment of lung squamous cell carcinoma**
D.W. Lee¹, G.F. Ho²; ¹MY, ²Wilayah Persekutuan/MY
- 18:40 - 18:40 **YO39 - Adenocarcinoma lung with sphenoidal metastasis**
M. Behera¹, L. Soy², F. Ansari², N. Panda², L. Sarangi²; ¹Delhi/IN, ²IN
- 18:40 - 18:40 **YO40 - Osimertinib in the Treatment of Leptomeningeal Disease in T790M-negative, EGFR-mutated NSCLC: A Case Report**
L. Kasherman¹, J. Chen², H. Soudy¹; ¹AU, ²NSW/AU
- 18:40 - 18:40 **YO41 - Hemodynamic instability caused by cardiac metastases of non-small cell lung cancer- case studies**
C.-I. Shen, B.-W. Hu, Y.-H. Wu, C.-H. Chiu, Y.-M. Chen, C.-L. Chiang; TW
- 18:40 - 18:40 **YO43 - The long term survival of a 78 year old female diagnosed with Malignant Epithelial Mesothelioma with peritoneal disease on Pembrolizumab plus Pemetrexed and Carboplatin: a case report**
K.R. Oracion, G. Cornelio; PH
- 18:40 - 18:40 **General interest**

- 18:40 - 18:40 **548P - Can we improve cost effectiveness of oncology clinical trials workflow? A prospective RECIST 1.1 study**
H. Beaumont, A. Iannessi, C. Klifa, S. Patrity; FR
- 18:40 - 18:40 **549P - Clinical association of antibiotics in immune check point inhibitors for advanced cancer treatment**
H. Kim, I.-H. Kim; KR
- 18:40 - 18:40 **550P - Effect of Reasons for Screen Failure (RFSF) on Standard of Care in Cancer Patients Screened for Clinical Trials**
C. Tiu¹, Z. Loh¹, C. Gan², J. Hakanson², H. Gan², T. John², E. Hawkes¹; ¹AU, ²VIC/AU
- 18:40 - 18:40 **551P - The reporting quality of prediction models in oncology journals: a systematic review**
T. Takemura, Y. Kataoka, Y. Uneno, T. Ootoshi, H. Matsumoto, Y. Tsutsumi, Y. Tsujimoto, M. Yuasa, T. Yoshioka, H. Wada; JP
- 18:40 - 18:40 **552P - Survival patterns of pediatric neuroblastoma at different primary sites**
A. Diab, I. Uthman; EG
- 18:40 - 18:40 **553P - Efficacy of chemotherapy for elderly patients with extrapulmonary neuroendocrine carcinomas**
C. Funasaka, O. Yasushi, Y. Kanemasa, T. Shimoyama; JP
- 18:40 - 18:40 **554P - Rational Combinations of Active and Passive Immunotherapy Mobilize Immune and clinical responses in terminal cancers**
R. Ruan¹, Q.Z. Ruan²; ¹CN, ²AL/US
- 18:40 - 18:40 **555P - Clinical Features and Outcomes of Carcinoma of Unknown Primary Site: A single center experience**
S. Gohar¹, S. Al-Hassanin², S. Soliman²; ¹Menoufia Governorate/EG, ²EG
- 18:40 - 18:40 **556P - Surgery for Nonhepatic malignancy in Cirrhotic Patients; 5 year Single Center Experience in India**
S. Galodha, S. Bains; IN
- 18:40 - 18:40 **557P - The National Liver Disease Biobank: A Good Resource for Liver and Associated Cancer Research**
B. Yadav¹, C. Bihari²; ¹Rohini/IN, ²IN

25-11-2018

08:30 - 09:15	Type: Young Oncologist session Title: Vesalius	Exhibition area
09:15 - 10:00	Type: Challenge Your Expert session Title: First line treatment in a fit advanced NSCLC patient with PD-L1 expression of 60% Chair: Shun Lu, CN	Hall 404

09:15 - 09:30 **First line treatment in a fit advanced NSCLC patient with PD-L1 expression of 60%**
S. Novello, IT

09:30 - 10:00 **Discussion led by**
S. Lu, CN

09:15 - 11:15 **Type: Special Session** **Hall 407**
Title: Working together: Illustration of combined modalities
 Chair: Françoise Mornex, FR; Suresh Senan, NL

09:15 - 09:30 **Early stage breast cancer: Case presentation 1: What is the recommended surgical approach?**
C.W. Chan, SG

09:30 - 09:45 **Early stage breast cancer: Is there a place for radiation after surgery?**
F. Lim, SG

09:45 - 10:00 **Lung SABR: Case presentation: Imaging and delivery techniques**

10:00 - 10:15 **Lung SABR: Post-SABR radiological evaluation: IASLC paper**
S. Senan, NL

10:15 - 10:30 **Castration-resistant prostate cancer: Case presentation: Indications for SABR, treatment planning and delivery techniques**
M.L.K. Chua, SG

10:30 - 10:45 **Castration-resistant prostate cancer: Is there a need for combined medical treatment?**
R. Kanesvaran, SG

10:45 - 11:00 **Esophageal and EG junction: How can the Medical Oncologist contribute?**
F. Lordick, DE

11:00 - 11:15 **Esophageal and EG junction: Clinical case presentation: Esophageal cancer treatment strategy, imaging and radiation delivery techniques**
T. Leong, AU

09:15 - 10:15 **Type: ESMO Colloquium** **Room 324**
Title: ESMO COLLOQUIUM - Metastatic gastric and oeso-gastric junction cancers

09:15 - 09:20 **Introduction**
K. Muro, Aichi/JP

09:20 - 09:30 **1st line treatment options for patients without a biomarker driven option**
L.-T. Chen, TW

09:30 - 09:40 **Biomarker driven option in 1st line treatment options**
M. Ng, SG

09:40 - 09:50 **2nd and later lines of treatment: What are the options?**
F. Lordick, DE

09:50 - 10:00 **Is there some hope from immunotherapy in metastatic gastric cancer?**
Y.-J. Bang, KR

10:00 - 10:10 **What's new in the guidelines?**
K. Muro, Aichi/JP

10:10 - 10:15 **Conclusions**
F. Lordick, DE

09:30 - 11:00 **Type: Educational session** **Hall 405**
Title: Challenges in head and neck oncology
 Chair: Christophe Le Tourneau, FR

09:30 - 09:55 **Hyperprogression following immunotherapy: Myth or reality?**
C. Le Tourneau, FR

09:55 - 10:20 **The role of plasma EBV DNA in management of nasopharyngeal cancer**
A. Chan, HK

10:20 - 10:45 **Surgery for low-risk HPV positive head and neck cancer**
C. Simon, CH

10:45 - 11:05 **Discussion**

09:30 - 10:20 **Type: Mini Oral session** **Room 311**
Title: Mini Oral - Melanoma and Sarcoma
 Chair: Rick L. Haas, NL; Caroline Robert, FR

- 09:30 - 09:35 **3450 - The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors**
J. Lai-Kwon¹, C. Khoo², S. Lo³, D. Milne¹, M. Mohamed¹, J. Raleigh¹, K. Smith¹, K. Lisy¹, S. Sandhu¹, M. Jefford¹; ¹VIC/AU, ²AU, ³ACT/AU
- 09:35 - 09:40 **3460 - PD-L1 expression and clinical outcome after nivolumab monotherapy in various subtypes of melanoma: a single-institutional retrospective study**
K. Namikawa, T. Mori, Y. Muto, S. jinnai, Y. Kage, E. Nakano, A. Takahashi, N. Yamazaki; JP
- 09:40 - 09:45 **3470 - A pilot study of intrahepatic Yttrium-90 microsphere radioembolisation in combination with intravenous cisplatin for uveal melanoma liver-only metastases**
S. Arulananda¹, S. Parakh¹, M. Goodwin², M. Andrews², J. Cebon¹; ¹VIC/AU, ²ACT/AU
- 09:45 - 09:55 **Discussion led by moderators**
- 09:55 - 10:00 **4060 - Multimodality, aggressive and sustainable care in metastatic osteosarcoma: A tertiary care cancer experience from India**
J. Bajpai, V. Simha, A. Chandrashekharan, J. Ghosh, B. Rekhi, T. Vora, S. Banavali, S. Gupta; IN
- 10:00 - 10:05 **4070 - Clinicopathological features of wild-type GISTs based on multiple-gene panel analysis**
T. Nishida, Y. Naito, T. Takahashi, Y. Honma, T. Saito, H. Ichikawa, S. Hirota; JP
- 10:05 - 10:10 **4080 - Can fairer sex, febrile neutropenia & compliance influence surviving probability in non-metastatic osteosarcoma: Experience over two decades from India**
J. Bajpai, V. Simha, A. Chandrashekharan, J. Ghosh, B. Rekhi, T. Vora, S. Banavali, S. Gupta; IN
- 10:10 - 10:20 **Discussion led by moderators**

10:15 - 11:15 **Type: Mini Oral session** **Hall 404**
Title: Mini Oral - Thoracic cancers
 Chair: Silvia Novello, IT; Masahiro Tsuboi, JP; Yasushi Yatabe, JP

- 10:15 - 10:20 **4530 - Quality of life in the CHISEL randomized trial of stereotactic ablative radiotherapy (SABR) versus standard radiotherapy for stage I non-small cell lung cancer (Trans Tasman Radiation Oncology Group 09.02).**

D. Ball¹, G.T. Mai², S. Vinod³, S. Babington⁴, J. Ruben¹, T. Kron¹, B. Chesson¹, A. Herschtal¹, M. Vanevski¹, A. Rezo⁵, C. Elder⁴, M. Skala⁵, A. Wirth¹, G. Wheeler¹, A. Lim¹, M. Shaw¹, P. Schofield¹, L. Irving¹, B. Solomon¹; ¹VIC/AU, ²QLD/AU, ³NSW/AU, ⁴NZ, ⁵ACT/AU

- 10:20 - 10:25 **4660 - ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: efficacy analysis by tissue or plasma T790M test**
H. Freitas¹, K. Park², D.-W. Kim², M. Tiseo³, M. Hochmair⁴, G.-C. Chang⁵, Y.-K. Shi⁶, T. Moran⁷, Y. Chen⁵, J. Laskin⁸, B. Solomon⁹, M. Miranda¹⁰, J. Rigas¹¹, P. Cheema¹², S.-W. Kim²; ¹SP/BR, ²KR, ³IT, ⁴AT, ⁵TW, ⁶CN, ⁷ES, ⁸British Columbia/CA, ⁹VIC/AU, ¹⁰GB, ¹¹MD/US, ¹²CA
- 10:25 - 10:30 **4890 - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes**
D. Planchard¹, M. Boyer², J.-S. Lee³, A. Dechaphunkul⁴, P. Cheema⁵, T. Takahashi⁶, A. Todd⁷, A. McKeown⁷, Y. Rukazenzov⁷, Y. Ohe⁶; ¹FR, ²ACT/AU, ³KR, ⁴TH, ⁵AB/CA, ⁶JP, ⁷GB
- 10:30 - 10:35 **4900 - Primary resistance mechanisms revealed in Asian TKI-sensitizing EGFR mutations NSCLC patient populations**
Q.-X. Zhang, C. Xu, W.-X. Wang, W. Zhuang, Z.-B. Song, Y.-C. Zhu, Y.-P. Chen, G. Chen, M.-Y. Fang, T.-F. Lv, Y. Song; CN
- 10:35 - 10:40 **4910 - Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: results from the KEYNOTE-407 East Asia subgroup**
T. Kato¹, S. Lee², Y. Cheng³, G.-W. Lee², K. Lee², A. Luft⁴, J. Trigo⁵, R. Hui⁶, B. Balint⁷, A. Robinson⁸, I. Okamoto¹, G. Gerstner⁹, L. Paz-Ares⁵, X. Li¹⁰, Y. Shentu¹⁰, B. Piperdi¹⁰, A. Tafreshi¹¹; ¹JP, ²KR, ³CN, ⁴RU, ⁵ES, ⁶ACT/AU, ⁷HU, ⁸ON/CA, ⁹IL/US, ¹⁰NJ/US, ¹¹AU
- 10:40 - 10:45 **4920 - Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC**
M.-J. Ahn¹, C.-H. Chiu², Y. Cheng³, J.-Y. Han¹, S.B. Goldberg⁴, A. Greystoke⁵, J. Crawford⁴, Y. Zhao⁶, X. Huang⁵, M. Johnson⁵, K. Vishwanathan⁴, A. Mendoza-Naranjo⁵, T. Mok⁶; ¹KR, ²TW, ³Jilin/CN, ⁴AL/US, ⁵GB, ⁶CN
- 10:45 - 10:50 **4930 - Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: phase 2 data**
H. Sakai¹, E. Felip², A. Cortot³, R. Veillon³, F. Griesinger⁴, J. Patel⁵, L. Horn⁶, J. Mazieres³, J. De Castro Carpeno², M. Morise⁷, T. Sakamoto¹, R. Bruns⁴, J. Scheele⁴, J. Straub⁴, P. Paik⁸; ¹JP, ²ES, ³FR, ⁴DE, ⁵IL/US, ⁶TN/US, ⁷Aichi/JP, ⁸NY/US
- 10:50 - 11:10 **Discussion led by moderators**

10:30 - 11:15 **Type: Challenge Your Expert session** **Room 324**
Title: Immunotherapy vs. targeted therapy in first-line treatment of mutation positive metastatic melanomas: How does one choose?
 Chair: Caroline Robert, FR

10:30 - 10:45 **Immunotherapy vs. targeted therapy in first-line treatment of mutation positive metastatic melanomas: How does one choose?**
J. Guo, CN

10:45 - 11:15 **Discussion led by**
C. Robert, FR

10:30 - 11:15 **Type: Challenge Your Expert session** **Room 311**
Title: Molecular biology and treatment of HCC
 Chair: Takuji Okusaka, JP

10:30 - 10:45 **Molecular biology and treatment of HCC**
L.-T. Chen, TW

10:45 - 11:15 **Discussion led by**

11:30 - 12:30 **Type: Industry Satellite Symposium** **Hall 405**
Title: Industry Satellite Symposium

11:30 - 12:30 **Type: Industry Satellite Symposium** **Hall 404**
Title: Industry Satellite Symposium

11:30 - 12:30 **Type: Industry Satellite Symposium** **Hall 407**
Title: Industry Satellite Symposium

11:30 - 12:30 **Type: Industry Satellite Symposium** **Room 311**
Title: Industry Satellite Symposium

- 12:45 - 14:15** **Type: Proffered Paper session** **Hall 405**
Title: Proffered Paper session 3
- 12:45 - 12:57 **1480 - Assessment of Tumor Response, Alpha-Fetoprotein (AFP) Response, and Time to Progression (TTP) in the Phase 3 CELESTIAL Trial of Cabozantinib (C) versus Placebo (P) in Advanced Hepatocellular Carcinoma (HCC)**
T. Yau¹, P. Merle², L. Rimassa³, B.-Y. Ryoo⁴, I. Cicin⁵, W. Harris⁶, E. Banu⁷, D. Sarker⁸, B. Tan⁹, H. van Vlierberghe¹⁰, S. Sen¹¹, C. Love¹¹, A.-L. Cheng¹², T. Meyer⁸, R. Kelley¹¹, G. Abou-Alfa¹³; ¹CN, ²FR, ³(MI)/IT, ⁴KR, ⁵, ⁶WA/US, ⁷RO, ⁸GB, ⁹MO/US, ¹⁰BE, ¹¹CA/US, ¹²TW, ¹³NY/US
- 12:57 - 13:09 **1520 - Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib**
T. Decaens¹, C. Barone², E. Assenat¹, M. Wermke³, A. Fasolo², P. Merle¹, J.-F. Blanc¹, V. Grando¹, R. Bruns³, J. Straub³, C. Zhao⁴, S. Faivre¹; ¹FR, ²IT, ³DE, ⁴MA/US
- 13:09 - 13:19 **Invited discussant**
S. Chan, HK
- 13:19 - 13:31 **1490 - Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies.**
Y.-K. Kang¹, M. Kudo², H.-Y. Lim¹, C.-H. Hsu³, A. Vogel⁴, G. Brandi⁵, R. Cheng³, I. Carton⁶, P. Abada⁷, Y. Hsu⁷, A. Zhu⁸, C.-J. Yen³; ¹KR, ²JP, ³TW, ⁴DE, ⁵IT, ⁶BE, ⁷AL/US, ⁸US
- 13:31 - 13:43 **1500 - Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): safety and clinical activity results from a Phase Ib study**
K.-H. Lee¹, C.-H. Hsu², M. Lee³, B.-Y. Ryoo¹, W. Verret⁴, A.R. He⁵, A. Kwan⁶, B. Liu⁶, K. Iizuka⁶, S. Stein⁷; ¹KR, ²TW, ³NC/US, ⁴AL/US, ⁵DC/US, ⁶CA/US, ⁷CT/US
- 13:43 - 13:55 **1510 - Practice Patterns, Radiologic Tumor Response, and Deterioration of Liver Function after Transarterial Chemoembolization (TACE): Final Analysis of OPTIMIS in Korea and Other Regions**
J. Heo¹, A.-L. Cheng², J.-L. Raoul³, M. Peck-Radosavljevic⁴, M. Kudo⁵, K. Nakajima⁶, I. Bayh⁷, S.-M. Lin², H.C. Lee¹; ¹KR, ²TW, ³FR, ⁴AT, ⁵JP, ⁶NJ/US, ⁷DE
- 13:55 - 14:05 **Invited discussant**

12:45 - 14:15 **Type: Joint Symposium** **Hall 404**
Title: ESMO-AACR: ALK gene fusions: From discovery to clinical use
 Chair: Tony S.K. Mok, HK

12:45 - 12:50 **Introduction**
T.S.K. Mok, HK

12:50 - 13:10 **Talk on basic science discovery of ALK/EML4 translocation**
T. Bivona, US

13:10 - 13:30 **Incidence and distribution of ALK translocation in human tumours and pre-clinical evidence**

13:30 - 13:50 **Early-phase clinical development and identification of second and third generation of ALK inhibitors**
B. Solomon, VIC/AU

13:50 - 14:10 **Present indication and therapeutic strategies of ALK inhibitors in lung cancer**
T.S.K. Mok, HK

14:10 - 14:15 **Conclusions**

12:45 - 14:15 **Type: Educational session** **Hall 407**
Title: Advances in targeted therapy in gynaecological cancer
 Chair: Keiichi Fujiwara, JP; Andres Maria Poveda Velasco, ES

12:45 - 13:10 **Anti-angiogenic therapy in ovarian and endometrial cancer**
D. Lorusso, IT

13:10 - 13:35 **PARP inhibitors and synthetic lethality in ovarian cancer**
E. Pujade-Lauraine, CEDEX 4/FR

13:35 - 14:00 **Targeted therapy for treatment of cervical cancer**
S. Gupta, IN

14:00 - 14:15 **Discussion**

12:45 - 14:15 **Type: Multidisciplinary tumour board** **Room 324**
Title: Locally advanced nasopharyngeal carcinoma
Chair: Brigette Ma, HK; Zhang Li, CN; Melvin Lee Kiang Chua, SG; Mingyuan Chen, CN

12:45 - 12:55 **Presentation of case/condition**
B. Ma, HK

12:55 - 13:15 **Timing of chemotherapy in nasopharyngeal cancer**
Z. Li, Guangdong/CN

13:15 - 13:35 **IMRT or proton therapy**
M.L.K. Chua, SG

13:35 - 13:55 **The role of surgery in the treatment of NPC**
M. Chen, Guangdong/CN

13:55 - 14:15 **General discussion**

12:45 - 14:15 **Type: Special Session** **Room**
Title: Integrating BRCA testing into routine cancer care in Asia - how **311**
can it be done?
Chair: Angela George, GB; Sook Yee Yoon, MY

12:45 - 12:50 **Introduction**
A. George, GB

12:50 - 13:10 **Barriers to BRCA testing in Asia**
T. Enomoto, JP

13:10 - 13:30 **Mainstreaming cancer genetics - BRCA testing in oncology clinics**
A. George, GB

13:30 - 13:50 **Expanding BRCA testing through Malaysia - the MaGiC trial**
S.Y. Yoon, MY

13:50 - 14:10 **Overcoming distance - BRCA telephone counselling programmes**
A. Trainer, AU

14:10 - 14:15 **Conclusions**
S.Y. Yoon, MY

14:30 - 16:00 **Type: Special Session** **Hall 405**
Title: Beyond panel based mutation profiling
 Chair: Miguel Quintela-Fandino, ES; Daniel Shao Weng Tan, SG

14:30 - 14:50 **The maximal potential of precision medicine needs to go beyond genomic sequencing**
L. Siu, Ontario/CA

14:50 - 15:10 **Emerging therapeutic opportunities in the non coding genome**
D.S.W. Tan, SG

15:10 - 15:30 **Unravelling resistance to multitargeted agents based on high-throughput phosphoproteomics**
M. Quintela-Fandino, ES

15:30 - 15:50 **Utilizing mutational signatures to inform treatment decisions**
H. Davies, GB

15:50 - 16:00 **The evolving role of molecular tumour boards**

14:30 - 16:00 **Type: Multidisciplinary tumour board** **Hall 404**
Title: Management of HER2 positive early breast cancer
 Chair: Giuseppe Curigliano, IT; Fatima Cardoso, PT; Masakazu Toi, JP; Wonshik Han, KR

14:30 - 14:35 **Presentation of case/condition**
G. Curigliano, IT

14:35 - 14:55 **Emerging strategies in neoadjuvant treatment of patients with HER2 early breast cancer**
F. Cardoso, PT

14:55 - 15:15 **Adjuvant treatment of patient with HER2+ breast cancer following neo-adjuvant chemo**
M. Toi, JP

15:15 - 15:35 **Optimal surgical intervention after neoadjuvant chemotherapy**
W. Han, KR

15:35 - 16:00 **General discussion**

14:30 - 16:00 **Type: Special Session** **Hall 407**
Title: ESMO-FACO Joint Symposium: Bridging clinical research and practice between Europe and Asia
 Chair: Fortunato Ciardiello, IT; Hideo Baba, JP

14:30 - 14:35 **Introduction**
F. Ciardiello, IT

14:35 - 14:55 **Guidelines adaptation: Principles and achievements to date**
G. Pentheroudakis, GR

14:55 - 15:15 **The European-Asian contribution of practice-changing in adjuvant chemotherapy of colon cancer: The IDEA study**
C.-H. Koehne, DE

15:15 - 15:35 **How may clinical research on gastric cancer in Asia contribute to European management?**
H. Baba, JP

15:35 - 15:55 **The challenge of defining oligometastasis for breast cancer in Europe and Asia**
Y.-H. Im, KR

15:55 - 16:00 **Conclusions**
H. Baba, JP

14:30 - 16:00 **Type: Educational session** **Room 324**
Title: Multidisciplinary management of retroperitoneal sarcomas
 Chair: Axel Le Cesne, FR; Akira Kawai, JP

14:30 - 14:55 **The role of surgery in retroperitoneal sarcomas**
M. Fiore, IT

14:55 - 15:20 **The role of radiotherapy in retroperitoneal sarcomas**
R.L. Haas, NL

15:20 - 15:45 **The role of systemic therapy in retroperitoneal sarcomas**
H. Loong, HK

15:45 - 16:00 **Discussion**

14:30 - 16:30	Type: Special Session Title: Rare cancers: A call to advancing partnerships between Asia and Europe Chair: Paolo G. Casali, IT	Room 311
14:30 - 14:35	Introduction <u>P.G. Casali</u> , IT	
14:35 - 14:50	What can we do on rare cancers: Lessons learned from “Rare Cancers Europe”, 10 years on <u>P.G. Casali</u> , IT	
14:50 - 15:05	Incidence of rare cancers: Results of an epidemiological comparison effort between Asia and Europe <u>A. Trama</u> , IT	
15:05 - 15:20	Which cancers are really rare in Asia? <u>Y.-J. Won</u> , KR	
15:20 - 15:35	The epidemiological/biological enigma of nasopharyngeal carcinoma from a European perspective <u>L. Licitra</u> , IT	
15:35 - 15:50	How to address the research questions on nasopharyngeal carcinoma: The case for an Asian/European partnership <u>A. Chan</u> , HK	
15:50 - 16:05	A clinical-pathologic web Sarcoma Tumor Board between Asia and Europe <u>A.P. Dei Tos</u> , IT	
16:05 - 16:20	Discussion	
16:20 - 16:30	Conclusions: Towards “Rare Cancers Asia” <u>R. Quek</u> , SG	